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Quorn® is a novel food produced from mycoprotein filaments from the Fusarium species 
ATC20334 (formerly Fusarium graminearum) bound together using egg protein. It has 
been available in the United Kingdom since 1985 and over 15 million packs have been 
sold in this country. 
A small number of individuals have reported adverse reactions following ingestion of this 
foodstuff including vomiting, skin rashes and even anaphylaxis. There have been no 
fatalities but reactions are uncomfortable and unpleasant. Possible underlying causes 
included a true immunologically mediated food allergy to either mycoprotein or egg, a 
toxic effect of mycotoxins known to be produced by this species, causing delayed gastric 
emptying and vomiting or a directly irritant effect of the foodstuff on the mucosa of the 
upper gastrointestinal tract. 140 individuals who had experienced such a reaction were 
contacted and invited to participate in an investigation into its aetiology. Subjects were 
invited to complete a postal questionnaire detailing the precise nature of their reaction, 
past medical and drug histories and asking whether they would be prepared to participate 
in more invasive investigations. These investigations entailed providing a blood sample 
for detection of IgE, IgG and IgA antibodies to mycoprotein and egg proteins, and 
undergoing either upper gastrointestinal endoscopy or isotope solid phase gastric 
emptying studies pre and post oral challenge with mycoprotein. An in house ELISA 
assay for IgE, IgG and IgA antibodies was developed. 
89/140 replied to the questionnaire and 54 sent a blood sample. 32/54 subjects were 
female with age range 18-82 years. 
9 
Affected subjects had a significantly elevated mean concentration of IgG antibodies to 
mycoprotein compared with normal controls and these levels approached those seen in 
controls with intestinal diseases such as Crohn's disease, ulcerative colitis and Coeliac 
disease. 
Three subjects agreed to have endoscopy, all had evidence of minor upper 
gastrointestinal pathology pre- challenge. There was no difference in either the 
macroscopic or microscopic appearances of the mucosa post- challenge and in particular, 
no excess of neutrophils or eosinophils. One subject had isotope gastric emptying studies 
which were normal at baseline and did not change post- challenge. 
There is no evidence of a true food allergy directed against either mycoprotein itself or 
the egg protein binders used in its manufacture. There is no evidence of any serious 
immunological abnormality in those affected. However, anti-mycoprotein antibodies 
produced by subjects have a greater affinity for binding mycoprotein in vitro than those 
produced by disease controls. This is unlikely to explain the reaction but may imply 
some increased susceptibility in affected subjects. Within the constraints of a small 
sample size, there was no evidence of any direct irritant or inflammatory reaction on the 
gastric mucosa when small doses of cooked mycoprotein are ingested. There was 
however, a high prevalence of minor upper gastrointestinal pathology noted on 
endoscopy of affected subjects, but this may be a chance finding. 
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Although sample size was too small to make useful comments, gastric emptying was not 
abnormal before challenge and was not affected by mycoprotein ingestion. 
The underlying aetiology of these reactions remains obscure and at present, the best 
advice to be given to those affected is to avoid mycoprotein- containing foods. 
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Chapter 1- Introduction And Aims 
1.1.0 Introduction 
Ut quod all cibus est aliis fugt acre venenum. 
"What is food to one is to others bitter poison. " 
Lucretius (c 95-55BC) 
"Food, glorious food" remains one of our basic requirements for life. The earliest 
societies evolved around the need to produce or procure sufficient food to sustain life. 
Food surpluses formed the basis for early trade, leading first to prosperity and later to 
warfare and conquest. 
However, even earlier than the first century BC (1), it was recognised that for a few 
unfortunate souls, seemingly wholesome staple foodstuffs could be a source of 
discomfort, pain and even, in some cases, death. 
In our own times, it is difficult to avoid the almost daily reports of the latest "food-scare" 
in the mass media. Increasingly, people are concerned that the food we eat, much of 
which is mass-produced and heavily processed may be to blame for a whole variety of 
symptoms, from diarrhoea to chronic fatigue. We are shaken to the core that something 
so integral to our existence may have the potential to make us ill. 
Leaving aside the issue of food-borne infection, the idea of food intolerance is an 
attractive explanation for a myriad of symptoms for many otherwise healthy people. 
What evidence exists to support the notion of food-related reactions as a clinical entity? 
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Coeliac disease is the classical case of an intestinal disease where the exposure of a 
genetically susceptible individual to a noxious element in food, in this case gluten 
contained in the storage proteins of cereals such as wheat ((x-gliadin), rye (secalins) and 
barley (hordeins) (2), leads to immunologically mediated damage to the intestinal 
mucosa. Avoidance of these peptides usually leads to alleviation of the symptoms within 
two weeks and eventual healing of the intestinal mucosa. 
Similarly, there is no doubt that allergies to specific foods and food additives exist. In a 
small number of immunologically susceptible people, these may manifest as eczema, 
uncomfortable urticarial rashes, oral-allergy syndrome (3), respiratory symptoms or even 
as life-threatening anaphylactic reactions. In susceptible infants and children, a variety of 
dietary components, including casein and whey proteins in cow's milk, may trigger 
gastrointestinal reactions characterised by diarrhoea and abdominal cramps such as 
dietary protein-induced proctitis of infancy (4), enteropathy (5), or enterocolitis (6,7). 
These conditions will respond to prompt withdrawal of the offending protein from the 
diet. 
However, do lesser degrees of food-related disease exist? For example, the irritable 
bowel syndrome is a common condition which has been estimated to affect up to 5% of 
males and 13% of females in a stratified randomised urban population in the South West 
of England (8). Could as yet poorly understood reactions to common foodstuffs be 
implicated in the pathophysiology of this condition? 
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It is difficult to quantify the number of individuals who experience adverse reactions, 
ranging from nausea and abdominal pain to diarrhoea and vomiting, following 
consumption of specific foods. Such subjective food intolerances are commonplace and 
may never come to medical attention since they are, generally, simply dealt with by 
avoidance of the offending substance. It is equally difficult to provide an adequate 
explanation for such idiosyncratic reactions. 
What are the possible mechanisms which underlie such intolerances? Do they have any 
role to play in triggering or perpetuating the chronic intestinal inflammation seen in 
individuals with inflammatory bowel diseases such as Crohn's Disease or Ulcerative 
colitis? If so, could dietary manipulation help to ease the symptoms, or the inflammation 
associated with these diseases? 
1.2.0 Background to adverse reactions to mycoprotein 
The fungal species Fusaria is widely distributed in nature and can infect a wide variety of 
plant species. One strain of Fusarium, ATCC 20334, previously known as Fusarium 
graminearum has been cultured to produce a novel foodstuff which is marketed in the 
UK as Quorn® (Marlow Foods Ltd, Middlesborough, UK). This is a high fibre, low fat 
foodstuff with a protein content similar to whole eggs, a texture which resembles lean 
meat and is suitable for consumption by vegetarians. A study of the safety, tolerability 
and nutritional value of this fungal species in 1984 (9) reported no adverse effects in 100 
subjects and it was deemed safe for human consumption. 
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The organism is fermented continuously on a glucose substrate, under strictly controlled 
conditions to produce large quantities of the basic fungal- or myco-protein which is 
composed largely of fungal mycelia and chitin. The fibrous fungal mycelia can then be 
mixed with binders, such as egg protein, then textured and shaped to produce a variety of 
food products including sausages, burgers and fillets. 
Since its introduction in the UK in 1985, over 15 million packs of mycoprotein- 
containing foodstuffs have been sold. During that same period a small number of 
individuals have contacted the manufacturer, drawing their attention to reactions which 
they have suffered in the context of eating these mycoprotein-containing products. A 
small number of these individuals have suffered symptoms, which are classical of food- 
borne infection, with vomiting and diarrhoea affecting all those who consumed the meal. 
This is, of course, unfortunate for the individuals affected, but like most cases of "food 
poisoning, " may relate more to food handling and preparation practices than to any 
component of the food itself. 
However, the majority of correspondents described symptoms which might only affect 
one member of the family and which were difficult to ascribe to contamination of the 
food with enteric pathogens. Indeed, any initial reaction was often put down to other 
causes, such as a "stomach bug", and may even have been forgotten. It was only after the 
affected individual suffered a similar reaction days, weeks or months later, after another 
meal containing mycoprotein, that the foodstuff was identified as a common factor. In 
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the spirit of experiment, some people even self-administered a small amount of 
mycoprotein as a challenge in order to provoke symptoms. 
The number of individuals affected by these reactions is very small and has remained 
stable at around 200 reported cases per annum (Dr G. Rodgers, personal communication). 
However, in the present political climate, the food industry as a whole is under close 
scrutiny. Thus, any link between a foodstuff, particularly a novel foodstuff, and health 
matters, excites considerable interest in the public domain. 
Prompted by concerns raised by the affected individuals, along with requests for any 
information regarding possible underlying mechanisms, Marlow Foods Ltd. approached 
Professor Anne Ferguson, late Professor of Gastroenterology at the Western General 
Hospital, Edinburgh, to commission a research project to discover the cause of these 
adverse reactions. This approach also coincided with the company's plans to market the 
mycoprotein based foodstuff in the United States and the requirement by the American 
Food and Drug Administration for evidence of its safety in humans. 
If one reads through a selection of these letters the most striking feature to note is the 
remarkable similarity of the reactions described, not just between different individuals 
but also within the same individual on different occasions. These similarities imply that 
there is some common organic process underlying these reactions. The nature of these 
reactions varied but could be placed in one of three broad categories, namely: 
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" Anaphylactic-type reaction. This was potentially the most serious type of reaction, 
but affected only 3% of respondents. Symptoms ranged from peri-oral tingling to 
swelling of the soft tissues around the eyes, mouth and airway. In some this was 
associated with breathing difficulties. 
" Generalised skin rash. Seen in 3% of cases. Rashes described include a generalised 
erythematous, papular eruption and the classic "wheals" of urticaria. 
" Abdominal pain, bloating and vomiting occurring between two and six hours after 
ingestion of the product. This was by far the commonest reaction described, affecting 
94% of respondents. Symptoms were relieved very quickly after vomiting and the 
individuals were not left with any significant residual symptoms thereafter. A small 
number had pain and bloating without vomiting. 
As it was felt that the less common, anaphylactic-type and skin reactions were almost 
certainly classical IgE-mediated food allergy reactions, attention was focussed on the 
largest group, those who had suffered the idiosyncratic but remarkably consistent 
vomiting reaction. Abdominal pain, bloating, vomiting and diarrhoea are all rather non- 
specific symptoms but are recognised to occur commonly in response to food allergy or 
food intolerance (10). This reaction may have been caused by sensitivity to mycoprotein 
or to the egg albumin used as a binding agent. As egg allergy is a commonly found food 
allergy (11) it was felt initially that this alone might explain the reaction. 
A previous study using Radioallergosorbent tests (RAST) and skin-prick testing (12) had 
investigated specific IgE responses to mycoprotein in the sera of 10 affected subjects and 
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compared these with 33 production workers employed in the manufacture of the product. 
Their results were largely negative; no affected subject had a positive RAST to 
mycoprotein, but 2 of 10 had positive skin-prick tests. 2 of the production workers had 
positive RAST results (>2% binding) but neither had experienced any adverse reactions 
to the product. 
The clinical history given by affected subjects was suggestive of a direct irritant or toxic 
effect of the mycoprotein on the gastric mucosa, or of delay in the normal emptying of 
the stomach. Fusaria species are known to produce a variety of mycotoxins including the 
type A tricothecenes diacetoxyscirpenol (13,14) and scirpentriol, the type B tricothecene, 
deoxynivalenol, and zearalenone (15). When ingested they can cause vomiting, diarrhoea, 
cardiac and central nervous system abnormalities. These mycotoxins are particularly 
toxic to mammals and are known to be capable of inhibiting protein synthesis (16). The 
nature of the toxins is well recognised and during the manufacturing process great care is 
taken to test for their presence. Any batch of F. graminearum showing signs of 
contamination is immediately discarded (G. Rodger, Marlow Foods, personal 
communication). 
1.3.0 Aims 
In this thesis, I propose to present and discuss the investigation of a specific group of 
individuals with no prior history of gastrointestinal disease, who experienced an 
idiosyncratic, adverse reaction to a novel, mycoprotein-based foodstuff. The 
investigation aimed to identify the underlying aetiology of these adverse reactions. The 
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original hypothesis was that adverse reactions may be due to an immunologically-based, 
humorally mediated mechanism, directed against a component of the foodstuff. This 
component may be the mycoprotein itself, or egg albumin used as a binding agent. The 
alternative hypotheses were that these reactions may be a consequence of a direct irritant 
effect on the gastric mucosa or a delay in gastric emptying. All three possibilities will be 
investigated in this study. 
By way of introduction, the potential interactions between dietary components and the 
intestine will be illustrated by describing the nature of the interface between the intestinal 
mucosal barrier and the luminal contents. I will concentrate mainly on the effects of 
dietary proteins on the gastrointestinal tract and will describe how interactions between 
these molecules and the intestinal barrier may manifest clinically as symptoms or signs. 
The evidence for and against a role for food sensitivity in the causation of irritable bowel 
syndrome (IBS) and in inflammatory bowel disease (IBD) will be reviewed along with 
the therapeutic role played by diet in inflammatory bowel disease. 
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Chapter 2- Literature Review 
2.1.0 Possible Mechanisms Underlying Food Reactions 
When food borne infection is excluded, reactions to foodstuffs may be categorised 
broadly into two categories, immunologically and non-immunologically mediated. Any 
immune response involves first recognising a potential pathogen, followed by mounting 
an effective reaction against that pathogen to neutralise it. Immune responses may be 
innate (or non-adaptive), or adaptive. The former is not antigen-specific and does not 
change with repeated exposure to a particular pathogen or antigen. The latter usually 
requires an initial priming phase on first exposure to an antigen (primary response), is 
highly antigen-specific, and will boost the reaction mounted in response to subsequent 
exposure to that antigen in the future (secondary response). 
Acquired or antigen-specific immune responses may be mediated by two different 
mechanisms: humoral, that is via the effects of circulating proteins or antibodies 
produced by B-lymphocytes (B-cells) and plasma cells, or cellular, via direct effects of 
immunologically active cells such as T-lymphocytes (T-cells). Humoral responses may 
be detected by measuring antigen-specific antibody levels in a body fluid, while cellular 
responses are more difficult to measure and require skin tests (in vivo) or measurements 
of cell proliferation in response to stimulation by an antigen (in vitro). 
The recognition of foreign antigens is the hallmark of the adaptive, antigen-specific 
immune response. Two types of molecule are involved in this process, immunoglobulins, 
secreted by B-cells, and T-cell antigen receptors (TCRs). Immunoglobulins are a group 
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of glycoproteins present in serum and other tissue fluids in all mammals, where they may 
be floating free in blood or lymph, or attached to the surface of B-cells, acting as specific 
receptors for antigen. There are five major classes of immunoglobulin antibodies. IgA 
predominates at mucosal surfaces, particularly in the intestinal and genitourinary tracts, 
but is found in very low concentrations in plasma. IgG is the predominant antibody class 
found circulating in plasma and is produced mostly in secondary responses to antigens. 
IgE is present in excess in atopic individuals and is produced in response to allergic 
reactions. IgM is mostly produced during the initial, primary reaction to an antigen. IgD 
accounts for less than 1% of the total plasma immunoglobulin but is found in large 
quantities on the surfaces of many B-cells. 
Immunological reactions to dietary antigens, with the production of an antibody response, 
are common but the nature and intensity of any clinical reaction varies widely. Exposure 
to a variety of different foods commonly leads to the production of specific IgG 
antibodies directed against these foods (17-19). Clinically apparent reactions to dietary 
proteins are rare and in most instances, no pathological consequences ensue. The most 
commonly seen, and often the most severe reactions tend to be mediated by 
immunoglobulin-E (IgE). For example, in susceptible or sensitised individuals, exposure 
to even tiny quantities of peanut may trigger urticarial skin rashes, oral allergy syndrome 
or less commonly, but potentially fatal anaphylaxis. 
Other immunological reactions to foods, not mediated by IgE are thought to be triggered 
by exposure of immunologically competent cells including macrophages and T- 
lymphocytes to particular dietary proteins. These cells produce a variety of pro- 
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inflammatory cytokines, such as tumour necrosis factor-a (TNF-a), which in turn 
precipitate and perpetuate inflammation. Lymphocyte stimulation experiments showed 
that peripheral blood lymphocytes from infants with cow's milk protein allergy produced 
significantly higher levels of TNF-a than non-allergic controls (20). The delayed 
reaction to ingested dietary gluten seen in Coeliac Disease and Dermatitis Herpetiformis 
does not involve IgE but is mediated by other immune mechanisms, mainly T-helpers cell 
mediated, with recruitment of large numbers of lymphocytes into the epithelial 
compartment of the small intestine. These autoimmune conditions are known to have a 
strong genetic basis and are most commonly associated with the human leukocyte antigen 
(HLA) DQA1*0501 and DQB1*0201 alleles. This HLA-DQ2 allelic combination is 
found in 98% of Northern European Coeliac patients (2,21). Furthermore, specific 
peptides of gliadin have been identified, which trigger an inflammatory T-cell response 
(22). 
Reactions which have no immunological basis may be regarded as food intolerances 
rather than true allergies. These can be defined as any abnormal response to an ingested 
food which is neither psychologically nor immunologically based. Pharmacological 
reactions to foods can occur, either by direct pharmacological or biochemical actions of a 
constituent of the food, e. g. caffeine, tyramine in cheeses, or by the non-specific, non- 
immune mediated release of pharmacologically active substances, such as histamine. 
Other mechanisms of intolerance include the specific inability to digest elements of the 
foodstuff adequately, as is the case in disaccharidase deficiencies such as lactase 
deficiency. Defining dietary components as antigens confers immediately an idea of a 
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reaction between these components and the intestinal immune system. In order to get a 
better understanding of the potential reactions between these two entities we must look in 
more detail at the structure and function of the intestinal mucosa itself. 
2.2.0 Interface Between Luminal Contents And The Intestinal 
Mucosa 
The intestinal mucosa constitutes the body's largest surface area, and is very much in the 
front line in terms of exposure to environmental antigens, bearing the heaviest burden of 
exposure to such antigens. Its structure reflects its dual role as a barrier to potentially 
harmful agents while allowing passive and active uptake of essential nutrients and 
selective "sampling" of luminal contents. The intestinal immune system is composed of 
finely tuned, extensively interacting populations of cells and their products. These are 
involved in both the innate and specific immune defence against ingested antigens. There 
is a constant compromise between the need to absorb adequate nutrients from food and at 
the same time exclude any harmful pathogens. The massive surface area and absorptive 
capacity of the intestine means it is constantly exposed to huge numbers of potentially 
antigenic substances. The mucosal barrier exists to limit some of this interaction and 
prevent potentially pathological reactions. 
Controlled uptake of luminal macromolecules allows delivery of nutrients and growth 
factors to the peripheral circulation and constant sampling of luminal antigens. However, 
it is possible that excessive or non-specific uptake of such luminal molecules may trigger 
immune reactions outwith the local response, recruiting large numbers of 
immunologically competent cells, such as macrophages and T-lymphocytes which, may 
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lead to damage to the intestinal epithelium. The "mucosal barrier" is made up of several 
components, some providing physical and others immunological protection. Non- 
specific protective mechanisms include the degradative actions of gastric acid and 
pancreatic digestive enzymes which begin the process of breaking down large, potentially 
antigenic molecules, to form smaller molecules with less antigenic potential. The 
continuous peristaltic activity of the gastrointestinal tract means that luminal contents are 
constantly being propelled along in an aboral direction, ensuring adequate mixing with 
digestive juices and limiting the time for which they are in contact with any particular 
point on the luminal surface. In addition, mucus and immunoglobulin A (IgA) are 
secreted onto the luminal surface. 
Mucus Intestinal mucus consists mainly of mucin glycoproteins which form a 
viscous coating over the epithelial cells, lubricating its surface and providing a thick 
physical barrier. These glycoproteins consist of a protein core bound by N- 
acetylgalactosamine links to a variety of complex carbohydrate side chains, which may 
constitute up to 80% of the total molecular weight. They are produced in the endoplasmic 
reticulum of mucosal goblet cells, packaged by the Golgi apparatus and secreted from the 
apical surface of the cell into the intestinal lumen. Here they provide a non-specific line 
of defence against potential pathogens in the intestinal lumen. Mucus secretion can 
increase in response to irritants, thus increasing the thickness of the protective layer. 
Over the past decade, twelve genes involved in coding for mucin proteins have been 
described (23,24). They are categorised depending on their function as visco-elastic 
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polymers or location as membrane anchored molecules in the cellular glycocalyx. Two 
clusters have been identified on chromosome 11p15.5 and on chromosome 7q22. A 
thinner mucus layer is seen in ulcerative colitis compared with normal colon or in 
Crohn's disease (25). In addition, sulphation of mucin tends to be reduced and this 
correlates with the severity of inflammation (26,27). 
Mucus can interfere with adherence of certain antigens and micro-organisms to specific 
carbohydrate receptors on the apical membrane of the epithelial cells thus inhibiting their 
pathogenicity. Mucus can similarly inhibit binding of lectins, carbohydrate-binding 
proteins derived from plants and bacteria, which can activate T-cells via their TCRs, or 
macrophages via cross linkage of IgE molecules. There is a possibility that competition 
occurs between mucin carbohydrates, micro-organisms and antigens for specific binding 
sites and subsequent uptake into epithelial cells. 
IgA IgA is present in small amounts in the circulation but is much more abundant in 
intestinal secretions. There is a huge predominance of IgA"producing cells in the 
intestine and in intestinal fluids. It is the most heterogenous of all the immunoglobulins, 
occuring in two distinct subclasses, IgAl and IgA2 and in different molecular forms; 
monomeric, polymeric and secretory (28,29), all of which are distributed differently 
between the circulating immune system and the mucosal immune system. Different 
molecular forms of IgA may have different functional properties, and these properties are 
also site-specific. Secretory IgA has several advantages over other IgA isotypes. It 
possesses between four and eight antigen binding sites, allowing more efficient antigen 
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binding (30,31). It is more resistant to proteolytic degradation because of the structure of 
its a chains and through a protective effect of secretory component (SC), the major 
extracellular fragment of the epithelial polymeric immunoglobulin receptor (pIgR), which 
remains covalently bonded to polymeric IgA and prevents proteoloysis during its 
transcytosis through epithelial cells. Unlike other immunoglobulin classes, IgA displays 
potent anti-inflammatory properties. Intact, native human IgA antibodies do not activate 
complement when complexed with antigen (32). Indeed, IgA appears to have an 
inhibitory effect on the complement-fixing and complement-activating properties of both 
IgG and IgM class antibodies (33,34). The protective effect of secretory IgA depends, in 
part, on its ability to inhibit the absorption of both soluble and particulate antigens within 
the lumen by complexing with them, neutralising infective antigens, such as viruses, and 
binding to other microbial antigens to prevent their adherence to epithelial cells. One 
mechanism by which this is achieved is through the chemical structure of the IgA 
molecule, whose Fc region is rich in mannose-type glycan side chains. These interact 
with mannose binding lectin on the fimbrial processes of enterobacteria, causing bacterial 
aggregation and thus preventing bacterial adherence to similar mannose rich residues on 
intestinal epithelial cells. 
Perhaps the best known clinical example of the protective, anti-inflammatory effect of 
IgA is that of the passive immunising effect of pre-formed secretory IgA (s-IgA) 
antibodies, produced through maternal exposure to microbial antigens, ingested by 
infants in maternal breast-milk, which protects them from subsequent gastrointestinal 
infections. This natural protective effect of maternal pre-formed IgA has been exploited 
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further by feeding low birth weight infants a formula fortified with a very high 
concentration (70%) of IgA to prevent the devastating complication of necrotising 
entcrocolitis (35). 
Intestinal Epithelium The entire intestinal tract is lined by a single layer of 
epithelial cells making them the most numerous cell population within the intestinal 
mucosa. There are four main types: columnar, polarised epithelial cells, capable of 
vectorial transport of nutrients and electrolytes; mucosal endocrine cells; goblet cells, 
capable of producing and secreting mucus and Paneth cells, capable of producing 
defensins. All gut epithelial cells originate from a population of stable stem-cells located 
near the base of crypts. They undergo differentiation as they migrate up the crypt-villous 
axis. As they reach the tip of the villi they ill undergo apoptosis and be sloughed off 
into the intestinal lumen. This whole process takes between three and five days. 
2.3.0 Reactions Between Luminal Contents And The Intestinal 
Immune System 
2.3.1 Antigen Uptake By Enterocytes 
Enteroc)ics in mammals of various ages have been shown to take up macromolecules 
from the gut lumen by cndocytosis (36-40). The molecules attach to the apical surfaces 
of the enterocytes to be taken up %%hole within an endosome which may then be 
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processed within the cell. Tiny amounts of unprocessed antigen may pass out into the 
interstitial space by exocytosis from the basolateral membrane of the enterocyte (41). 
Cornell et al, using Horse Radish Peroxidase (HRP) injected into ligated loops of rat 
intestine, were able to demonstrate the presence of particles in the apical membrane of 
the enterocyte, within membrane-bound cytoplasmic structures, between enterocytes and 
finally in the lamina propria, indicating transcellular, non-specific transport of 
macromolecules across the enterocytes (38). 
Specific surface receptor-mediated transport across the enterocyte can also be shown in 
mammalian models. For example, intact IgG in ingested milk has been shown to be 
taken up by a Fc-receptor mediated process facilitated by low pH in the gut lumen (42). 
Similar receptor-mediated processes may be important for uptake of trophic substances 
such as Epidermal Growth Factor (EGF). However, the EGF receptor lies on the 
basolateral aspect of the enterocyte, implying that EGF would have to get across the 
epithelium before binding to it (43,44). 
2.3.2 M-cells 
Membranous epithelial cells or M-cells are specialised for transport of macromolecules 
across the intestinal mucosal barrier. They are so-called because of the wrinkled 
appearance of the apical surface of the cell, seen on electron microscopy, due to 
numerous microfolds (45,46). Uptake of whole macromolecules is necessary for the 
generation of secretory immune responses such as IgA. This population of cells has 
evolved to allow controlled transfer of macromolecules across the mucosa. They are 
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found in greatest numbers overlying lymphoid follicles in the intestine e. g. over Peyer's 
patches in the terminal ileum. They differ in structure from the surrounding enterocytes. 
Those components of the enterocyte, which comprise the normal barrier function, are less 
well developed in M-cells. There are relatively few microvilli on their apical surfaces and 
correspondingly little of the glycocalyx that typifies enterocytes. There is considerable 
heterogeneity of M-cells with respect to their expression of polysaccharides of membrane 
bound glycoproteins and glycolipids. The pattern of glycoslyation may differ from that 
in surrounding enterocytes. Human M-cells express the sialyl Lewis A antigen (47), 
which can be used as a marker of M-cells. In addition, the usual layer of overlying 
mucus tends to be thinner and hydrolytic enzymes, such as alkaline phosphatase, which 
are present in the microvillous brush border of enterocytes are reduced or absent in M- 
cells. This lack of alkaline phosphatase can be used to identify M-cells by light 
microscopy, although this technique may be unreliable since other follicular associated 
epithelial cells may also be deficient in this enzyme (48). Intracellularly, lysosomal 
enzymatic activity is reduced. On the basal aspect of the M-cell there is a deep 
invagination of the cellular membrane (often called the M-cell pocket) into which cells of 
the mucosal immune system can intrude. These cells are separated from the apical 
membrane by only a very thin rim of intracellular cytoplasm allowing the lymphocytes 
and macrophages of the intestinal immune system to rest close to the contents of the 
intestinal lumen. 
A number of pathogenic micro-organisms including Vibrio cholerae, Campylobacter 
jejuni and Shigella jlexneri (49) are known to be transported across the mucosa by M- 
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cells. They may also be of significance in the uptake of other infective agents, such as 
prions (50). Horse radish peroxidase (HRP) has been used as a marker of 
macromolecular transport. Despite the adaptation of the M-cell for efficient 
macromolecular transport, as demonstrated by studies using uptake of HRP (51), the total 
absorptive surface area of these cells is small when compared to the vast absorptive area 
of the mucosal surface taken as a whole. We know that in the face of increased 
concentrations of HRP, enterocytes are also capable of significant uptake, so it is likely 
that the relative importance of these two pathways will depend on the amount of antigen 
within the lumen. 
2.3.3 Paracellular uptake 
This represents a "third way" for passage of potential antigens from the intestinal lumen 
to the immunologically active cells in the lamina propria. It has long been appreciated 
that water and electrolytes may pass between cells but only more recently was it 
discovered that other larger soluble molecules may also cross the intestinal barrier by this 
route. Indeed, the paracellular route is the dominant path for the passive flow of solute 
across the intestinal epithelial barrier (52). 
The major barrier to paracellular uptake is the tight junction, which is capable of 
selectively controlling the diffusion of ions and small, water-soluble molecules from the 
intestinal lumen to the bloodstream. This selective control allows for counter-regulation 
of concentration or ionic gradients across the epithelial barrier which may arise as a 
consequence of transcellular transport mechanisms (53). The anatomical structure of the 
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tight junction has been studied in some detail. In freeze fracture preparations, (54), these 
structures are seen to be composed of strand-like filaments passing between cells. The 
precise composition of these filaments is unknown but the number of strands within a 
tight junction determines the ionic resistance of the epithelial monolayer, and thus, the 
degree of permeability by the paracellular route. 
Using the technique of solvent drag, Pappenheimer showed that the rate of uptake of 
molecules less than 5500 Daltons was proportional to the rate of fluid absorption (55-57). 
He calculated that the size of the pore at an open tight junction to be 5 nm (54), similar to 
the size of small macromolecules. The passage of larger polypeptide molecules may be 
facilitated by sodium-glucose transport, but significantly larger, potentially immunogenic 
macromolecules (such as HRP) will not pass tight junctions under physiological 
conditions. In the healthy intestine, tight junctions are impermeable to HRP. 
Tight junctions are dynamic structures and their function can change rapidly in response 
to the prevailing physiological and pathological circumstances. More recently, Fasano et 
al have done much to elucidate the possible mechanisms by which tight junction 
permeability is regulated. The zonula occludens toxin (Zot) produced by Vibrio cholerae 
and zonulin, an endogenous intestinal Zot analogue, have been shown to bind to a 
common intestinal receptor on the luminal surface, inducing protein kinase C dependent 
polymerisation of actin microfilaments within the tight junction complex (58-60). The 
net effect of this binding is a relative opening or "loosening" of the tight junction, 
increasing the permeability of the epithelial barrier. The surface receptor is only 
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expressed in the jejunum and distal ileum, not in the colon (61). This may be a potentially 
important mechanism in those diseases, such as Coeliac disease, which predominantly 
affect the small intestine, leading to increased intestinal permeability and thus greater 
exposure of luminal antigens to antigen-presenting and other immunologically active 
cells within the lamina propria. 
2.4.0 Responses To Luminal Antigen Uptake 
In the preceeding sections I have described some of the means by which the intestinal 
immune system takes up or samples antigens within the lumen, and exposes them to the 
immuno-compentent cells within the lamina propria. Once antigen has been taken up it 
must be processed and presented in an acceptable form to immunologically competent 
cells such as T-lymphoctyes in the intra-epithelial or lamina propria compartments. 
Distinct populations of specialised antigen presenting cells (APCs), usually macrophages, 
dendritic cells and B-cells accomplish this presentation of exogenous antigen. 
Prior to their presentation, antigens must first be processed, and this usually occurs either 
in the macrophage or in epithelial cells. Antigens are not presented by major 
histocompatibility complex (MHC) as intact proteins but rather as processed peptide 
fragments at the cell surface. The majority of epitopes recognised by T-cells are 
fragments from peptide chains which would be inaccessible in terms of immune 
recognition in the intact protein. Only a minority of peptide fragments from a protein 
antigen is able to bind to a particular MHC molecule. Different MHC molecules bind 
different sets of peptides. The peptide binding site on the MHC molecule has a variety of 
32 
clefts, hollows and depressions which depend on the precise nature of the amino acids 
within the binding "groove". This will vary from one haplotype to the next. Peptide 
binding depends on the nature of the peptide side chain branches and their 
complimentarity with the MHC molecule's binding groove. 
The processing of intact antigens to generate peptides that can bind to MHC molecules 
occurs in intracellular organelles following the internalisation of antigen into the cell. 
Partial proteolytic degradation of the antigen proceeds within the phagolysosome to 
degrade it into peptide fragments. These are transported through the cell, coming into 
contact with MHC class II molecules on their way to the surface of the antigen- 
presenting cell. 
CD4+ T-helper lymphocytes will recognise cell-processed antigen in association with 
MHC molecules and can only be stimulated by antigen which is presented to them by 
cells expressing MHC class II on the cell surface. Cells expressing MHC class II (APCs) 
present antigen to CD4+ T-cells and this is the route for exogenous antigens taken up 
from the mucosal surfaces or blood. In contrast, cells expressing MHC class I (which 
includes all nucleated cells) will present antigen to CD8+ T-cells, and this is especially 
important for responses to intracellular pathogens such as viruses. 
Dendritic cells have been described as the most important single population of cells 
within the immune system although since they are an extremely heterogenous cell group, 
and exist in a huge number of different forms, it may be misleading to label them as a 
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"single" group. Not only do dendritic cells process and present luminal antigens which 
have succeeded in crossing the epithelial barrier, they are capable of directly sampling 
luminal contents. Using epithelial cell monolayers, Rescigno et al have demonstrated 
that this is achieved through the expression of tight junction proteins on the dendritic cell 
surface. Through their interactions between the dendritic cell and epithelial tight 
junctions, these proteins are then exploited by allowing dendritic processes to extrude 
through the epithelial barrier, between the tight junctions and into the lumen, while still 
maintaining the integrity of the epithelial layer (62). 
It has been postulated that in inflammatory bowel disease, (63) the presentation of certain 
luminal antigens such as bacteria or bacterial cell wall products e. g. lipopolysaccharide 
(LPS), or even dietary proteins, may trigger increased expression of MHC class II 
molecules on epithelial cells. This in turn increases activation of macrophages and other 
antigen presenting cells. This increased presentation of antigen to immunologically 
competent cells may increase activation and expansion of CD4+ T-helper lymphocytes. 
This further encourages T-cell activity, enhances proliferation and maturation of B-cells 
and ultimately can increase the numbers of immunoglobulin secreting plasma cells. 
Further insight into the importance of the innate immune response to luminal antigens, 
particularly that of bacterial cell wall LPS, in the aetiology of Crohn's disease was gained 
earlier this year from genetic studies. Groups working in Europe and the USA described 
genetic defects in the Crohn's disease susceptibility locus on Chromosome 16. These 
genetic variants, code for a variant NOD2 protein which, acting via nuclear transcription 
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factors such as nuclear factor-i<B (NF-KB) in monocytes may lead to over activation of 
the intestinal cellular immune response to intra luminal bacteria (64-66). 
2.5.0 Generation Of Antibodies Directed Against Dietary 
Antigens 
Antigen uptake by the mammalian intestine is influenced by age, and by the stage of 
maturation of the intestine. Humans differ from other mammals in that the intestinal tract 
is at a relatively advanced stage of maturation at the time of birth. This means that the 
human neonate is theoretically less able to absorb large macromolecules such as maternal 
immunoglobulins in colostrum than for example the calf (67). This is of no functional 
significance as, in humans, passive maternal immunity is passed on through 
transplacental transfer of immunoglobulin in utero. However, increased levels of 
macromolecules such as Bovine Serum Albumin (BSA) do penetrate the human neonatal 
intestine and can be measured in serum. This is not the case in older children fed 
equivalent doses of BSA (68). Other studies (37,69,70) have confirmed this finding. 
They show that there are higher levels of detectable antibodies directed against food 
antigens in the first three months of life than in later infancy. This suggests that proteins 
can pass across the intestinal mucosa more easily in earlier life, but also that there may 
come a point at which this passage ceases or diminishes significantly, a point known as 
"closure" of the intestine. Whether this concept is relevant in humans is debatable in 
view of findings which conflict with the above. For instance, Roberton et al concluded 
that closure was complete in humans at birth. They were unable to demonstrate bovine 
ß-lactoglobulin in the sera of term human neonates fed on bovine milk (71). Many other 
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authors have demonstrated detectable levels of IgA class antibodies in serum directed 
against food antigens such as egg albumin and cow's milk proteins in adults (17,18). At 
least some of the differences encountered may relate to the methods employed to look for 
antibodies with a variety of techniques being used over the years including 
radioimmunoassay (RIA), and enzyme-linked immunosorbent assay (ELISA). However, 
the presence of antibodies directed against dietary components suggests that the process 
of "closure" is not as simple as previously supposed and is probably never totally 
complete. This situation allows sampling of antigens in the intestinal lumen to persist 
long into adulthood. Recent electron micrograph studies have demonstrated that 
dendritic cells can extrude into the intestinal lumen, coming into contact with the 
antigenic material contained therein (72). Thus, increases in intestinal permeability may 
result in not only increased movement of luminal contents across the mucosal barrier to 
the lamina propria, but also a greater number of lamina propria dendritic cells sampling 
luminal antigens. The situation is not one of a simple one-way barrier, which is either 
open or closed, but allows a constant traffic to cross to and fro in a controlled manner. 
De Weck et al described a high prevalence of IgG antibodies to milk, egg, soybean, 
peanut and fish mix in a group of 105 healthy male blood donors aged between 20 and 25 
(73). A number of other authors have found higher levels of IgG class antibodies to 
cow's milk in the sera of cow's milk allergic patients but this is not a consistent finding 
(74-80). It is most likely to be a reflection of the physiological response of the intestinal 
immune system to exposure to substances in the lumen. However, when compared with 
normal subjects, increased levels of antibodies to many different dietary substances have 
been reported in individuals with inflammatory disorders of the intestine including 
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Coeliac disease, Crohn's disease and Ulcerative colitis. In the majority of the earlier 
reports, authors have concluded that the presence of these antibodies is due to increased 
permeability of the mucosal barrier as a consequence of intestinal inflammation(81). 
However, other mechanisms may be at play, such as a break down of the normal 
protective mechanisms which prevent excessive activation of the mucosal and systemic 
immune systems in response to ubiquitous dietary components. 
Following antigenic stimulation, lymphocytes in Peyer's patches migrate to mesenteric 
lymph nodes via lymphatic channels. From here they travel in the lymphatic system to 
the systemic circulation. Suitably activated or sensitised cells will then "home" to sites 
which will facilitate their interaction with absorbed antigen such as the intra-epithelial 
lymphocyte compartment and the lamina propria. 
It must be noted that the mucosal immune system is largely independent of the systemic 
immune system and that responses to antigenic stimuli are also different. For example, 
there is a relative lack of IgG producing plasma cells within the intestinal mucosa and so 
mucosal stimulation will tend to produce the local secretion of IgA class antibodies. 
Systemic responses are characterised by secretion of IgG, the most abundant 
immunoglobulin in the blood. As a result of the enormous quantity and diversity of 
antigen presented to the mucosal immune system, in the form of ingested or inhaled 
material, robust systems must exist to avoid excessive or inappropriate immune responses 
to innocuous substances. These mechanisms will be discussed in more detail in section 
2.6.0. 
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The investigation of intestinal mucosal humoral immunity presents particular logistical 
problems not least of which is the relative inaccessibility of the vast majority of the 
intestinal mucosal surface. Investigators have attempted to study intestinal mucosal 
immunity in a variety of ways by measuring immunoglobulins and specific antibodies in 
intestinal secretions. This generally involves intubation of the gastrointestinal tract to 
allow perfusion of isolated segments of small intestine, aspiration of small intestinal 
juices or the taking of biopsies of intestinal mucosa. Such methods are, by their very 
nature, invasive and unpleasant for the subject under examination. Largely for these 
reasons, investigators historically tried to extrapolate data obtained from serum, which 
indicated a systemic immune response, as representative of events occurring in the gut. 
This may be a valid method in certain circumstances, such as described by Forrest in the 
study of IgA secreting B cells or plasma cells following enteric infections or 
immunisation (82). However, it is potentially misleading to make such extrapolations, 
and wherever possible, efforts should be made to directly study events at a mucosal level. 
Without recourse to intestinal intubation, the only methods available for doing this 
adequately involve measurement of substances excreted in intestinal secretions or faeces. 
This is not a problem if one is measuring substances which are robust, stable and do not 
degrade readily. In view of the plethora of digestive enzymes and fermenting bacteria 
within the digestive tract which may denature or inactivate proteins in the form of 
antibodies, enzymes or immunoglobulins, such techniques may present major technical 
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challenges. Similarly, intestinal transit times, if very long, may result in the denaturing of 
a number of unstable proteins. 
However, the technique of whole gut lavage, using a polyethylene glycol (PEG) solution 
identical to that used in pre-operative bowel preparation, first described by Gaspari et al 
(83), offers a relatively non-invasive means of assessing intestinal levels of a variety of 
proteins. O'Mahony et al, working in Edinburgh, published extensively on the use of this 
technique. They were able to quantify the levels of total immunoglobulins(IgA, IgG and 
IgM) in addition to detecting specific antibodies to gliadin, other common food proteins 
and a number of bacteria in the intestinal secretions of immunologically normal healthy 
control subjects as well as in those with Crohn's and coeliac disease, who had disordered 
intestinal immunity (84-88). Furthermore, the same group went on to show that the 
elevated levels of whole gut lavage fluid proteins such as IgG and ul-antitrypsin seen in 
patients with active inflammatory bowel disease, also correlated well with other clinical 
assessments of disease activity (89). 
A number of very interesting observations arise from the use of this novel technique, 
reflecting the differences between systemic immune responses, as measured in serum, 
and mucosal immune responses, measured in whole gut lavage fluid (WGLF). In an 
attempt to characterise the systemic and immune responses to common food proteins, 
paired samples of serum and WGLF were obtained from 12 healthy volunteers and a 
rather heterogenous group of 54 patients with Crohn's disease, ulcerative colitis and 
coeliac disease. These were assayed for serum IgG antibodies and WGLF IgA antibodies 
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to gliadin, ovalbumin and ß-lactoglobulin (88). There was no reciprocal relationship 
between serum IgG and intestinal IgA levels in either group, indicating that the presence 
of systemic antibodies did not reflect a lack or absence of mucosal IgA response. There 
were no healthy controls who had intestinal IgA antibodies to any of the foods tested with 
no detectable serum IgG response. Very few of the disease controls had positive 
intestinal IgA antibodies in the absence of positive serum IgG antibodies, but the majority 
of those who did were coeliac patients. In the disease control group, 42% of coeliac 
patients had this pattern compared to 6% of Crohn's and 3% of ulcerative colitis patients. 
Enhanced intestinal antibody production to gliadin and other common food antigens in 
coeliac patients had previously been demonstrated and may represent a breakdown of the 
usual tolerigenic protective mechanisms active within the mucosal immune system. 
Levels of serum IgA and IgG antibodies to gliadin were seen to fall in response to 
treatment with a gluten free diet, while JgA antibodies in jejunal aspirates and WGLF 
remained high. This highlighted a dissociation between the systemic and mucosal 
humoral immune responses to gliadin in patients with coeliac disease. Although there 
was a correlation between levels of serum and jejunal aspirate antibody levels in the 
untreated coeliacs (r=0.68, p<0.001), this was lost after withdrawal of gluten (84). In a 
study of the systemic and mucosal immune responses to Klebsiella pneumoniae in two 
groups of patients with Crohn's disease and ankylosing spondylitis, there was no 
correlation between serum and WGLF levels of IgG antibodies to K pneumoniae in the 
Crohn's patients. This further illustrates the potential pitfalls of extrapolating 
information from systemic antibody levels as a reflection of intestinal mucosal responses 
(87). 
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In immunologically healthy individuals, most interactions between antigen absorbed from 
the intestinal lumen and immuno-competent T cells will usually result in a state of 
immune hypo-reactivity or tolerance, thus reducing the potentially harmful effects of the 
absorbed antigen. Only very rarely will a state of hypersensitivity result. 
2.6.0 Oral tolerance 
The ability of the mammalian immune system to generate appropriate responses to the 
almost infinite variety of potential allergens it may encounter depends on the expression 
of vast numbers of immuno-competent cells with different antigen-specific lymphocyte 
receptors. In so doing, the risk of expressing receptors which will attack "self' proteins, 
and developing a state of auto-immunity, or of expressing receptors which will attack 
otherwise harmless, often useful exogenous "antigens", such as food proteins, is 
relatively high. However, this is the price we must pay for an immune response which is 
effective against any potentially antigenic substance. In order to minimise this risk, a 
number of strategies exist to induce or to facilitate a state of immunological tolerance. 
This is achieved by two main strategies, namely, central and peripheral tolerance. 
Central tolerance is the better understood mechanism and involves the physical 
destruction or deletion of self-reactive T and B lymphocytes (90). However, this central 
strategy alone is insufficient to account for antigens which may not be represented in the 
primary lymphoid organs or which are only found in certain peripheral sites. Therefore 
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central tolerance has to be complemented by peripheral mechanisms of tolerance, of 
which oral tolerance is one such mechanism. 
For many years it has been known that exposure of the immune system, via the mucosal 
(oral or nasal) route to soluble dietary antigens leads to a state of immune hypo- 
responsiveness or tolerance to that specific antigen (91), even when the immune system 
re-encounters that antigen systemically. It is a protective mechanism to limit potentially 
harmful immunologically mediated damage triggered by otherwise innocuous substances 
encountered in the intestinal lumen. 
Whether an antigen will induce tolerance in the periphery is probably dependent on the 
balance of co-stimulatory signals to the T cells from other antigen presenting cells 
(APCs). The form taken by any particular antigen is also important in determining 
whether an immunogenic or a tolerogenic response is elicited. For example, antigen 
presented in soluble, monomeric form is likely to induce tolerance and immune 
hyporesponsiveness if subsequently encountered. In contrast, antigen presented in 
particulate form, especially if administered in the presence of an adjuvant is more likely 
to induce production of pro-inflammatory cytokines including TNF and IL-1, along with 
upregulation of co-stimulatory molecule expression (such as B7.1 and B7.2), ultimately 
resulting in an immune response on subsequent challenge (92). 
The non-specific effects of digestion of potential antigens, coupled with the combination 
of intestinal mucus and the intestinal epithelial barrier may be one way of denying 
potential luminal antigens access to the lamina propria and APCs. T cell clones may be 
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unresponsive to antigen if they have never encountered it and are immunologically 
"ignorant" or naive. However, the available evidence would suggest that such a 
possibility is unlikely, as the intestinal "barrier" is not an impermeable structure. Indeed, 
oral tolerance can only be induced if the appropriate T cell clones do encounter luminal 
antigen. The non-specific barrier effect of the gut wall may instead act as a filter, 
allowing highly soluble antigens, perhaps in monomeric form, access to the relevant 
APCs and T cell clones and inducing T cell anergy. 
Up-regulation of production of secretory IgA antibody production occurs in order to deal 
with ingested antigen within the intestinal lumen. In addition, there has to be suppression 
of the systemic immune response to that antigen. This suppressive effect may be 
achieved in several ways. Stimulating T cell clonesvia their TCRs, may induce a state of 
immune unresponsiveness or clonal anergy. Whitacre et al demonstrated that, in an 
encephalitis model, this state can be reversed in vitro by the administration of exogenous 
IL-2 (93), indicating that hyporesponsive T cells do still retain their ability to respond to 
antigen. Alternatively, T-cell clones may be physically eliminated or deleted, either 
through apoptosis (programmed cell death) or through release of toxic cytokines and 
deprivation of cell growth factors. All the available evidence for T cell deletion is derived 
from animal studies with conflicting results and there is still controversy as to whether 
apoptosis mediated cell deletion is truly a relevant phenomenon in this context. A further 
possible mechanism may be via the activation and up-regulation of antigen-specific 
regulatory CD8 + cells. These may produce regulatory cytokines such as transforming 
growth factor (TGF)-ß, which has non-specific suppressive effects on surrounding cells, 
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regardless of their antigen-specificity (94). However, animal studies utilising genetically 
engineered, CD8 knockout mice and mice given anti-CD8 antibodies (95) showed that 
oral tolerance could be induced without difficulty. Therefore it is inferred that the 
presence of CD8+ cells is not an absolute requirement for the induction of oral tolerance, 
and CD8+ cells may play only a minor role. In contrast, CD4+ cells appear to play a 
crucial role, as shown in studies where CD4+ cells have been depleted in vivo or in 
genetically engineered CD4 knockout mice (96). Finally, a number of immunoregulatory 
cytokines, including IL-4, IL-10 and TGF-ß have been studied in relation to the induction 
of immunological tolerance. Both IL-4 and IL-10, so-called Th2 cytokines have been 
found to be upregulated in oral tolerance, although they have failed to live up to their 
initial promise as mediators of this process through the down regulation of Thl 
responses (97,98). 
Emancipator and Lamb (99) showed that mice orally immunised to bovine gamma 
globulin or to gliadin developed elevated titres of IgA antibodies to the fed antigen; 
however, intravenous administration of the same antigens produced elevated titres of IgG 
and IgM antibodies. A breakdown of the normal mechanisms of oral tolerance is 
responsible for the lesions seen in Coeliac disease and other food sensitive enteropathies 
(100). It is possible that some form of impaired tolerance is also implicated in the 
pathogenesis of inflammatory bowel disease (101-104). For eample, Duchmann et al 
were able to demonstrate in a mouse model that normal oral tolerance to intestinal flora 
could be completely abrogated by the induction of a chemically-induced experimental 
colitis. In the same model, administration of either exogenous IL-10 or antibodies to the 
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proinflammatory cytokine IL-12, was observed to restore tolerance. It is not clear, 
however, whether this was due to any particular tolerogenic effect of the cytokine therapy 
or rather to their ameliorative effect on the experimentally induced colitis. In either case, 
induction of experimental colitis in an animal model resulted in a loss of tolerance to the 
intestinal flora which could be restored by adequate, effective therapy for that condition. 
2.7.0 Food Allergy 
True food allergy is an abnormal reaction resulting from heightened immunological 
responses to antigens (usually glycoproteins) in foods. Those foods most commonly 
implicated include peanuts, soy, cow's milk, eggs, tree nuts, fish and wheat (105). 
Symptoms are more common in atopic individuals, and severe systemic reactions, such as 
anaphylaxis are more frequent in asthmatic individuals (106-108), some of whom may 
also have allergies to pollens. 
There is, unfortunately, a lack of a good, robust animal model of food allergy. In spite of 
this, most of the experimental evidence regarding the pathophysiology of intestinal 
hypersensitivity reactions is derived from animal studies, particularly rodent studies (10). 
There are potential problems associated with using a rodent model for the study of 
reactions occurring in humans. The human and rodent immune systems are not identical 
and extrapolating data from rodent studies to explain responses in humans is potentially 
very misleading. Animal studies can provide a paradigm for events occurring in humans, 
but do not necessarily replicate or even reflect those events. An illustration of the 
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potential problems encountered when one extrapolates immune responses in the rodent to 
the human situation is seen in the case of interleukin-3. Interleukin-3 (IL-3) has been 
shown to be an important regulatory cytokine in rodent mast cell function, but human 
mast cells do not express the IL-3 receptor (109). Rodent studies therefore highlighted 
the importance of IL-3 in mast cell function, but to assume that similar mechanisms apply 
in the human mast cell is obviously a mistake. Where possible, studies involving human 
tissue are preferable but may not always be possible. In the absence of human material it 
may be necessary to resort to the rodent model but care must be taken in the 
interpretation of the data thus obtained. With respect to this study, which aimed to 
describe the mechanism of a gastrointestinal reaction to mycoprotein in humans, animal 
models may potentially be misleading. 
The mechanism underlying food allergy is thought classically to involve 
immunoglobulin-E (IgE) mediated aggregation and activation of mast cells and basophils 
within the affected tissue e. g. the skin, airways or intestine. Mast cells are found 
throughout the body but fall into two main populations, mucosal mast cells and 
connective tissue mast cells (110). A very high density of mucosal mast cells is found 
within the gastrointestinal tract. Intestinal mast cells make up 2-3% of the population of 
lamina propria cells. Connective tissue mast cells are found adjacent to blood vessels, 
nerves and lymphatic channels. They are larger than intestinal mast cells and contain 
more histamine. In connective tissue mast cells, histamine release may be inhibited by 
administering disodium cromoglycate, which has no effect on intestinal mast cells. In 
health, mast cells function as part of the host defence mechanism, playing a critical role 
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in protecting against intestinal infection, especially parasitic and bacterial infections 
(111,112). Increased numbers of intestinal mucosal mast cells have been described in 
untreated Coeliac disease (113) and in Crohn's disease. Endoscopically administered 
antigen provocation tests in humans, with injection of antigen into the gastric (114,115) 
or caecal (116) mucosa, have revealed elevated levels of tissue histamine and increased 
mast cell numbers in biopsies taken from allergic subjects. Such information reinforces 
the importance of these cells and their mediators in the pathogenesis of intestinal allergic 
reactions. 
Cross-linking of antigen or anti-IgE to IgE bound to specific receptors on these 
specialised cells, causes them to "degranulate" releasing a cocktail of biologically active 
substances, including histamine, prostaglandins, leukotrienes and tumour necrosis factor- 
a (TNF-a). These in turn induce an inflammatory response with a number of 
consequences within the gut, such as increased epithelial ion transport, increased vascular 
permeability, impaired integrity of the mucosal barrier, mucosal oedema, increased 
mucus secretion and increased peristaltic activity (117,118). Clinically, this may 
manifest as abdominal pain, bloating and diarrhoea. Reactions may not occur after first 
exposure, when the subject becomes sensitised to an allergen, but may be apparent on 
subsequent exposures. They then usually occur immediately on contact with the allergen 
but occasionally may be delayed in time. Since mast cell activation in both the 
connective tissue and mucosal compartments is dependent on IgE-mediated mechanisms, 
those individuals with high levels of circulating total and antigen-specific IgE are most 
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likely to experience the clinical manifestations of atopic disease whether in the skin, 
airways or nasal and gastrointestinal mucosa. 
Mast cells are a major effector cell type in IgE-mediated Type 1 hypersensitivity 
reactions. Stem cell factor (SCF) has been shown to regulate the development of human 
mast cells from primitive progenitor cells (119). In addition, it enhances the release of 
histamine and leukotrienes from human mast cells in the lung (120,121) and 
gastrointestinal tract (122) and selectively promotes survival of gastrointestinal mast 
cells. In the presence of SCF, interleukin-4 (IL-4), a T-cell derived cytokine, which acts 
as a B-cell growth factor, enhances the proliferation and survival of mast cells and 
increases the IgE dependent release of inflammatory mediators (123). However, in the 
absence of SCF, IL-4 has little discernible effect on human mast cells. Human mast cells 
also constitutively produce small amounts of the potent, pro-inflammatory cytokine, 
TNF-a (124) which may be important in their protective role against micro-organisms. 
However, cross linkage of IgE stimulates increased production of TNF-a and this may 
account for some of the heightened inflammatory response seen in allergic individuals 
exposed to allergens. IgE cross linking also stimulates the secretion of other cytokines 
including IL-3, IL-5 and IL-13 which serve to attract other cell populations, such as 
eosinophils, to the site of inflammation (125,126). Non- IgE mediated mechanisms 
including activation of IgGI receptors (127) and nitric oxide (128) can also activate mast 
cells leading to degranulation and mediator release in human and rodent models. 
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Interactions between mast cells and nervous tissue may also be of importance. In the rat 
trachea, Joos et al described the neurokinin-1 (NK-1) receptor mediated release of 
serotonin from mast cells stimulated by substance P and neurokinins (NKs) (129). In 
rodents, nerve growth factor (NGF) increases the number of mast cells and primes them 
for histamine release (130). NGF levels are known to be elevated in the sera of atopic 
human subjects (131) and this may represent another, neurally mediated pathway leading 
to histamine release and allergic reactions in susceptible individuals. 
Attraction of eosinophils to the site of inflammation is important in the generation and 
perpetuation of the inflammatory response in non-intestinal allergic conditions (132). 
However, less is known about the role of these cells in the pathophysiology of intestinal 
allergic reactions to foods. The discovery that levels of eosinophil granule proteins such 
as eosinophil cationic protein (ECP) and eosinophil protein X (EPX) are elevated in the 
faeces of individuals with food allergy (133,134) would support the notion that they are 
also of great importance in these reactions. Local stimulation of the intestinal mucosa by 
food antigens in patients who are sensitive to cow's milk protein leads to increased faecal 
levels of ECP (135). In the same study, the authors noted that eosinophil activation 
occurred rapidly, usually within 20 minutes of allergen exposure. Just how eosinophils 
are activated is not clear. There may be a direct stimulating effect of the offending 
allergen leading to cross-linking of IgE or IgA receptors on the cell surface. 
Alternatively, eosinophil activation may be indirectly regulated by the activation of mast 
cells, leading to increased release of chemoattractants including prostaglandins and 
histamine, recruiting eosinophils to the affected area (136). A number of cell types 
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including fibroblasts, macrophages, monocytes, T-cells and endothelial cells can secrete 
polypeptide chemotactic cytokines which act as powerful chemoattractants. Macrophage 
chemotactic protein (MCP) -2 and -3, macrophage inflammatory protein 1-a (MIP-l(x), 
RANTES and eotaxins 1 and 2 can bind to the chemokine receptor 3 (CCR-3) expressed 
on eosinophils (137,138) where they may trigger release of further inflammatory 
mediators or merely function as chemokines. The release of other cytokines, such as IL- 
3, IL-5 and granulocyte/macrophage colony stimulating factor (GM-CSF) has been 
shown to be of great importance in allergic inflammation, particularly in late phase 
allergic inflammation (139). IL-3, IL-5 and GM-CSF enhance the release of IgE- 
independent inflammatory mediators from human eosinophils (140,141) contributing to 
increased vascular permeability, mucosal oedema and recruiting more inflammatory 
effector cells to the site of inflammation. Hogan and co-workers (142) described a new 
mouse model of antigen-induced gastrointestinal allergy which illustrates the role of 
eotaxin in such reactions. IL-5- or eotaxin- knock-out mice, deficient in either IL-5 or 
eotaxin, a cytokine constitutively expressed in the intestine, were studied to assess the 
relative roles of these cytokines. After oral administration of food antigens, both groups 
developed increased levels of IgE. However, the eotaxin-deficient mice had no evidence 
of eosinophil accumulation in the gastrointestinal tract, while the IL-5-deficient group 
had an attenuated eosinophil accumulation compared with controls. However, as 
previously discussed, it remains to be seen whether such murine studies reliably parallel 
the events in humans. 
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Some food glycoproteins are known to be more allergenic than others but the reasons 
underlying this are far from clear. It may be due to factors pertaining to the protein itself; 
its size, solubility, resistance to digestion or the quantity ingested. Differences may 
reflect prior exposure to that antigen or to an immunologically similar substance. Prior 
exposure need not be by the oral route but could reflect cross reactivity with an inhaled 
antigen. 
Pollen allergies are well known to occur in association with food allergy to fruits or nuts. 
Major birch pollen allergen Bet v1 and birch profilin Bet v2 share allergenic motifs 
found in potatoes, carrots, apples, pears and celery (143) and Mad d 1, the major apple 
allergen shares IgE epitopes with Bet vl, leading to cross sensitisation mediated by 
specific T helper lymphocytes (144). Other compounds, such as peptides which stimulate 
T-cells or antigen presenting cells, may be present in the same food which may augment 
or attenuate the immune response. 
Food allergy or hypersensitivity is common in paediatric populations but is an uncommon 
diagnosis in adults. The prevalence of food allergy depends on the criteria used in its 
definition, but using blinded oral food challenges, Bock et al found that 6% of an 
unselected population of children had proven evidence of food allergy. Following these 
children to age three, it was apparent that the in the majority outgrew their allergy (145). 
Host also found that 85% of infants sensitised to cow's milk protein, lost their sensitivity 
by the age of three (146). European and Scandinavian studies quote a prevalence of 
cow's milk protein allergy of between 1.9% and 2.8% (147-149). Eggesbo et al describe 







a point-prevalence for egg allergy in 2 year old children in Norway of 1.6% (95% CI 1.3- 
2.0%) (11). This study raises another interesting point; the perceived prevalence of food 
allergy by lay-people within the wider population is much higher than the actual 
prevalence, especially when rigorous diagnostic criteria are applied. In the Norwegian 
study, questionnaires were filled in by parents who were convinced that their child had 
suffered a reaction to egg. Two thirds of these reactions were indeed verified by either 
skin prick testing or oral food challenges, but this still leaves a third which were not 
verified as true allergic reactions. The positive predictive value of a parentally perceived 
reaction was 50%, if that reaction had been reported on a single occasion. This rose to 
100% if the reaction had been reported on three occasions. Although precise data are 
lacking, it is estimated that <1% of the adult population in the United States is affected by 
allergic reactions to foods (150). 
The diagnosis of true food allergy is challenging as many of the symptoms produced are 
non-specific and may overlap greatly with symptoms of the irritable bowel syndrome. 
Diagnosis is largely clinical and depends upon a good history of appropriate symptoms 
consistently elicited within a defined timescale after ingesting a specific food or food 
ingredient. It is important to elicit a complete account of which symptoms and signs 
occurred, which foods were implicated, the precise relationship in time between ingestion 
and onset of symptoms, the reproducibility of the reaction and some indication of the 
minimum quantity of the offending food which will precipitate symptoms. 
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The American Gastroenterological Association has recently published guidelines on the 
evaluation of food allergy in gastrointestinal disorders in an attempt to provide a rational 
approach to this area and to standardise practice (151,152). These guidelines reinforce 
the notion that the diagnosis of food allergy is largely a clinical one. It is based upon a 
history of an allergic or "allergic-type" reaction which is temporally associated with 
ingestion of the offending food and backed up by certain in vivo or in vitro tests. In 
selected cases, the diagnosis may be confirmed by the resolution of symptoms on an 
elimination diet and recurrence of symptoms after oral challenge. 
There are a number of pointers within the history which are useful in determining 
whether a reaction is likely to be due to food allergy. The diagnosis is more likely in 
infants or children than in adults. One of the most reliable clinical correlates of 
immediate reactions to foods is the presence of a personal or a family history of atopic 
disease. However, by its very nature, the presence of such a history may be based largely 
on the patients' ability to understand and to recall a that a diagnosis of atopy had been 
made. Further corroborative evidence may, of course, be available in the form of case 
records (but equally, may not be). A history of atopy, with extraintestinal manifestations 
(dermatitis, urticaria or asthma), or symptoms of an acute illness, (vomiting or diarrhoea) 
which occur shortly after ingestion of the suspected food, increases the likelihood of a 
diagnosis of food allergy. The importance of a family history of atopy, as well as 
personal history, indicates that IgE production in relation to food exposure may be 
subject to inherited patterns of IgE synthesis and regulation (153). Evidence exists to 
point to the inheritance of an isotype specific defect which greatly diminishes the ability 
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to down-regulate an IgE-mediated response (153). However, not all patients who 
experience IgE mediated food allergy give a family history of such reactions. Therefore 
the development of IgE in relation to food exposure is likely to be multifactorial, and not 
a wholly genetically determined phenomenon. 
In spite of its pivotal aetiological role in allergic reactions to foods, particularly with 
reference to mast cell and eosinophil activation, the measurement of total (ie non- 
specific) IgE in the serum is only of limited use in the diagnosis of food allergy. It 
cannot and should not be taken alone as evidence of the presence of a food allergy, or 
indeed, atopy. Host et al did demonstrate that measuring total IgE in the serum of "high- 
risk" neonates was useful in predicting their subsequent risk of atopy (146) but other 
studies have reached conflicting conclusions. Hide et al, measuring total IgE levels in 
umbilical cord blood, was unable to demonstrate any useful predictive value of such 
measurements for atopic risk in neonates, even in the presence of some very high values 
of total IgE (154). 
Those individuals who have specific IgE-class antibodies directed against the suspected 
food in their serum are also more likely to be suffering from truly allergic reactions to 
foods. These cases are, however, in the minority (6,155-159). 
A search for evidence of elevated IgE, or IgE-dependent pathways is the mainstay of 
laboratory investigation into allergies at present. This can be achieved simply with 
minimum discomfort to the patient by means of either RAST in vitro testing of serum, or 
in vivo skin prick testing. RAST was developed in the 1970s to look for specific IgE 
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antibodies in serum to a range of potential allergens. The test has the benefit of allowing 
the testing of subjects who are taking antihistamine medication, removes the need for 
provocation testing and its attendant risk of anaphylaxis. However, a number of reviews 
have highlighted and criticised the poor specificity of RAST testing, and its poor positive 
predictive value (160,161). RAST testing cannot differentiate whether a reaction is due 
to the allergen being tested, or to some cross reactivity between that and another, 
unidentified allergen. In spite of these problems, testing for specific IgE antibodies to 
foods still has an important role. Sampson et al recently prospectively studied sera from 
100 consecutive children and adolescents referred for evaluation of food allergy. Sera 
were analysed for specific IgE antibodies to six common foods using a proprietary 
quantitative immunoassay, the Pharmacia CAP System FEIA®. Results were compared 
with those of a carefully taken food history or oral food challenge. They concluded that 
in the case of symptomatic allergy to egg, fish, peanut and milk, in the paediatric 
population studied, quantification of specific IgE was a useful test for the diagnosis of 
food allergy (162). In particular, using previously determined cut-off levels for specific 
IgE antibodies in serum, RAST testing allowed the clinician to predict correctly the 
likelihood of a child suffering an allergic reaction to a specific antigen on subsequent 
double blind placebo controlled oral challenge with that food in 95% of cases. Of the 
100 children studied, gastrointestinal reactions occurred in 14 of 21 positive egg 
challenges, 10 of 21 positive milk challenges, 13 of 21 positive soy challenges and 9 of 
17 wheat challenges. Sampson suggests that the utility of such testing lies in the ability to 
predict who will react to a food challenge and may in future eliminate the need for time- 
consuming, unpleasant, double-blind, placebo-controlled food challenges in a significant 
55 
number of children. From the available data, in children at least, a positive RAST may 
be seen in two thirds of cases of food allergy manifesting with gastrointestinal symptoms 
when verified by a food challenge. 
Skin prick testing is also useful in evaluating individuals with suspected hypersensitivity 
reactions to foods. This is in effect the in vivo equivalent of the RAST test and detects 
the presence of systemic, not mucosal antigen-specific IgE. As with RAST testing, 
patients with gastrointestinal manifestations of food allergy may have negative skin tests, 
further emphasising the potential role of local mucosal production of IgE in such 
reactions. Liquid preparations of potential allergens, with appropriate controls are placed 
on the skin and a tiny puncture made through these preparations. A positive test is 
indicated by a "wheal and flare" reaction, more than three millimetres in diameter at the 
puncture site. A negative skin test carries a high negative predictive value (>95%), but, 
in common with RAST, a poor positive predictive value (<50%) (163,164). Positive 
results may be used to identify those who require oral food challenges. However, unlike 
RAST, the skin prick test involves further exposure to the putative allergen and so carries 
a potential risk of anaphylaxis to the subject. The combination of this risk and the poor 
postive predictive value of the test means that its use in the diagnosis of food 
hypersensitivity reactions is limited (160). 
IgE-mediated reactions, linked closely to mast cell activation, originally evolved as the 
main protective mechanism against parasitic infestations (165) but other primarily 
protective roles may be important. For example, the dramatic mechanical body responses 
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elicited by IgE/mast cell interaction and activation, such as sneezing, coughing, itching or 
diarrhoea, represent the body's primary defence mechanism against large particles (as 
opposed to bacteria or viruses). In spite of the close functional relationship between IgE 
and mast cells of both the mucosal and connective tissue types, there is little or no 
information available from human or animal studies on correlations between circulating 
levels of IgE and measures of mast cell activation. However, Goldman and Proujansky 
noted positive RAST tests or elevated circulating IgE levels in just over a third of 53 
biopsy proven paediatric cases of allergic proctitis or gastroenteritis, with higher levels 
most often seen in the older children (>2 years) (166). This study is one of the more 
robust in the literature as it uses histologically proven diagnoses as its benchmark and 
thus removes much of the subjectivity which surrounds the field of food related 
gastrointestinal reactions. Whether the elevated levels of specific or total IgE are related 
to activation of eosinophils or mast cells is not discussed. This is most probably because 
any such discussion would be merely speculative, since, at present, no test exists to 
adequately examine or dissect the closely linked, interdependent nature of IgE-mediated 
mast cell and eosinophil activation within the gut. 
Tests for specific IgE antibodies to foods are more likely to be positive when there is a 
history of symptoms which occur rapidly following antigen ingestion, or in patients who 
have other atopic diseases. There are few studies which attempt to correlate the results of 
RAST or specific serum IgE testing with IgE levels in intestinal or other mucosal 
secretions. One study of subjects with house-dust mite allergic rhinitis who had negative 
RAST and skin prick testing, found high levels of specific IgE in nasal secretions (167). 
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Nasal secretion antibody titres did not correlate with serum titres, another example of 
dissociation between systemic and mucosal immune responses. It has been suggested that 
a similar local IgE response is important in the gut. IgE levels have been measured in 
faeces and in the jejunal fluid of children with food allergy and found to correlate poorly 
with levels of circulating IgE (168,169). These findings support the notion that serum IgE 
measurements may be a sub-optimal means of assessing patients with a history 
suggestive of food allergy, and imply that IgE produced locally in the gut ie at the 
mucosal level, is of more significance. However, the validity and reproducibility of the 
faecal IgE assay may be questionable, especially in view of the findings of the Edinburgh 
group. Serial sampling of WGLF revealed negligible quantities of IgA in early, semi- 
liquid stool samples, but higher, reproducible levels when clear WGLF samples (and 
hence, a steady state intestinal perfusate) were obtained (85). Such methods are 
unpleasant for patients and have failed to gain widespread acceptance. It is of interest that 
although these faecal extract studies were performed and published almost 20 years ago, 
the recent American Gastroenterological Association technical review on the evaluation 
of food allergy in gastrointestinal disorders makes no mention of them, far less any 
recommendation to their use in clinical practice (151,152). While this is not a comment 
on their scientific value, and is not intended to dismiss the potential importance of locally 
produced intestinal mucosal IgE, it does reflect their perceived clinical relevance. The 
utility of measuring IgG antibodies to common foods is more debatable and is unlikely to 
represent a pathological response. The production of IgG class antibodies against most 
food antigens is almost certainly a physiological response, which is seldom accompanied 
by any clinically significant reaction in terms of symptoms (17-19,91). However, high 
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levels of food-specific IgG antibodies may be indicative of a pathological reaction 
(170,171) but this is controversial. 
There are enthusiasts for more invasive provocation procedures, where samples of the 
offending food are injected or placed directly onto the luminal surface of the stomach or 
colon (114-116). These do have the benefit of allowing assessment of any potential 
allergic reaction at the mucosal level, as opposed to distant site testing with specific IgE 
in serum or skin prick testing. They are invasive, however, may require general 
anaesthesia for children and do carry a potential risk of severe anaphylactic reaction to 
the test substance. Their use is confined to those centres with a special interest in these 
techniques. 
The gold standard for the diagnosis of food allergy remains the double blind placebo 
controlled food challenge using the suspected food. This was first introduced in the 
1970s (172) but many physicians, parents and patients find it impractical and time- 
consuming. 
2.8.0 Food Intolerance 
These reactions may be defined as any abnormal response to an ingested food. Reactions 
may occur as a result of a direct toxic effect or from a pharmacological property of any 
component of a food. In such cases one might expect that the degree of response will be 
dependent on the dose ingested but this is not always the case. Reactions may also occur 
as a result of some abnormal host metabolic response to the ingested food. Like food 
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allergy, it is a widely held lay-belief that the prevalence of food intolerance is relatively 
high - we have all experienced some foodstuff which does not agree with us - and the 
terms are often used interchangeably. A study of American housewives (173) found that 
one in three believed that at least one member of their household suffered from a food 
allergy. Two British studies reported similar levels of perceived food reactions (174,175). 
The earlier study, by Burr (175), based upon a postal questionnaire answered by 475 
subjects, described that 14% of males and 18% of females reported adverse 
gastrointestinal reactions to foods. Young et al conducted a more rigorous study of 7500 
households in South London and a further 7500 drawn from throughout the United 
Kingdom. Possible cases were initially identified by means of a postal questionnaire, 
followed up by interviews and finally evaluated thoroughly by double blind placebo 
controlled food challenges with cow's milk, hen's egg, wheat, soya, citrus fruit, fish and 
shellfish. The number of respondents in each group was 10552 and 8328 respectively, 
giving an overall reply rate of 52.7%. Of these respondents, 20.4% reported food 
intolerance but, when the results of double blind placebo controlled food challenge with a 
panel of eight foods are taken into account, the true figure is between 1.4% and 1.8%, 
depending on how strictly the authors defined a reaction during the challenge period 
(174). The authors conclude that this discrepancy between true and perceived food 
intolerances may have significant financial and nutritional consequences as individuals 
expend time and money in the search for foods which will not cause adverse reactions, or 
lose weight as a consequence of strict, but unnecessary elimination diets. The prevalence 
of intolerance to food additives is even lower than that of foods (176), which again runs 
contrary to that perceived by the media and the wider public. 
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There is a similar perception among the general public that dietary factors play an 
important role in other gastrointestinal diseases, particularly IBS, but also IBD. But what 
evidence actually exists to support notion that food intolerances may be implicated in the 
aetiology these disorders? 
2.9.0 Role Of Dietary Factors In The Aetiology Of Irritable Bowel 
Syndrome 
IBS is a chronic, non-fatal functional disorder of the intestine. The syndrome is defined 
clinically by the Rome II criteria (177) in individuals who complain of abdominal 
discomfort or pain for at least 12 weeks (which need not be consecutive) over the 
preceding 12 months. The discomfort must also satisfy at least two of the following three 
criteria: (a) relief by defecation; (b) association with an alteration in stool frequency; or 
(c) alteration in stool form. 
Its underlying aetiology remains obscure and is most likely to be multifactorial, involving 
both physiological and psychological factors. It may be thought of as a disorder of 
sensory or motor function (or both) within the enteric nervous system, although no 
consistent abnormalities have as yet been identified. Food sensitivity is commonly 
perceived by patients as a key factor in their symptom complex and has been examined 
by a number of authors over the years (178,179). The main evidence that food 
hypersensitivity may have a role in the aetiology of IBS comes from studies where 
dietary manipulation has been shown to improve symptoms. Alun Jones et al (178) 
conducted three studies on a total of 25 consecutive patients with a clinical diagnosis of 
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irritable bowel syndrome in the absence of any other pathology. In the first study, an 
elimination diet was prescribed in which, all patients were asked to limit their diet to a 
single meat, a single fruit and distilled or bottled water for one week. Of the 21 patients 
who followed the diet, 14 experienced an improvement in their symptoms. They were 
then asked to reintroduce a single food each day to see whether this might provoke 
symptoms. If a food was thought to cause and adverse effect, this challenge was repeated 
on three occasions. Foods described as provoking symptoms included wheat, corn, dairy 
products, coffee, tea and citrus fruits. No patient with a wheat intolerance had Coeliac 
disease as all underwent jejunal biopsy to exclude this condition. Six patients were then 
admitted, and for four days followed a diet free of foods which provoked their symptoms. 
Breakfast on each day was served as a liquidised preparation of a test or control food, in a 
double blind fashion, via a nasogastric tube. The authors describe significant increases in 
levels of prostaglandin E2 (PGE2) in rectal dialysates following administration of test 
foods, not seen on days when control foods were given. There is no mention of whether 
symptoms were provoked on test days in these patients. In a third experiment, rectal 
PGE2 levels were only increased in patients who developed diarrhoea. This complicated, 
time consuming study must have been difficult to perform and presumably recruited a 
number of highly motivated subjects. It does illustrate two interesting points: (a) that an 
elimination diet can be effective in reducing the symptoms of irritable bowel in a 
significant number of patients; and (b) that measurable physiological changes do take 
place in individuals with IBS when re-challenged, in a blinded manner, with certain 
foods. Many patients will have tried their own dietary manipulation prior to consulting 
with medical professionals (180). How much is true allergy and how much is placebo 
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effect is difficult to tease out. The largest trial to date of dietary manipulation was 
conducted in Oxford (181). This trial studied a total of 200 patients, with a marked 
predominance of female subjects (144 female). When subjects were placed on an 
elimination diet, 96 subjects (48%) reported an improvement in their symptoms. 
Improvements were maintained for a mean period of 14.7 months. Of the responders, 73 
were able to identify one or more foods which would provoke symptoms. However, of 
the non-responders, 95/98 still complained of symptoms at the final follow up visit, over 
a year later. We may infer from this that in many, but by no means all, patients suffering 
from IBS, food intolerance may have some part to play. Identification and avoidance of 
that food is likely to give sustained relief from symptoms. 
A multi-centre European study compared the effect of an elimination diet with that of 
treatment with oral disodium cromoglycate, a mast cell "stabiliser, " which inhibits 
degranulation of mast cells and consequent release of inflammatory mediators. In a study 
of 428 patients, they found that 67% of those treated with cromoglycate experienced 
symptomatic improvement, comparable to 60% of those on an elimination diet. Of note 
is the fact that the presence of a positive skin prick test to food allergens predicted a 
greater response to both modes of treatment (75% vs 54% on elimination diet, and 81% 
vs 58% on cromoglycate). This might be expected if predominantly IgE mediated 
mechanisms are at work (182). The results of this study are unusual when one 
remembers that cromoglycate stabilises connective tissue mast cells, and should have no 
effect on mucosal mast cells, the cell population which might be expected to be most 
relevant in intestinal reactions. It is possible that cromoglycate has other actions, 
63 
independent of its effects on mast cells. However, it should be pointed out that although 
this study involved a large number of patients, there was no placebo group against which 
to measure the effects of both interventions. It is impossible to quantify how much of the 
observed benefits arose as a result of a placebo effect. 
Positive skin prick tests, elevated total serum IgE and food-specific IgE (RAST) have 
been cited as evidence that IBS may be caused by IgE mediated mechanisms, particularly 
in atopic patients (183-185). One problem with this hypothesis is that both conditions are 
very prevalent, particularly in the developed world. Therefore, such positive results may 
simply reflect the atopic tendency, as opposed to being central to the pathogenesis of 
intestinal symptoms, in individual patients. In most cases, since the intestine has only a 
limited repertoire of responses to any form of insult, there is tremendous overlap between 
the symptoms of IBS and that of food allergy. This can make differentiation between the 
two conditions difficult. Neri et al, working in Italy, described a group of 288 patients 
attending their clinic complaining of intestinal symptoms. Of these, 99 had IBS and 22 
had food allergy, as diagnosed by elimination diet, skin prick tests and RAST. In this 
study population, at least, symptoms of lower abdominal pain, abdominal pain relieved 
by defaecation, frequent episodes of abdominal pain and abdominal bloating were all 
significantly more likely to be found in those with food allergy compared to those with 
IBS (186). 
In summary, food sensitivity may play an important role in the pathogenesis of irritable 
bowel syndrome in many cases. This is supported by information from elimination diet 
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studies and treatment with mast cell stabilisers such as cromoglycate. The precise 
mechanisms by which this occurs remain uncertain, but IgE mediated mast cell activation 
is likely to play a significant role (10) as it does in atopic conditions like asthma and 
eczema. 
2.10.0 Role Of Dietary Factors In The Aetiology Of 
Inflammatory Bowel Disease 
One of the most commonly asked questions when the diagnosis of inflammatory bowel 
disease (IBD) is first explained to patients in our out-patients department is, "will I have 
to stick to a special diet? " This question more than anything else, serves to highlight the 
link, which exists in the minds of patients and the lay public, between diet and disorders 
of the gastrointestinal tract. Many patients with IBD remark that the clinical course of 
their disease is affected by the food they consume. Such a link may seem intuitive but 
there is surprisingly little evidence to support the idea. There is no clear evidence that 
dietary factors have any influence in the causation of inflammatory bowel disease, but 
some interesting epidemiological points have been noted. Perhaps the best known of 
these is the association between a high intake of refined simple carbohydrates and an 
increased risk of Crohn's disease (187,188). Whether this is a causal association or 
simply an effect of the disease is unclear. McDonald and Fazio conducted detailed diet- 
focussed interviews in 71 patients with Crohn's disease, all of whom had undergone 
some form of surgery (189). They obtained information about the effects of 32 different 
foodstuffs, what dietary advice had been given, who had given that advice and the 
patients' attitudes to food in general. Healthy controls (n=27) were also interviewed. 
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Compared to controls, patients who had had an ileostomy reported significantly higher 
rates of adverse gastrointestinal reactions to carbonated drinks, high in sugar. Only 2/71 
patients felt that foods may be responsible for their disease, but the majority thought that 
dietary factors were important in controlling their symptoms. Stokes described a 
correlation between the incidence of Crohn's disease and national margarine 
consumption (190). Shoda et al (191) demonstrated a correlation between the rising 
incidence of Crohn's disease in Japan and rising dietary intake of animal protein, milk 
protein and total fat, with n-6 polyunsaturated fatty acids a particular association. A diet 
rich in fruit and vegetables may offer some protection from IBD (187,191,192). Kirsner 
et al dismissed the role of reactions to potential food allergens as non-contributory (193). 
However, the precise nature of the association between various foods and IBD is difficult 
to ascertain, not least because all of the published epidemiological studies rely on patient 
recall of a pre-morbid dietary history. When it is borne in mind that many patients may 
have experienced symptoms of intestinal disease for several years prior to their eventual 
diagnosis, the reliability of such histories is cast further into doubt. 
2.11.0 Food Antibodies In Inflammatory Bowel Disease 
Several authors have described increased levels of circulating antibodies to common 
foods in the sera of patients with IBD when compared to normal controls. However, their 
findings are often contradictory. Truelove and co-workers found increased levels of 
antibodies to cows' milk proteins in patients with ulcerative colitis (194). At one time the 
presence of detectable antibodies to milk proteins was thought to represent an aetiological 
link between such proteins and ulcerative cölitis. This was backed up, to some degree, by 
66 
two studies claiming beneficial effects in patients with ulcerative colitis who followed a 
milk free diet. This benefit was shown to be independent of possible secondary lactase 
deficiencies (194,195). Paganelli et al, using more sophisticated techniques, showed that 
these serological findings were not limited to ulcerative colitis, but were also seen in 
patients with Crohn's disease. They found increased levels of antibodies of the IgG and 
IgM classes to the cows' milk protein ß-lactoglobulin in individuals with IBD (196). No 
difference was seen in levels of IgA class antibodies in these groups. Similarly, Knoflach 
et al found increased levels of IgG and IgM class antibodies to five major milk proteins 
(ß-lactoglobulin-A, ß-lactoglobulin-B, a-lactalbumin, casein and bovine serum albumin) 
in a group of patients with inflammatory bowel disease compared to levels in normal 
controls. There was no difference in antibody levels in patients with Crohn's disease 
compared to those with Ulcerative colitis. IgA antibody levels were not significantly 
different (197). An earlier study revealed raised titres of antibodies directed against 
maize in the sera of patients with Ulcerative colitis, Crohn's disease and Coeliac disease 
(198). These studies span several decades and different techniques such as RIA and 
ELISA were employed to detect antibodies. In view of this, direct comparisons are 
unhelpful. The finding by Knoflach of no significant differences in levels of IgA 
antibodies in sera of IBD patients (197) compared with normal controls is of some 
interest. It is known that in the normal intestine, the majority of lamina propria plasma 
cells secrete IgA. IgA is protective against luminal pathogens, does not fix complement 
and does not excite an intense inflammatory reaction. In contrast, in the setting of 
inflammatory bowel disease, lamina propria plasma cells have been shown to switch to 
secreting IgG. This switching is thought to represent terminal differentiation of plasma 
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cells. IgG can fix complement and is capable of activating natural killer (NK) 
lymphocytes and phagocytes and hence may contribute to intestinal inflammation. 
These studies all measured levels of antibodies in serum, which may not reflect what is 
happening at the level of the intestinal mucosa. Hoque et al studied the levels of IgA 
antibodies to bacterial cell wall components and to ovalbumin in whole gut lavage fluid 
from healthy volunteers in Edinburgh and Dhaka. Antibody levels to the core 
oligosaccharide of bacterial lipopolysaccharide from several Gram-negative species were 
significantly higher in the Dhaka group, while antibodies to ovalbumin were higher in the 
Edinburgh group (199). In populations where there is a reduced exposure of the intestinal 
immune system to enteric pathogens, there may be generation of inappropriate immune 
responses to dietary antigens. In turn, this may have implications for the development of 
inappropriate intestinal inflammation. 
Observations that patients suffering from inflammatory diseases of the intestine, such as 
Crohn's disease and Ulcerative colitis, had elevated serum levels of antibodies directed 
against various common food components were of moderate interest in their own right. 
However, no obvious differences in the level of expression of antibodies between these 
two phenotypically different inflammatory bowel diseases had been demonstrated. 
In 1988, Main et al (81) working in Aberdeen, published the first report of increased 
levels of circulating antibodies to Saccharomyces cerevisiae, an organism found in 
bakers' and brewers' yeast, in the sera of patients with Crohn's disease but not those with 
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ulcerative colitis. In their original paper, Crohn's patients were found to have 
significantly elevated levels of IgG antibodies, detected by ELISA, directed against the 
organism when compared with results from ulcerative colitis patients and normal 
controls. They hypothesised that this may indicate a pathological response to this 
organism, which by its use in the processes of both baking and brewing, was likely to be 
found in a wide variety of foods central to a modern, Western diet. Here was a 
possibility, once again, that a hypersensitivity reaction to a common foodstuff might be 
implicated in IBD, in this case, specifically Crohn's disease. 
In a subsequent paper, these authors set out to investigate whether their original findings 
were exclusive to S. cerevisiae, or if they could be extended to other yeast strains. Using 
similar methodology, they examined the antibody response to 12 commonly used strains 
of S. cerevisiae and to Candida albicans, types A and B. These Candida strains are the 
two commonest serotypes found in the human digestive tract, in up to 50% of normal 
healthy individuals and in a higher proportion of hospital in-patients (200). They found 
increased levels of serum antibodies to S. cerevisiae, in all but one of the 12 strains 
studied, in Crohn's disease patients, compared with ulcerative colitis patients and normal 
controls. There was no difference seen in the levels of antibodies expressed against the 
remaining strain of S. cerevisiae, nor in antibodies against either strain of C. albicans. 
The authors inferred from these data that the increased antibody levels to S. cerevisiae 
could not be explained simply on the basis of increased intestinal permeability and hence 
increased exposure of the intestinal immune system to luminal antigens. This was 
evidence of a selective antigenic response to S. cerevisiae in patients suffering from 
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Crohn's disease. Further characterisation of the antigenic response and cross reactivity 
between these 12 strains of Saccharomyces and C. albicans was performed by cross- 
absorption testing of antibodies from the serum of a single Crohn's patient. In addition, 
cross-reaction experiments between Saccharomyces and Candida were carried out using 
sera of eight different Crohn's patients. This revealed considerable antigenic 
heterogeneity between the different strains of Saccharomyces. There was also a limited 
degree of cross reactivity between the different Saccharomyces strains and Candida 
albicans. This lends support to the notion that the anti-Saccharomyces cerevisiae 
antibodies (ASCA) were directed against multiple antigens. It is possible that S. 
cerevisiae itself may play an important aetiological role in Crohn's disease, rather than 
simply acting as an innocent bystander which, by coincidence, shares an epitope with the 
true, as yet unidentified agent. One potential weakness of these studies was the failure to 
use another control group with a different type of intestinal disease (e. g. Coeliac disease), 
or a different inflammatory disease (e. g. Rheumatoid arthritis), to determine whether 
ASCA positivity is exclusively a feature of Crohn's disease. Later work did reveal 
increased antibody levels in patients with Coeliac disease but to a lesser degree than that 
seen in Crohn's (N. Reynolds, personal communication). McKenzie correctly predicted 
that the antibody response was directed against mannan residues (201), a common 
antigenic component of both yeast and mycobacterial cell walls. He also hypothesised 
that the unidentified aetiological agent might be an atypical mycobacterium which 
supported another theory on the possible aetiology of Crohn's disease (202). 
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Several other groups reproduced these results but found wide variations in the 
antigenicity of different strains of Saccharomyces cerevisiae, as well as variation in the 
degree and nature of individual patients' antibody response (203,204). Using 
Saccharomyces cerevisiae uvarum 1 (a strain related to that rogue non-responding twelfth 
strain in earlier work), Sendid confirmed McKenzie's hypothesis that the ASCA response 
was indeed directed against mannose sequences in the cell wall. Crude mannan extracts 
from this strain were used as the coating antigen in an ELISA in which a positive ASCA 
result was shown to be 64% sensitive and 77% specific for Crohn's disease (205). This 
same group also undertook a larger study of the relationship between ASCA and Crohn's 
disease in 1998. In this study, involving a total of 391 patients and controls, they 
examined the utility of a combination of ASCA and perinuclear anti-neutrophil 
cytoplasmic antibodies (p-ANCA) for the diagnosis of Crohn's disease and ulcerative 
colitis. p-ANCA are produced by B-cells in the colonic mucosa and react with a nuclear 
envelope protein of neutrophils, giving perinuclear "highlighting" on indirect 
immunofluorescence. They are a useful serological marker of ulcerative colitis but are 
also found in a subgroup of patients with Crohn's colitis (206). They are not, however, 
raised against food components. Quinton et al (207) looked at ASCA and p-ANCA 
expression in the sera of 100 Crohn's disease patients, 101 ulcerative colitis patients, 163 
healthy members of hospital staff and 27 other disease control patients. This final control 
group was made up of patients with a variety of diarrhoeal diseases, including 
microscopic colitis, schistosomiasis, infectious colitis and a single patient with Coeliac 
disease. Results showed that IgA, IgG or IgM antibody classes of ASCA were positive in 
61/100 Crohn's disease and 12/101 ulcerative colitis patients. This gave ASCA a 
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sensitivity of 61%, a specificity of 88% and a positive predictive value of 89% for 
Crohn's disease. The authors do not mention in the paper what combination of positive 
IgA, IgG or IgM results was taken to be an overall positive result. Compared to those 
with a negative result, ASCA positive Crohn's patients were significantly more likely to 
be diagnosed at an earlier age (median age 21 years, range 10-59 vs 24 years, range 15- 
47, p<0.05). Of those with a positive ASCA result, 62% had small bowel disease alone, 
46% had colonic disease alone and 74% mixed small bowel and colonic disease. There 
was no relationship between disease activity as measured by Crohn's disease activity 
index (CDAI) and a positive ASCA result. A multivariate analysis showed that only the 
presence of small bowel disease was significantly associated with positive ASCA (odds 
ratio 2.7,95% Cl 1.1-6.7, p<0.027). Only one of the healthy control patients had a 
positive ASCA. However, there were three positive results amongst the non-1131) 
inflammatory disease control group: one patient with eosinophilic colitis, another with 
radiation proctitis and the third had sarcoidosis (207). 
There has been great commercial interest in the diagnostic potential of ASCA in IUD, 
especially when used in combination with p-ANCA as an aid to differentiating between 
Crohn's disease and ulcerative colitis. At least four commercial ELISA kits are now 
available, all using subtly different components of the S. cerevisiae organism as the 
coating antigen. These are marketed as office based tests to help the clinician distinguish 
between the two diseases. In another large series, Vermiere et al (208), analysed sera 
from 100 Crohn's disease patients, 100 ulcerative colitis patients, 100 healthy controls 
and a further 78 non-IBD controls from their local population, based in North Belgium. 
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This study was a serious attempt to compare the sensitivities, specificities and positive 
predictive values of all ASCA and pANCA tests in a large cohort of inflammatory bowel 
disease patients. They critically inspected the results from the four available commercial 
ASCA ELISA kits. There was wide variation in the sensitivities calculated using 
different kits, ranging from 41% to 76%. Specificity was inversely related to sensitivity. 
There was good overall correlation between IgG and IgA ASCA results in all four assays 
and the interassay receiver operating characteristic (ROC) curves also correlated well. 
These correlations indicate that there were no differences in the overall performance of 
all the tests and that the four manufacturers had validated their individual assay cut-off 
values in similar ways. However, it appeared that different manufacturers had settled on 
different cut-off values depending on whether a more specific (higher value) or sensitive 
(lower value) test was required. In contrast to Quinton, Vermiere did not find any 
relationship between the presence of ASCA, age at onset or site of disease. As seen in 
the French study, there was no relationship with disease activity. The authors advocate 
caution in the use and interpretation of these tests and call for standardisation of assays. 
They conclude that ASCA may be of use in differentiating between Crohn's and 
ulcerative colitis but is not sufficiently sensitive to be used to screen for the presence of 
Crohn's disease in a population. 
The use of ASCA as a diagnostic tool has been largely motivated by the search for a non- 
invasive, reliable means of diagnosing IBD, and differentiating between Crohn's disease 
and Ulcerative colitis, but also by financial concerns. It does, however, mark a shift 
away from interest in the precise aetiological role of S. cerevisiae in Crohn's disease. 
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This is in spite of the fact that the exact origin of these antibodies and the significance of 
their presence remains far from clear. Two groups have studied relatives of Crohn's 
patients and described increased expression of ASCA in the sera of both affected and 
unaffected family members (209,210). This would support a genetic basis for the 
expression of these antibodies, but this has yet to be described. Reviewing this subject 
recently, Rutgeerts reminded us that the gene for ASCA is known to be associated with 
the tumour necrosis factor microsatellite haplotype Al 1B4C1D3E3. This suggests that a 
gene involved in ASCA expression may be present in the human leucocyte antigen 
(HLA)-region on chromosome 6 (211). It is still not certain whether the finding of a 
positive ASCA result represents the cause or is simply an effect of Crohn's disease. 
2.12.0 Nutritional Therapy Of Inflammatory Bowel Disease 
Perhaps the most compelling evidence that dietary components are implicated in 
inflammatory bowel disease, particularly Crohn's disease, is the effect of dietary therapy 
in this disease. Even if specific dietary factors may be of secondary importance in the 
causation of inflammatory bowel disease, nutrition forms a vital part of their treatment, 
either as an adjunct to other forms of therapy, or indeed, as a primary therapy in its own 
right. 
Gassul et al report that up to 85% of patients admitted to hospital for the treatment of a 
relapse of their IBD had evidence of protein energy malnutrition (212). Gee et al 
described evidence of protein-energy malnutrition in 23% of outpatients with Crohn's 
disease, judged by biochemical and anthropomorphic data (213). Furthermore, weight 
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loss, anaemia, deficiencies of vitamins A, D and E, magnesium, calcium and zinc are all 
well described in patients with Crohn's disease (214-220). Growth failure and delayed 
sexual development have been reported in between 25 and 40% of children with Crohn's 
disease (215,218). In spite of knowledge of these problems, recording of basic data in an 
affected child's medical records, such as height and weight, has been shown to be poor 
(221). Careful attention to the detection and treatment of specific nutritional deficiencies 
as well as ensuring an adequate caloric intake forms a vital part of the management of 
patients with Crohn's disease. 
Surgical data from the 1970's supported the use of perioperative feeding with an 
elemental diet to improve outcomes of surgery in patients with inflammatory bowel 
disease (222) and prompted the authors to ask whether nutritional measures may have a 
role to play as a primary therapy in Crohn's disease. 
Approximately 30 trials of the use of total parenteral nutrition (TPN) as primary therapy 
for inflammatory bowel disease have been published and reviewed in detail by Greenberg 
(223). Most of these trials are retrospective or contain small numbers of patients who 
differ widely with regard to disease extent and activity. The criteria used for a definition 
of remission are also variable. There are eight prospective trials involving a total of 170 
patients with Crohn's disease (224-231). Patients were treated with "bowel rest" and 
TPN for between seven and 84 days. Of these 170 patients, 137 (81%) achieved some 
form of initial clinical remission. However, at follow up, ranging between 12 and 64 
months, only 23/102 patients remained in remission. The results are even less striking in 
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ulcerative colitis. In all, 38 patients were studied in three trials (224,225,230), only 42% 
achieved an initial remission and only 11% remained in long-term remission over a 
follow up period of 16 to 64 months. Muller et al described initial remission in 25/30 
(83%) patients with Crohn's disease treated with TPN for 84 days (231). However, 60% 
of these had suffered a relapse within two years of treatment, a rate four times higher than 
that seen in a historical cohort of patients treated surgically in the same institution. The 
actual efficacy of TPN is likely to be even less than the figures quoted as four of the trials 
in Crohn's disease (224,226,228,230) and two of the ulcerative colitis studies (224,230) 
allowed concomitant treatment with corticosteroids or azathioprine, while two studies did 
not report whether other forms of therapy were employed (225,229). 
Interest in using supplemental enteral feeding in Crohn's disease began in the 1960's 
when low residue, defined formula liquid diets were developed for the United States 
space programme. In an uncontrolled study in 1973, Voitk (222) et al observed that 
several patients who were taking elemental diet while awaiting surgery experienced an 
improvement in their symptoms as well as their nutritional status. Unfortunately, no 
patient avoided surgery in this group. The use of these diets became more widespread on 
the strength of that report, even though it was an uncontrolled study. Defined formula 
liquid diets are usually categorised by their nitrogen source and are described as 
elemental, where dietary nitrogen is a mixture of amino acids, or as oligo-peptide, a 
mixture of short peptides, or polymeric, where nitrogen is provided as whole protein. 
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Many possible theories, over and above simply correcting nutritional deficiencies, have 
been put forward to explain the efficacy of defined-formula diets. These include the 
exclusion of dietary antigens, thus decreasing the presentation of potentially antigenic 
stimuli in whole food, alteration of intestinal bacterial flora, decreased entero-hepatic 
circulation of bile salts (232), decreased synthesis of inflammatory mediators, and 
provision of specific intestinal nutrients, including glutamine (233). It is increasingly 
likely that the fat composition of the diet may be more important than the nitrogen 
source. Diets containing fish oils (omega-3 fatty acids) may compete for substrate in the 
lipo-oxygenase pathway and so favour the production of a less potent inflammatory 
mediator (234). Diets which contain low levels of the proinflammatory eicosanoid 
precursor, linoleic acid, may also have some anti-inflammatory role (235). Defined 
formula liquid diets have never been tested against placebo as it has been considered 
unethical to knowingly offer placebo to patients with active Crohn's disease. However, 
two meta-analyses (236,237) and a recent Cochrane review (238) have examined two 
main issues in the treatment of active Crohn's disease with enteral nutrition; firstly, the 
comparative efficacies of enteral nutrition and corticosteroids, and secondly, the 
comparative efficacies of different formulations of enteral nutrition based upon their 
nitrogen source. 
Griffiths et al (237) brought together eight randomised controlled trials of enteral 
nutrition vs corticosteroids, involving 413 patients. They concluded that enteral nutrition 
was the inferior treatment (pooled odds ratio, 0.35; 95% confidence interval, 0.23-0.53). 
Fernandez-Banares (236) considered a total of 16 randomised trials and calculated pooled 
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odds ratio for all types of enteral nutrition vs corticosteroid therapy as 0.35 (95% Cl, 
0.23-0.53). This study found peptide-based diets to be significantly inferior to 
corticosteroids (pooled odds ratio 0.32,95% CI, 0.20-0.52) with only a trend towards 
poorer remission rates with elemental diet than with steroids (pooled odds ratio 0.44, 
95% CI, 0.17-1.12). Zachos et al (238) examined six trials, including two abstracts 
(239,240) which satisfied their inclusion criteria. The four published papers (241-244) 
included a total of 253 patients with active Crohn's disease (130 treated with enteral diet 
and 123 with corticosteroids). Meta-analysis showed a pooled odds ratio of 0.30 in 
favour of treatment with corticosteroids (95% CI: 0.17,0.52). The number needed to 
treat (NNT) with corticosteroids to achieve one remission was four. 
These studies confirm that corticosteroid treatment is superior to enteral diet as a primary 
therapy for achieving initial remission in Crohn's disease. This remains the case even 
when allowing for the considerable numbers of patients who dropped out from the enteral 
diet arms because of difficulties tolerating the feed. Most trials using defined-formula 
enteral diet reflect the situation in clinical practice with a relatively high dropout rate as 
subjects are unable to tolerate either the feed or the naso-enteral tube. Using a 
questionnaire administered to 89 patients receiving a total of 147 treatments with enteral 
diet, Teahon et al (245) recorded the reasons given by patients for intolerance to dietary 
therapy. Sip feeding was tolerated by 85% but the remainder required nasogastric tube 
feeding. The most frequently cited problem was the sheer volume of fluid consumed 
daily. Nausea and postural hypotension were common in the first few days of treatment. 
However, after the first week, only six of 89 patients questioned felt that the taste of the 
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preparation was a significant problem. It is interesting that in spite of all the perceived 
problems with dietary therapy, two thirds of patients stated they would choose the same 
treatment again. 
One possible method of action for elemental diet is through a reduction in antigen load 
delivered to the intestinal lumen by virtue of their lack of whole proteins or peptides. 
Polymeric diets tend to be more palatable than elemental, but does the presence of whole 
protein reduce their clinical efficacy? 
Griffiths (237) reported on five trials with a total of 134 patients, studying elemental vs 
non-elemental formulae. No difference in effect was noted (pooled odds ratio 0.87, 
95% CI, 0.41-1.83), a finding confirmed by Fernandez-Banares (236) who showed a 
pooled odds ratio for polymeric vs elemental diets of 1.28 (95% CI, 0.40-4.02). In the 
Cochrane review, 11 trials (including one abstract) comparing different formulations of 
enteral diet met predetermined quality criteria for inclusion in the study. Of these, 10 
(246-255) compared one or more elemental formulations with a non-elemental 
formulation while the eleventh trial compared two non-elemental, polymeric diets which 
differed only by glutamine enrichment in one arm of the trial (256). The primary analysis 
did not include this study or the abstract. Meta-analysis of the remaining nine studies 
involving a total of 298 patients with active Crohn's disease (170 patients treated with 
elemental diet and 128 with non-elemental diet) showed no significant difference in rates 
of remission between the different formulations of diet [OR 1.15 (95% CI: 0.64,2.08)]. 
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Elemental and non-elemental diets are equally efficacious in the primary treatment of 
active Crohn's disease but inferior to treatment with corticosteroids. Patients find the 
diets difficult to tolerate which leads to a high rate of attrition. This can be avoided to 
some extent by the use of nasogastric tubes or gastrostomy feeding. The mode of action 
of enteral feeding is unclear but does seem to involve more than simply improving 
nutritional status. 
The relationship between diet and Crohn's disease activity is likely to be more complex 
than we think. Although corticosteroids have been shown to be superior to enteral diets 
in achieving remission, diet may have a more important role to play in maintaining 
remission. In children, supplemental feeding with enteral diet after induction of 
remission can help to maintain remission (257). A controlled study from Cambridge 
showed that, once remission has been achieved, by use of either TPN or elemental diet, 
patients treated with an exclusion diet, were more likely to remain in remission over six 
months follow-up than those allowed an unrestricted diet (258). Of the 10 patients in the 
exclusion diet group, where a single food was reintroduced each day, and subsequently 
avoided if it provoked symptoms, seven remained in remission at six months, compared 
to no patient out of 10 who ate an unrestricted diet rich in unrefined carbohydrate fibre. 
This was followed by a multicentre study in which 136 patients with active Crohn's 
disease were started on an elemental diet. Of the 93 who persevered with the diet for two 
weeks, 78 (84%) achieved remission and were randomised to either a 12 week tapered 
course of prednisolone or an exclusion diet with a similarly "tapered" placebo. After two 
years of follow-up, the median length of remission in the corticosteroid group was 3.8 
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months (interquartile range 5.0 months) compared to 7.5 months (15.3) in the diet group. 
There was a significant difference in relapse rates, adjusted for withdrawals, at two years 
(79% and 62% for the respective groups [p=0.048] (259)). 
2.13.0 Conclusions 
The general public perceives food allergy and food intolerance as one and the same thing. 
This is not surprising as the symptoms can be very similar, overlapping with those of 
IBS. The public also see food allergy and intolerance as a much more common problem 
than is actually the case. The diagnosis of food allergy, with gastrointestinal 
manifestations, is largely clinical. It is made more likely by features in the history such 
as an illness of acute onset, temporally associated with ingestion of the offending 
foodstuff, a personal or family history of atopic disease, the presence of other, extra- 
intestinal features of allergy such as dermatitis, wheezing or skin rashes, particularly 
urticaria. Limited in vitro testing using RAST to detect specific IgE class antibodies to 
implicated foods or in vivo testing with skin prick tests help to confirm the diagnosis. 
Other in vitro tests are unlikely to be helpful. The gold standard, for now at least, remains 
double blind placebo controlled challenges with the offending food but these are time- 
consuming and unpleasant for the patient. In a significant minority of cases, the 
symptoms if IBS may be alleviated by avoidance of specific foods. This, however, does 
not imply a true allergy. Nutritional issues are vitally important in the therapy of IBD, 
particularly Crohn's disease, as part of a holistic approach to the management of a 
malnourished, anorexic patient. However, specific nutritional therapy is inferior to 
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conventional corticosteroid therapy in terms of inducing remission of disease, but may be 
of more relevance in the maintenance of that remission. 
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Chapter 3- Methods 
Ethical Approval 
The Lothian Medicine and Oncology subcommittee of the Ethics in Research Committee 
granted ethical approval for this study (Appendix 4). A number of ethical issues required 
consideration prior to commencing this study. In particular, since all the individuals 
concerned were volunteers, and apart from their reaction to mycoprotein, fit and well, it 
was vital to ensure that no affected subject would be exposed to any potential health risk 
by taking part in any aspect of the study. This was particularly relevant with respect to 
healthy volunteers being subjected to invasive investigations. Any intervention 
undertaken had to be not only safe, but also relevant to the aims of the study and likely to 
produce results which were meaningful and from which firm conclusions could be drawn. 
Furthermore, the degree of intervention proposed had to be appropriate for the likely 
benefit accruing to either the participants or to the greater good. To expose a healthy 
volunteer group to interventions falling short of these requirements would not have been 
ethical. With these points in mind, upper gastrointestinal endoscopy, gastric emptying 
studies and WGL were proposed as appropriate investigations. Subjects were not being 
exposed to novel, hitherto undescribed procedures. The utility of endoscopically 
delivered food challenges have been widely described in the literature, even if they have 
not gained widespread acceptance (114,116,260), and a similar situation holds true for 
WGL (84-88,261). 
Informed consent was vital and so detailed information was made available to potential 
participants regarding a description of the nature of each procedure and the risks 
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associated with each of them. These ranged from the risks of pain and bruising following 
venepuncture, through to the potential complications of upper gastrointestinal endoscopy 
under sedation. The use of a "stepped" approach to investigation allowed subjects to 
choose the level to which they wished to participate. Further written information on 
more invasive tests was only given if subjects expressed a wish to consider participating. 
At each step it was made clear that subjects could withdraw at any time. Failure to reply 
was seen as implicit evidence of a wish to withdraw their consent to participate further, 
and no further attempts to contact the subject was made, thus respecting their wish for 
privacy. 
All subjects were volunteers and none received any payment in cash or in kind from the 
investigators for their participation. Those who agreed to travel to Edinburgh had all 
their travelling and accommodation expenses paid for and were not left out of pocket. 
Subjects were under no compulsion to take part other than their own desire to participate 
and were free at any time to withdraw their support for the study. 
Our hope was to recruit six patients for each of the invasive studies, and six for WGL if 
serum studies suggested an immunological basis for the adverse reactions. No formal 
power calculation was made however, and the decision to recruit six individuals was 
based on the knowledge that this is the minimum number required in a group to show a 
statistically significant difference before and after an intervention. 
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The potential risk of an overwhelming anaphylactic-type reaction to mycoprotein on re- 
exposure was the most serious risk to be considered. Information was available on the 
type of initial reaction suffered for each subject who had replied to the questionnaire. To 
minimise the risk of precipitating a further reaction, it was decided in advance that no 
subject who had experienced an anaphylactic-type reaction would be exposed to 
mycoprotein again. Many subjects who had experienced the vomiting reaction described 
a self-administered mycoprotein challenge which had finally alerted them to the 
possibility that their symptoms were due to the food. There were no reports of serious 
adverse events following these challenges, suggesting that further challenge was a safe 
intervention. 
It was also felt that to use a double blind placebo controlled food challenge, which would 
mean exposure of volunteer subjects to mycoprotein in the expectation of reproducing the 
vomiting reaction, would not be appropriate. This is because although the challenge 
would prove (or disprove) that mycoprotein could provoke such a reaction, it would not 
offer any useful information on the mechanism of the reactions produced. Volunteer 
subjects would be exposed to the potential harm of mycoprotein, in terms of vomiting 
and a potential risk of anaphylaxis, without deriving any benefit in terms of elucidating a 
mechanism for the reaction. Double blind placebo controlled food challenges are very 
useful in making a diagnosis of food allergy or intolerance but are time consuming, and 
unpleasant for physicians and patients alike. A similar case can be made for avoiding the 
use of skin prick testing although a positive test might indicate whether an immediate or 
delayed type hypersensitivity reaction was implicated in the aetiology of the reaction. 
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Furthermore, the relevance of skin prick test results to reactions occurring within the gut 
is controversial. As previously discussed RAST testing offers a non-invasive means of 
identifying antigen specific-IgE in serum without exposing subjects to a potentially 
harmful direct antigen challenge. However, the specificity and positive predictive value 
of RAST is poor, and an excess of false positive results is obtained. As a result of these 
problems, along with the lack of an available RAST for mycoprotein, it was decided to 
avoid RAST testing in the present study. 
In view of the small, but significant radiation exposure involved in the use of two, back to 
back isotope gastric emptying studies, only male subjects or females who were no longer 
of child-bearing age were considered for this aspect of the study. The amount of 
radiation exposure involved was described to subjects in as near to layman's terms as 
possible, by reference to radiation exposure in comparison to a standard postero-anterior 
chest radiograph. 
Only subjects who were medically fit to undergo two, back to back upper gastrointestinal 
endoscopies, under intravenous sedation were considered for this aspect of the study. 
Subjects were assessed on arrival in Edinburgh to ensure that this was indeed the case. 
All endoscopies were performed by a single endoscopist, experienced in the procedure 
and in administration of intravenous sedation. Full facilities were available for 
resuscitation in the event of an anaphylactic reaction. Continuous oxygen therapy was 
administered by nasal sponge throughout the procedures and vital signs were monitored 
by pulse oximetry. 
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3.1.0 Subject Recruitment and Questionnaire 
Individuals who had suffered adverse reactions after eating products manufactured from 
mycoprotein initially contacted Marlow Foods Ltd. This initial contact took the form of 
letters or telephone calls from the affected individual, giving a brief description of what 
had happened and often enquiring whether any other consumer had experienced similar 
problems. Marlow Foods Ltd. then contacted each individual, asking them to give more 
details of the problem including what precisely had been consumed and whether alcohol 
had been taken along with the product. This information was recorded on a pro forma in 
an attempt to create a standard data set. 
A total of 140 consecutive cases were prospectively collected by the Customer Relations 
staff at Marlow Foods Ltd, between January 1997 and December 1997 and their details 
passed to the Gastrointestinal Unit, Western General Hospital, Edinburgh. These include 
all "complaints" relating to adverse reactions to mycoprotein received by the company 
during that 12-month period. In subsequent years, the number of reports of adverse 
reactions has peaked and remained stable at 200 cases per year. The information 
contained within these 140 pro formas acted as a starting point for the study. However, it 
soon became apparent that there was considerable variation in the quantity and quality of 
information available from such a source, with even basic details, such as date of birth 
and gender, absent in some cases. It was therefore necessary to construct a standard 
dataset consisting of the relevant demographic and clinical details of each individual 
case. In order to obtain the information required, a short questionnaire was devised 
(Appendix 1). 
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Questionnaires have been widely used in medicine in general, and in the field of allergic 
disorders in particular, to collect data from large groups of individuals. They are cost 
efficient and allow investigators to obtain information from the patients' own perspective 
of the experiences and symptom history. The information obtained from a well designed 
questionnaire can be useful for documenting the burden of an illness across a given 
population, or for investigating health service utilisation rates for specific diseases. 
However, there are a number of general problems associated with the use of 
questionnaires to obtain clinical information. They allow a degree of subjectivity in 
terms of a respondent's description of a symptom or event for which it is difficult to 
control. All questionnaires are subject to recall bias on the part of the respondent, and, by 
the use of "loaded" or "closed" questions, may be subject to bias in terms of responses 
favored by the investigator. For example, a respondent's memory of symptoms or events 
may be patchy, or may be skewed by other personal factors, not always pertinent to the 
matter under investigation, but nonetheless important to the individual. Similarly, vital 
details may be forgotten or misinterpreted. Some respondents feel obliged to give an 
account of events which they feel is expected by the investigator rather than a true 
representation of what actually happened. 
However, all medical consultations revolve around the acquisition of information from 
the patient by the physician. We have to accept that any information obtained in taking a 
medical history is subject to the same recall bias as that obtained by means of a 
questionnaire. Questionnaires tend to replicate the methods employed by physicians to 
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acquire the necessary information to formulate a diagnosis during a consultation. 
Interviewer administered questionnaires seek to remove some of the subjectivity 
associated with self-administered questionnaires but run the risk of introducing further 
bias by the interviewer. 
It was decided that to travel to all affected subjects to administer a structured 
questionnaire would be time consuming and an inefficient use of resources. Instead, a 
self-administered questionnaire would be posted to all affected subjects. In order to be a 
useful tool, a questionnaire has to be written and presented in terms which are easily 
understood by the respondent, and relatively short to encourage compliance. It must also 
ask questions which are relevant and valid in relation to the underlying problem. 
Furthermore, the answers received from respondents should be repeatable or 
reproducible. 
There is no validated questionnaire in existence which explores the prevalence and nature 
of adverse reactions to mycoprotein. There are a number of validated questionnaires 
which are pertinent to atopic diseases such as asthma and allergic rhinitis and these have 
been used extensively in the study of the prevalence of such disorders across the world 
(262-264). However, meaningful and useful studies of atopic disorders have been 
performed which utilised short, simple and easily-understood, self-administered 
questionnaires (265,266). Even with well-validated questionnaires, controversy exists as 
to whether they alone can adequately measure disease prevalence or give sufficient 
epidemiological information to comment on clinically important risk factors (267). 
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Two large population-based studies of food intolerance in the United Kingdom had been 
published at the time of this study (174,175), one supported by the Medical Research 
Council. Both used simple, short and easily understood questionnaires which asked 
"open" questions on perceived food intolerances such as, "do any foods make you ill? ", 
in addition to enquiring about past or family history of atopic disease in terms of a 
doctor's diagnosis of "asthma", "eczema" or "hayfever". 
The questionnaire devised for this study was based on that employed by Young et al 
(174), in her study of almost 20,000 individuals which asked standard questions directed 
to a personal or family history of atopy and past medical history. It took the form of a 
standard medical history, based around the pertinent details in a history suggestive of an 
allergic reaction. The mycoprotein study involved an alleged reaction to a specific 
foodstuff, and so the primary aim of the questionnaire was to elicit more detailed 
information regarding the precise nature of the reactions suffered. The questionnaire, 
therefore, began with an "open" question, asking for a description of the individual's own 
experience of the reaction, in order to avoid the investigator bias which a series of 
"closed", symptom-directed questions might introduce. 
A subject was included in the atopic grouping if they answered in the affirmative to 
having a pre-existing diagnosis of "asthma", "eczema or dermatitis" or "hayfever". 
Other details included the subjects' age, gender and address, as well as details of each 
General Practitioner (GP) to allow contact to be made for the purpose of collecting blood 
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samples. Most attention was given to a precise account of the reaction suffered including 
the temporal relation to ingestion of mycoprotein and the amount of mycoprotein 
consumed. In addition, details of subjects' past medical history were sought with 
particular reference to history of allergy or atopic diseases, drug history, family history 
and details of tobacco and alcohol consumption. The questionnaire also inquired whether 
individual subjects would agree to have a blood sample taken locally by their own 
General Practitioner to be sent to Edinburgh for antibody testing (as described in 2.3.11). 
In a pilot study, 10 individuals, comprising members of medical and non-medical staff 
within the Gastrointestinal Unit filled in questionnaires to assess for general comments 
regarding the ease of comprehension and the relevance of questions being asked. No 
significant changes required to be made to the questionnaire following this exercise. 
All affected subjects were assigned a sequential identification number (1-54) as their 
blood samples arrived in Edinburgh. Whole blood samples were centifuged and the 
serum removed and frozen at -20°C in 100 µl aliquots awaiting analysis. 
All questionnaires were sent by post to the addresses given in the original Marlow Foods 
pro forma. A stamped, self-addressed envelope was enclosed. In addition a letter was 
sent to each subjects' GP, containing an explanation of the study, a venepuncture kit and 
a small honorarium (a cheque for five pounds sterling) for taking and returning the 
sample. 
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If no reply was received within a period of four weeks, no further mailing or attempts to 
contact subjects was made. Since this was entirely a volunteer study, involving subjects 
who were otherwise fit and well, an initial failure to reply was taken as implicit evidence 
of a wish not to participate further. All information thus obtained was stored on a 
Microsoft Access® database. 
A stepwise approach to investigation was used. Those subjects who did agree to send a 
blood sample were approached again by post to ask if they would consider giving up 
more of their time to travel to Edinburgh to undergo a more invasive investigation, such 
as upper gastrointestinal endoscopy, whole gut lavage or isotope gastric emptying 
studies. The procedures themselves along with the rationale for performing them were 
explained in detail in these letters. 
3.2.0 Selection of Normal and Disease Controls 
After a full explanation of the nature of the study, fresh serum samples were obtained 
from healthy laboratory volunteers (n=14), or permission was obtained to use stored, 
frozen sera. Disease controls were chosen from a storage bank of samples from 
individuals undergoing investigation of gastrointestinal disorders in the Gastrointestinal 
Unit, Western General Hospital, Edinburgh. This consists of paired samples of serum 
and whole gut lavage fluid (WGLF), stored at -70°C. Sera from patients suffering from 
Crohn's disease (n=22), ulcerative colitis (n=17) and Coeliac disease (n=15) were 
obtained. As far as possible, attempts were made to match the ages and sex of the 
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controls to the affected subjects. However, due to the limited availability of stored sera 
this was often not possible. Details of diagnosis, date of whole gut lavage procedure and 
results of levels of IgG, a-1 antitrypsin, albumin and haemoglobin are all held on file in a 
Microsoft Access® database. Using this information it was possible to assess the 
presence or absence of intestinal inflammation in each of the IBD-control patients. 
Normal ranges for IgG (<10µg/m1), albumin (<26pg/ml), a-1 antitrypsin (<I9pg/ml) (89) 
and haemoglobin (1-5µg/ml) (261) in WGLF had been established previously. Active 
IBD was defined by the presence of increased levels of these inflammatory markers in 
whole gut lavage fluid. This has been shown to correlate well with other markers of 
disease activity such as the Crohn's disease Activity Index (CDAI) (89,261). 
3.3.0 Development of an ELISA for measurement of 
mycoprotein-specific antibodies in serum and Whole 
Gut Lavage Fluid 
3.3.1 Initial preparation of mycoprotein antigen 
The ELISA method measures the antigen specific antibody levels to a soluble antigen in 
body fluids (serum in this case). This method requires insoluble antigens to be made 
soluble for antibody measurement, often by treating with heat, acid, alkali or by 
dissolving in organic solvents prior to dissolving in non-organic solvents. 
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The main constituents of Quorn® are mycoprotein (MP) from the fungus Fusarium 
species ATC 20334 (Fusarium graminearum) and egg. Freeze-dried MP and egg 
albumin were supplied by Marlow Foods Ltd as well as four varieties of the commercial 
product: Quorn® Pieces, Quorn® Mince, Quorn® Burgers and Quorn® Sausages. As all 
these Quorn® products are insoluble in water, the antigens had to be processed before 
use. The antigen preparation and ELISA development was carried out by Dr. Marian 
Aldhous. 
It was decided to try to mimic the procedures which would have occurred in the cooking 
and eating of these products. A small amount of the freeze-dried MP, uncooked Pieces or 
uncooked Mince was heated in glass bottles on a hot-plate for approximately 5 minutes. 
After the addition of 5 ml of distilled water, the foods were 'simmered' for a further 10-15 
minutes. Similarly, a small amount of (uncooked) Burger and Sausage was cut into 
smaller pieces before being heated on the hot-plate in glass bottles for approximately 15 
minutes (to mimic grilling). This "cooking" method followed the manufacturer's 
instructions as near as possible. 
The cooked food was allowed to cool slightly and then Pepsin (1Opg/ml in O. 1M HCl) 
was added (to mimic the action of hydrochloric acid and Pepsin in the stomach on the 
food proteins) and incubated for one hour at 37°C. An incubation period of one hour was 
chosen as the individuals had indicated that nausea and vomiting usually occurred 
between one and four hours of eating. It was thought that if the reaction described was 
immunologically mediated, then the responsible epitopes were likely to be unmasked 
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during this time period. The antigen preparation was then neutralised with alkali and the 
supernatant was collected for use in the ELISA. An insoluble residue of Quorn® products 
was left at the end of this procedure. This was discarded and was not assayed further in 
any way. Each batch of antigen was stored at -20°C in 150µl aliquots. One aliquot of 
antigen was used for each plate. 
3.3.2 Preparation of egg antigen 
A commercial preparation of egg protein, identical to that used in the manufacture of 
Quorn®, was supplied by Marlow Foods for use in another ELISA. This preparation is a 
mixture of two common egg antigens, ovalbumin and ovomucoid. The powdered egg 
antigen was soluble in water and so did not require any of the preparation mentioned 
above. 
3.3.3 Quality control- inter-batch variation 
In order to look at variation between batches of antigen preparations, batches of all 
antigen preparations were made up on three separate days using the same methods. On 
days one and two, 150 µl aliquots of antigen were frozen at -20°C, and on day three, 
antigen was prepared freshly. The thawed antigen preparations from days one and two 
and the fresh antigen were all used on day three to coat six 96-well Immulon-2® (Dynex 
Laboratories) ELISA plates. All six plates were run in parallel using standard sera in the 
ELISA procedure described below. The frozen/thawed antigen and fresh antigen 
preparations were found to give similar results of antigen recovery and so variation was 
thought to be negligible. It was also reasonable to use frozen antigen, thawed as required 
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on the day of each batch of experiments. The same batch of MP antigen was used for all 
the subsequent antibody assays on subjects, normal and disease controls. 
3.3.4 ELISA Method For Specific IgG And IgA Antibodies In 
Serum And Whole Gut Lavage Fluid 
The development of the ELISA method for these antigens was an adaptation of an 
established method for measurement of antibodies to Ovalbumin (268). 
Investigation of humoral mucosal immunity presents significant practical and logistical 
difficulties. From the outset, it was decided to explore the possibility of a humorally 
mediated immunological reaction in affected subjects by measuring levels of specific 
IgA, IgG and IgE antibodies to mycoprotein and egg in serum. In spite of the potential 
problems with a study based on serum measurements alone, there were several reasons 
for choosing serum as the initial medium. Not least of these was the logistical problem of 
obtaining samples from subjects scattered throughout the UK. Serum could be more 
easily obtained by the subjects' GP and posted to Edinburgh for assay. In the first 
instance serum was seen as the most convenient fluid to obtain and assay. 
It is potentially misleading to use information obtained from serum or saliva as 
representative of events at the mucosal level. Previous work performed in our laboratory 
did show a poor correlation between levels of systemic and mucosal antibodies to food 
antigens (88) and to Klebsiella pneumonia (87), illustrating the potentially misleading 
results obtained from studies which relied on measurement of systemic antibodies alone. 
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For example, in comparison to normal controls, patients with Crohn's disease and 
ankylosing spondylitis, demonstrated significantly higher levels of serum IgA class 
antibodies to Klebsiella, while levels of WGLF IgA antibodies to Klebsiella were similar 
in the three groups (87). In coeliac disease, there was no correlation between systemic 
and mucosal humoral immune responses to the food antigens gliadin, ß-lactoglobulin and 
ovalbumin (84). These studies highlight the need for more direct study of the mucosal 
responses to luminal antigens in definitive, descriptive studies of intestinal immunity, 
rather than relying on studies of serum antibodies alone. 
There are circumstances where the extrapolation of serum results does appear to be 
representative of mucosal events, such as the study of specific IgA-secreting B-cells 
following enteric infection or immunisation (82). In the clinical arena, serum levels of 
antibody to gliadin have been extensively used in the interpretation of mucosal events in 
coeliac disease, although their use had been superceded by more sensitive and specific 
assays of anti-endomysium and anti-tissue transglutaminase antibodies. Anti-gliadin 
antibodies of IgA and IgG class have been used in the diagnosis of gluten sensitive 
enteropathy and subsequently in the monitoring of patients' compliance with a gluten free 
diet. 
However, in the same laboratory, studies on systemic and mucosal responses to food 
antigens in 15 normal healthy controls and 54 patients with Crohn's disease, ulcerative 
colitis and coeliac disease, Ferguson et al found very few instances where mucosal 
antibodies were present in the absence of serum antibodies (88). The present study 
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involved otherwise healthy volunteers, all of whom would either have to travel to 
Edinburgh to undergo WGL, or have the procedure performed nearer to their home by 
one of the investigators travelling around the country. Neither of these options was ideal 
in practical terms, firstly, as subjects would be reluctant to travel and secondly since the 
WGL procedure should be performed under the close supervision of an experienced 
practitioner in the hospital setting, which would require permission to use space within a 
local hospital. Furthermore, proper processing of WGLF, especially the addition of 
proteases to prevent degradation of immunoglobulins is crucial if the samples obtained 
are to reflect accurately levels of antibodies and immunoglobulins in intestinal secretions. 
Any significant delay in the addition of proteases, such as might occur if samples are 
obtained in settings outwith the Gastrointestinal Unit, has been shown to lead to 
significant loss of immunoglobulin content in WGLF (85). 
Finally, although previous work does demonstrate dissociation of the systemic and 
mucosal immune responses to luminal antigens, these responses are not by implication 
completely independent. For example, the increased levels of IgG seen in active 
inflammatory bowel disease may be partly explained by isotype switching of B-cells and 
plasma cells in the lamina propria in response to inflammation, but are also derived in 
part from spillage of serum IgG from the vascular compartment into the lumen across an 
increasingly permeable mucosal barrier. The issue of the degree to which plasma leakage 
contributes to the presence of IgG in WGLF has not been adequately resolved although it 
is quite certainly not the only source of the IgG detected. By the same token, increased 
serum levels of IgA antibodies to food proteins may be seen in coeliac patients, which 
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after a period on gluten free diet return to levels seen in normal controls. This may be 
partly derived from spillage across the inflamed mucosa in the opposite direction, into the 
vascular compartment. 
For these reasons it was decided that it would be reasonable to use measurements of 
levels of serum antibodies to mycoprotein and egg as a "screen" to look for evidence of 
an immunological reaction. WGL was reserved as a second line investigation to be used 
if these initial results in serum suggested an immunological basis to the reaction. In the 
original outline of investigation presented to the ethics committee, it was stated that WGL 
would only be performed if any possible humoral immune response was discovered in 
initial testing performed on serum. In this way it would be possible to minimise the need 
for travel and avoid invasive investigations in this group of subjects. 
In spite of the lack of intestinal intubation, WGL is not a simple procedure and many 
patients find it unpleasant. To describe WGL as "non-invasive" is to ignore the 
considerable distress suffered by a significant minority of patients who have experienced 
it. The volume required to obtain "clear" samples is variable but can be far in excess of 4 
litres and the procedure can go on for hours. Complaints of nausea, vomiting, abdominal 
bloating and cramps are common and indeed, anecdotally, many patients who have 
experienced WGL are quite definite that they will never undergo the procedure again, 
after finding it more traumatic than the subsequent barium study or colonoscopy. 
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In summary, it was accepted that in view of the nature of this study, involving otherwise 
healthy subjects scattered throughout the UK, collection of WGLF from each subject 
would present enormous logistical difficulties. Any attempt to collect samples on such a 
scale would have been impractical. WGLF samples might not be adequately processed 
and large numbers of otherwise healthy individuals would be exposed to a comparatively 
invasive, uncomfortable procedure. Previous data from our laboratory demonstrated a 
very low yield of positive mucosal antibodies in WGLF in inflammatory bowel disease 
patients with no corresponding serum antibodies and no positive mucosal antibodies in 
healthy individuals without corresponding serum antibodies. In the specific 
circumstances of this study, it was felt reasonable to undertake a study for mucosal 
antibodies in WGLF in a subset of subjects only if there was compelling evidence for an 
immunological reaction from the initial serum studies. 
3.3.5 Choice Of Conditions 
Dr Marian Aldhous performed the preliminary sets of ELISA experiments to determine 
the best conditions for the assay. These experiments also determined the optimum choice 
of ELISA plate, dilution of antigens for plate coating, dilution of samples and the need 
for blocking the non-specific binding of serum proteins to the ELISA plates. Details of 
the assay procedure are given in section 3.3.11. 
3.3.6 Choice Of Plates 
Immulon-2® "High-binding" ELISA plates (Dynex Laboratories) were used, as opposed 
to the Immulon-1® "Medium/Low-binding" ELISA plates. These 96-well, plastic plates 
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are often used when binding of a potential antigen is anticipated to be weak. They are 
thought to have a greater affinity for antigen and so may enhance binding of proteins. On 
comparison of the plates, Immulon-2® plates were found to be more efficient at binding 
the antigen. 
3.3.7 Coating 
The optimal dilution of all antigens for coating was found to be 1: 100, except egg 
albumin, which was used at a concentration of 1 Oµg/ml. 
3.3.8 Blocking 
Initial pilot experiments showed more non- specific binding of serum proteins to the 
plastic wells than expected, but this was eradicated when a blocking protein in the form 
of human haemoglobin was added to each well. Human haemoglobin was chosen as it 
did not interfere with the assay and was unlikely to be present as a normal ingredient in 
the foods. 
3.3.9 Addition of Samples (Choice of Dilutions) 
Details of sample dilutions are given in the individual section dealing with each assay. 
3.3.10 Choice Of Standards And Quality Controls 
Sera from patients being investigated for gastrointestinal symptoms in the Western 
General Hospital, Edinburgh, were stored in Gastrointestinal Unit Laboratory. These 
were screened to find individuals demonstrating consistently high levels of specific- 
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antibody to the food proteins being tested. Progressive dilutions of these sera were then 
used on each plate, in each batch of experiments to construct a standard curve against 
which all other sera would be tested. In addition, sera were chosen from two other 
individuals who showed consistently high levels of specific antibody to the egg and 
various mycoprotein preparations. These were used on each plate in each batch of 
experiments as quality controls to allow a measure of the degree of variability of the 
assay between plates and from day to day. The "standard" serum, against which all other 
samples would be compared, and two quality controls were all obtained from patients 
suffering from Coeliac Disease, already adhering to a gluten-free diet. In accordance with 
local policy, the nature of the study was explained to the individuals concerned and 
written permission was obtained both for testing their serum for Human 
Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C viruses (HBV and HCV) 
prior to use for the assay. 
3.3.11 Sandwich ELISA Procedure 
The Quorn® antigen-preparations were diluted in coating buffer (bicarbonate/carbonate 
buffer (pH 9.6), Sigma Laboratories) at a dilution of 1: 100. The egg albumin was used at 
a concentration of 10µg/ml. One plate was used for each antigen. After incubation for 5 
hours at 22°C in a moist box, the plates were washed three times with ELISA wash (0.9% 
Saline (Baxter's) containing 0.05% Tween 20 (Sigma). The plates were blocked with 
extra protein (ELISA wash containing l0pg/m1 human haemoglobin (Sigma) and 1% 
adult bovine serum (Scottish Antibody Production Unit)) to stop non-specific binding of 
irrelevant proteins to the plastic. The plates were then incubated for 1 hour at 37°C. The 
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plates were washed again. Serum samples were diluted 1: 100 in ELISA diluent (ELISA 
wash containing 1% adult bovine serum) and added to the plates in duplicate, against a 
"standard" and quality control (QC) samples (as described in 3.3.10). The plates were 
incubated overnight at 4°C. The amount of specific antibody in serum was detected using 
an Alkaline Phosphatase-conjugated antibody, specific for either IgA or IgG, diluted in 
ELISA diluent at 1: 1000 and incubated at 22°C for 5 hours. The assay was developed 
using a colourless substrate for the alkaline phosphatase enzyme (p-nitrophenyl 
phosphate dissolved in diethanolamine buffer). This chemical is cleaved by alkaline 
phosphatase to produce a yellow-coloured product (p-nitrophenol) which can be 
measured by optical density on a spectrophotometer (ELISA reader) at 405 nm 
wavelength. The amount of colour produced is directly proportional to the amount of 
antibody present in the serum sample assessed and the results were calculated from the 
standard curve. Samples that were found to have high levels (above the top standard) of 
MP-specific IgA antibodies in serum, were re-assayed, double-diluting the samples from 
1: 100,1: 200 to 1: 12800 so that at a higher dilution a value within the standard curve 
range was obtained and an accurate titre could be determined. 
3.3.12 ELISA Method For Specific IgE Antibodies In Serum. 
This was based on the same method, but was only used for MP. The main difference in 
the assay is that an Alkaline Phosphatase-conjugated antibody specific for IgE was used 
at a dilution of 1: 500. As no standard was found with IgE-specific antibodies for MP, the 
patient samples assayed were used at a dilution of 1: 2 and titrated down the plate. The 
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results were compared between patients and the values are expressed as the optical 
density (OD) at a 1: 2 dilution. 
3.3.13 Measurement of total IgE in serum of affected 
subjects 
Total IgE level in 54 affected subjects was measured using a standard ELISA assay at the 
Department of Clinical Immunology, Blood Transfusion Service, Royal Infirmary, 
Edinburgh. These were compared with previously calculated normal levels from the 
local population. 
3.4.0 ELISA Method For Detection Of Specific Mycotoxins 
in serum. 
These assays were performed with the help of Dr. Marian Aldhous. ELISA assays for the 
toxins Zearalenone (ZL), Deoxynivalenol (DON) and Diacety-scirpenol (DAS) were also 
set up. These toxins are insoluble in aqueous solution, so they were first dissolved in 
organic solvents, according to the manufacturer's recommendation, and then diluted with 
the coating buffer. DAS and DON were dissolved in a small volume of chloroform 
followed by ethanol and then subsequently in ELISA diluent, while ZL was dissolved in 
ethanol and subsequently in ELISA diluent. Immulon-2® plates were used, one plate per 
patient. For coating, the first 2 columns contained the MP antigen at 1: 100 and then 
titrated out down the plate. Then, each of the next 6 columns contained a toxin: DAS, 
DON and ZL and titrated out from 1 µg/ml down the plate. The next 2 columns contained 
a cocktail of all three toxins together and the last 2 columns contained the diluent alone, 
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to check that the small amount of organic solvent present did not interfere with the assay. 
The plates were incubated and blocked as previously described in section 3.3.11. The 
patient samples were added to the whole plate at 1: 100 dilution and incubated and 
detected as described in section 3.3.11. 
3.5.0 Competition ELISA Method For Mycotoxins, 
Mycoprotein & Egg 
Immulon-2® plates were coated with the MP antigen preparation at a dilution of 1: 100 in 
coating buffer. After incubation, the plates were washed and blocked as previously 
described. One patient serum sample was used for each plate. The toxins used as 
competing antigens are not soluble in water and were prepared again as in section 3.4.0. 
For the assay, in the first two columns (duplicates) the patient serum was diluted at 1: 100 
and titrated out down the plate, to create a "standard curve" for each patient. For the rest 
of the plate the serum was used at 1: 100. In the next two columns, DAS was added to the 
diluted serum as a competing antigen (at a concentration of 1 pg/ml). The competing 
antigen (i. e. DAS) was titrated out down the plate. Likewise, in the next two columns 
DON was added to the diluted serum (at a concentration of 1 µg/ml) and titrated out down 
the plate. In the next two columns ZL (also at a concentration of I µg/ml) was added to 
the serum and titrated out down the plate. In the next two columns the competing antigen 
was the egg albumin (used at a concentration of 5pg/ml), to determine whether there was 
a preferential binding of the antibodies to either of the two components of Quorn®. In the 
last two columns the competing antigen was the MP itself (at a dilution of 1: 10) to show 
that it can bind the antibodies in solution and not just when it is attached to a solid 
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surface. The plates were incubated overnight as before. After washing the plates, the 
amount of specific antibody bound to the antigen on the plate, i. e. which had not been 
bound by the competing antigen, was detected as previously described, using the IgA or 
IgG specific Alkaline Phosphatase-conjugated antibodies. The assay was developed as 
previously described and the results were compared with the curve produced from the 
serum with no competing antigen i. e. the highest value of the curve without competition 
was taken to be the value of 0% inhibition and all other values were compared 
accordingly. The results were expressed as the percentage inhibition of binding by the 
competing antigen. 
3.6.0 Competition ELISA for Saccharomyces cerevisiae 
S. cerevisiae is the organism present in baker's and brewer's yeast and hence is a 
ubiquitous dietary protein and potential antigen. As previously stated, high levels of 
specific anti-Saccharomyces cerevisiae IgG and IgA antibodies have been reported in the 
sera of patients with inflammatory bowel disease, and in Crohn's disease in particular 
(81,201). In the past, it has been suggested that S. cerevisiae may play a role in the 
aetiology of Crohn's Disease, either as a causative agent, or perhaps more likely, by 
sharing antigenic epitopes with another, as yet unidentified causative agent. 
Competition assays using S. cerevisiae as the competing antigen were performed to see if 
there was any cross-reactivity between Fusarium species ATC 20334 and this ubiquitous 
dietary protein. These assays were carried out in the same way as described above, with 
the competing antigen added at 100µg/ml. 
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3.7.0 Endoscopic & Histological Appearance of Gastric 
Mucosa Pre & Post Mycoprotein Challenge 
Three subjects, (subjects 14,35 and 47) who had experienced the idiosyncratic vomiting 
reaction consented to travel to Edinburgh and undergo two upper gastrointestinal 
endoscopies under sedation with intravenous midazolam. All subjects were thought to be 
medically fit to undergo such procedures. All six procedures were performed by a single 
endoscopist (myself). Subjects were given supplemental oxygen during each procedure 
and monitored in the standard manner employed in our unit by continuous pulse oximetry 
throughout the procedure. 
Following an overnight fast, upper gastrointestinal endoscopy was performed using an 
Olympus Q-200 video endoscope. The oesophagus, stomach and duodenum as far as its 
second part were carefully examined and specific comment made on the presence or 
absence of gross macroscopic pathology such as hiatus hernia, mucosal erosions or 
ulceration and evidence of past ulceration. Endoscopic photographs were taken, along 
with a gastric antral biopsy for rapid urease test (CLO® test) to detect the presence of 
Helicobacter pylori infection, and two gastric antral and two gastric body biopsies for 
conventional histological staining. When the subject regained consciousness an oral 
mycoprotein challenge in the form of 5g (cooked weight) Quorn® Sausage was given. 
This dose was chosen to produce an attenuated version of subjects' original symptoms 
without producing undue distress and was derived from information obtained from 
replies to our original questionnaire. Within the constraints of a busy endoscopy list, we 
attempted to standardise the period of time between the mycoprotein challenge and the 
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second endoscopy. Three hours later the procedure was repeated looking for macroscopic 
evidence of acute inflammation, with particular reference to areas of mucosal erythema 
or petechial haemorrhage, and repeating all biopsies except the rapid urease test. All 
biopsies were examined and reported by a single Consultant Histopathologist who was 
blinded as to the subjects' details, the dates of the procedures and the presence or absence 
of a mycoprotein challenge. 
3.8.0 Isotope Gastric Emptying Studies Pre & Post Oral 
Mycoprotein Challenge 
One subject (subject 27) agreed to attend for isotope gastric emptying study pre and post 
oral mycoprotein challenge. Similar, paired experiments were carried out on a volunteer 
control subject who had previously consumed mycoprotein but had never experienced 
any adverse reaction. 
Following a 10 hour fast, at 5pm on day one, each subject was given a standard test meal 
of 150 ml of pasteurised egg mixed with a radio-pharmaceutical in the form of 
99mTechnetium-labelled macro-aggregated human serum albumin (12 MBq of radio- 
activity) microwaved to scrambled egg texture. This was washed down with 20-30m1 of 
water. Time zero was taken as the point at which all the test meal had been swallowed. 
The subjects were positioned in the anterior and posterior erect position and the amount 
of radio-active isotope remaining in the stomach was measured using a gamma camera 
(Elscint®, General Electric) at 0,5,10,15,30,45,60,90 and 120 minutes. Views were 
acquired for 60 seconds at the "General" setting with frame size 128,1.0 zoom. The rate 
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of solid phase gastric emptying was calculated using a standard software package 
(Elgems, General Electric). Subjects were allowed an evening meal and a light breakfast 
the following morning. They then had to begin another 10 hour fast, so that at 5pm on 
day two, the procedure could be repeated with the same test meal but with the addition of 
a mycoprotein challenge in the form of 5g (cooked weight of Quorn® sausage). 
All isotope gastric emptying studies were reported by a single Consultant Radiologist 
with an interest in Nuclear Medicine who was blinded as to the subjects' details, the dates 
of the procedures and the presence or absence of a mycoprotein challenge. 
3.9.0 Whole Gut Lavage 
One affected subject (subject 5) also underwent a Whole Gut Lavage (WGL) procedure, 
under supervision in the Gastrointestinal Laboratory, Western General Hospital, 
Edinburgh. This technique has been well described by Ferguson et al (86,89,261) and 
involves drinking 2000-4000m1 of polyethylene glycol (PEG) electrolyte solution at a 
steady rate of 100ml per hour, which has a powerful laxative effect, until the faecal 
effluent runs clear. The PEG solution is ingested and moves through the gut at a steady 
rate of about 20m1/min, collecting all the substances secreted into the lumen. Once the 
faecal effluent runs clear, it is effectively a "steady-state" gut perfusate. The effluent is 
then filtered and can be stored at -70°C awaiting further analysis. 
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3.10.0 Statistics 
Comparisons between antibody levels in the different groups of subjects and controls 
were made using the Kruskal-Wallis test, the non-parametric equivalent of the ANOVA 
test. This is the most appropriate test to identify significant differences between three or 
more groups and is particularly useful when data includes outlier values. The Mann- 
Whitney-U test was used where comparisons between two groups of data were required. 
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Chapter 4- Results 
4.1.0 Questionnaire Results 
4.1.1 Initial respondents and non-respondents 
Respondents 
A total of 90/140 subjects replied to the questionnaire giving a 64% response rate. Of 
these, 44.4% were male and 55.6% were female. The mean age of this group was 47 
years with a range between five and 88 years old. Subjects aged less than 16 years were 
excluded from further testing. Of these 90 subjects, 81 agreed to consider further tests to 
explore the cause of their reaction. Of the remaining nine subjects, five declined any 
further testing, three made no comment and one declined as she was now living in 
Australia. 
Replies were received from all over the United Kingdom, with no obvious geographical 
clustering of cases, with the exception of two subjects who lived within two miles of one 
another in Mickleover, in the Derby area. There was no preponderance of urban or rural 
addresses. 
Fifty-four percent (49/90) of respondents stated that they had never experienced an 
allergic reaction prior to this episode. However, of these 49 individuals, 12 (24%) also 
stated that they had suffered from an atopic condition at some point in their lives. In 
addition, on specific questioning, four (8%) gave information on previous reactions to 
drugs including penicillin, tetracycline and aspirin, and three (6%) stated they had 
suffered from nickel allergy. 
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The remaining 41/90 (46%) of subjects had experienced an allergic reaction of some kind 
in the past but only 23/41 actually gave an example of the offending substance. In total, 
10/23 (43%) had reacted to another foodstuff, such as mushrooms (2/23), shellfish (2/23), 
peanut (1/23), and egg white (1/23). Contact allergy to nickel jewellery occurred in 7/23 
(30%), with reactions to animal dander and to drugs accounting for the remaining 27%. 
The questionnaire deliberately made the distinction between a history of "allergy" and 
that of atopic conditions, with asthma, eczema and hay-fever mentioned specifically. Of 
90 initial respondents, 43 (48%) described a personal history of such atopic conditions. In 
37/43 (86%) of cases, these problems were current but 14% of subjects had "grown out" 
of a childhood atopic tendency. One subject was taking regular medication, oral 
Prednisolone, for severe asthma. In spite of specific enquiry about medication, no other 
subject gave information on use of inhaled corticosteroids or bronchodilators. 
With the exception of atopic disease, a history of any other past medical problems was 
unusual in this group. One subject suffered from juvenile chronic arthritis, another from 
coronary heart disease, another had been an intravenous drug abuser in the past, one 
suffered from chronic fatigue syndrome and two had chronic skin conditions (psoriasis 
and acne rosacea). Two out of 90 subjects gave a significant history of dyspeptic 
symptoms over and above those suffered after consuming mycoprotein, one was awaiting 
upper gastrointestinal endoscopy to investigate this further. One subject had symptoms of 
irritable bowel syndrome affecting the lower gastrointestinal tract. No other subject had 
any history of significant gastrointestinal disease. Atopic history is included in Figure 
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4.1 as a pointer towards previous allergic type reactions. Figure 4.2 shows that the 
majority (81%) of subjects who described vomiting had reacted on their first exposure to 
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50/140 subjects declined to respond to the postal questionnaire. As previously stated, an 
initial failure to reply was taken as implicit evidence of a decision not to participate and 
the subjects' privacy was respected thereafter. One of the primary aims of setting the 
questionnaire was to address the paucity of information on those affected by adverse 
reactions to mycoprotein and to produce a standard dataset of information which could be 
used for comparison. Because none of the non-responders provided any additional 
information the demographic information on this group is patchy with many omissions 
and some apparent incongruities of data. For example there is no information on age in 
the initial pro-formas issued by Marlow Foods Ltd, but 36/50 questionnaire non- 
respondents have provided postcode information. Therefore, only limited comparisons 
can be made between initial responder and non-responder groups according to the 
information available. 
However, in spite of this, some comparisons can be made. There was a much higher 
proportion of females in the questionnaire non-responder group at 86% (vs 55.6% 
females in the responder group). Overall, the relative proportions of subjects suffering 
nausea or vomiting (42/50), skin rashes (3/50) or respiratory difficulties (3/50) after 
ingestion of mycoprotein is remarkably similar in non-responders compared with the 
responder group. Of the 36 non-responders on whom postcodes were available, 21 were 
urban addresses and 15 rural. Of the 31 who commented on whether adverse reactions 
had occurred on their first, or subsequent, exposure to mycoprotein, 20 reacted on first 
exposure. 
«G 
Of the non-responders, 10/50 had alluded to a previous allergy when first contacting the 
company. Previous allergies mentioned specifically included sensitivities to mushroom, 
penicillin, seafood, dairy and nickel. The remaining 40/50 non-responders had made no 
comment so no conclusion can be drawn from their silence. No useful comment can be 
made on the presence of atopic disease since only 5/50 volunteered a previous history of 
atopy, with 9/50 denying any atopic tendency and the remaining 36/50 making no 
comment. 
In summary, from the incomplete dataset consisting of the limited information available 
from the initial Marlow Foods Ltd pro forma, it can be seen that there was a much 
greater percentage of females in the questionnaire non-responder group compared to the 
responders. Furthermore, the relative proportions of those suffering vomiting, skin rash 
or respiratory type symptoms after ingestion of mycoprotein was similar in both groups. 
As with the questionnaire respondents, there was no preponderance of urban or rural 
postcodes. Unfortunately, there is insufficient data to make any other useful comment or 
comparison on age, previous history of allergy or presence of atopic disease or whether 
reactions occurred on first or subsequent exposure to mycoprotein between the two 
groups. 
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4.1.2 Respondents Sending Serum For Analysis 
A total of 54/90 (60%) of the initial group of respondents sent serum samples for 
analysis. Of this group, only 10 indicated that they would be willing to consider travelling 
to Edinburgh to have one of the more invasive procedures involving re-challenge with 
mycoprotein. The subgroup of 54 subjects was representative of the initial sample, as 
39% were male and 61% female compared with 44.4% and 55.6% respectively in the 
whole group. The mean age was 50 years (47 years in the whole group) with a range 
from 16 to 82 years old. One subject did not complete the questionnaire fully and only 
limited information is available regarding past history of allergic or atopic disease. 
Of this subgroup of subjects, 31/54 (57%) stated that they had never experienced any 
allergic reactions prior to this episode. However, once again, 6/31 (19%) described a 
history of atopic disease and, on specific questioning, 3/31 (10%) described reactions to 
drugs and 1/31 (3%) to nickel. 
A previous allergic reaction was described in 22/54 (41%) of subjects. Reactions to 
another foodstuff were described in 5/22 (23%) of cases. Contact allergy to nickel was 
reported in 4/22 (18%), reactions to a prescribed drug in 4/22 (18%) and to a wasp sting 
in one (5%). A personal history of atopic disease was reported by 16/22 (73%) of 
subjects describing a previous reaction, of which 14/16 (88%) were current problems and 
12% had been childhood diagnoses. 
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Again, for this subgroup, 47/54 (87%) presented with the vomiting reaction, 79% 
reacting after their first exposure to mycoprotein. Of these individuals, 32/47 (68%) 
described vomiting as their sole symptom, 9/47 (19%) described vomiting with 
abdominal pain or bloating, and 6/47 (13%) described vomiting with diarrhoea. 
Of the remaining seven subjects presenting with a non-vomiting reaction, five (9%) 
presented with abdominal bloating alone, two (4%) with anaphylaxis (involving swelling 
of the lips or mouth with respiratory difficulties, but no cardiovascular collapse) and one 
(2%) with an urticarial skin rash. Only four (57%) of the non-vomiting group 
experienced a reaction following the first exposure to mycoprotein. 
In contrast to the larger group, the prevalence of atopic disease was broadly similar in 
both the vomiting and non-vomiting group (48% and 42% respectively). 
4.2.0 Details Of Affected Subjects, Normal & Disease 
Controls 
Table 4.1 shows the gender mix and mean age (standard deviation) of those affected 
subjects who sent blood for analysis along with normal and disease controls. 
Of 22 Crohn's disease (CD) controls, four had disease confined to the ileum alone, four 
had disease of the colon alone, eight had disease involving both ileum and colon, two had 
more proximal small bowel disease and one had isolated peri-anal disease. There was no 
information obtainable on disease extent in the remaining three patients. Active disease 
(as defined in section 3.2.0) was present in 12/18 Crohn's disease patients. Active 
mucosal inflammation or blood loss was present in 12/18 patients with Ulcerative Colitis 
119 
(UC) at the time of this study. Of the 15 patients with Coeliac disease, all claimed to be 
adhering to a strict gluten free diet at the time of anti-endomysium antibody testing. 
However, this may not be strictly true, as all Coeliac patients included in this study were 
positive for anti-endomysium antibody, suggesting recent exposure to gluten. 
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4.3.0 ELISAs For IgA & IgG In Serum 
Assays were performed for IgA and IgG antibodies to mycoprotein itself (MP), a range of 
products containing mycoprotein (Quorn® Mince, Pieces, Burgers and Sausages) and also 
to egg albumin. The results for levels of antibodies to the purified, freeze dried 
mycoprotein were found to be more reproducible than the values seen for the individual 
types of Quorn® product. As the Quorn® products contain other ingredients which may 
themselves have caused a serological reaction, only the results for mycoprotein and egg 
albumin (ie the individual constituents of Quorn®) are presented. 
Results for IgG and IgA antibodies in serum are presented in the form of scatter plots 
with a horizontal line to represent the median value. All results are expressed in arbitrary 
units derived from the same standard in each assay. 
4.3.1 Serum IgA & IgG Antibodies to Mycoprotein in 
Subjects and Controls 
Looking first at specific IgA antibodies to mycoprotein (figure 4.3), the highest median 
titres of IgA antibodies were seen in the Coeliac disease control group (544 units, range 
34-27500) and the lowest in the normal control group (53 units, range 24-933). When 
compared to normal controls, patients suffering from CD , UC and Coeliac disease all 
had significantly higher titres of antibodies (p=0.013). However, there was no significant 
difference between IgA antibody titres in normal controls and affected subjects 
(p=0.097). Similarly, there was no significant difference between antibody titres in 
III, 
affected subjects and patients with CD (p=0.082), UC (p=0.213) or Coeliac disease 
(p=0.142). No significant differences were noted between CD and UC (p=0.591), CD 
and Coeliac disease (p=0.734) or UC and Coeliac disease (p=0.796). 
In contrast, the highest median titres of specific IgG class antibodies to mycoprotein in 
serum were seen in affected subjects (68 units, range 0-987) and the lowest in normal 
controls (21 units, range 14-149). The titres of IgG antibodies, in arbitrary units, were 
considerably lower than those observed for IgA antibodies (Table 4.2). 
Levels of IgG specific for mycoprotein were significantly elevated in affected subjects 
when compared to normal controls (p=0.019), and were marginally higher than the levels 
observed in disease controls (Figure 4.4). There was no significant difference in the IgG 
antibody titres to mycoprotein in affected subjects compared to CD (p=0.779), UC 
(p=0.370) or Coeliac disease (p=0.09). Normal controls did have significantly lower 
titres of IgG antibodies to mycoprotein compared to CD (p=0.012) and UC (p=0.023), 
but not Coeliac disease. Again, the levels of specific IgG class antibodies to mycoprotein 

















Figure 4.3 Serum IgA titres to mycoprotein 
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Figure 4.4. Serum IgG titres to mycoprotein 
l fo 
n=54 n=14 n=22 n=17 n=16 
4.3.2 Serum IgA & IgG Antibodies to Egg 
In the case of specific IgA class antibodies to egg protein (Figure 4.5), the highest median 
titres were seen in Coeliac disease control patients (184 units, range 15-24300) and the 
lowest in normal controls (51 units, range 16-257). Compared to normal controls, the 
levels of specific IgA antibodies to egg in affected subjects and Coeliac disease controls 
were significantly elevated (p<0.01). However, titres in CD and UC controls were not 
significantly different from normal controls. The higher titres of IgA antibodies to egg 
protein, seen in affected subjects compared to CD controls, just reached a statistically 
significant level (p=0.049), but were not significantly different when compared to UC or 
Coeliac controls. 
Coeliac disease control patients showed the highest titres of specific IgG antibodies to 
egg albumin (226 units, range 0-1429) and UC controls the lowest titres (33 units, 0-939). 
In contrast to the levels of antibodies to mycoprotein, IgA and IgG titres to egg albumin 
were broadly similar (Table 4.3). However, no significant differences in IgG antibody 
titres to egg albumin were seen between any of the groups tested (Figure 4.6). 
Scatter plots have been used (figures 4.3 to 4.6) to illustrate the wide spread of values 
seen in all our assays and thus the considerable overlap between these groups of 











































































































































Subjects Normals Crohn's UC Coeliac 
n=54 n=14 n=22 n=17 n=16 
Groups 
Figure 4.6 Serum IgG titres to egg albumin 
X30 
4.3.3 Effect of atopy on IgA & IgG Titres in Affected Subjects 
Further statistical analysis (Mann Whitney test) of the affected subjects was carried out 
depending on the presence (n=22) or absence (n=32) of atopic disease. There was no 
significant difference in the titres of IgA and IgG antibodies to either mycoprotein or egg 
albumin. However, there may be a trend toward a significant difference in IgG class 
antibodies to mycoprotein between atopic and non-atopic subjects (Table 4.4). 
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4.3.4 Effect Of Disease Activity On IgA & IgG Titres In Disease 
Controls 
The presence of active disease in IBD patients was judged by the presence of elevated 
levels of IgG (>10µg/ml), albumin (>26µg/ml), a-I antitrypsin (>19µg/ml) or 
haemoglobin (>5µg/ml) on WGLF analysis. As previously stated (section 3.2.0), this has 
been shown to correlate well with clinical scores of inflammatory bowel disease activity 
such as the CDAI (89,261). 
Table 4.5 demonstrates that in CD control patients, there was no significant difference 
between titres of either IgA or IgG antibodies to either mycoprotein or egg albumin, 
when patients with active and inactive disease were compared. 
Similarly, Table 4.6 shows that in UC control patients, there was no significant difference 
between titres of either IgA or IgG antibodies to either mycoprotein or egg albumin when 
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4.3.5 Effect of previous ingestion of mycoprotein on IgA and IgG 
titres in normal controls 
Of the normal controls, 6 could recall having previously consumed mycoprotein and the 
remaining 8 were quite definite that they had never consumed the foodstuff. Comparison 
of IgA and IgG titres to mycoprotein and egg albumin showed no significant difference 
between these two groups. 
4.4.0 ELISA For IgA Antibodies In Whole Gut Lavage Fluid 
One subject underwent whole gut lavage as part of this study (Subject-5, female aged 18 
years). IgA antibodies to mycoprotein were detectable in whole gut lavage fluid using 
the same method as used for serum. At a dilution of 1: 2, a level of 34 arbitrary units per 
ml was detected 
6c 
4.5.0 ELISAs For Total & Specific IgE in Serum 
A wide spread of values (figure 4.7) for total serum IgE was noted in the subjects 
(median 35 kU/L, range 5-3589 kU/L). 21% of subjects were found to have an 
abnormally high level of total IgE (>114kU/L). 
However, on testing for the more clinically relevant specific IgE levels (Figure 4.8) only 
four subjects (subjects 5,16,28 and 33) had any evidence of specific IgE antibody to 
mycoprotein at a1 in 2 dilution i. e. a very concentrated sample. Even in these 
individuals, the levels detected were extremely low. 
In addition, there was no correlation between levels of total IgE and specific IgA or IgG 
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4.6.0 ELISAs for mycotoxins 
No evidence of production of specific IgA or IgG antibody to any of the mycotoxins 
tested (zearalenone, deoxynivalenol, or diacetyl scirpenol) was found (data not shown). 
4.7.0 Competition Assays 
Competition assays were performed on all those subjects and disease controls showing 
high levels of mycoprotein-specific IgA antibodies. No individual in the normal control 
group showed high levels of mycoprotein-specific IgA antibodies and so this group is not 
represented here. 
4.7.1 Competition ELISAs with Mycotoxins, Egg & 
Mycoprotein 
The competing antigens used were zearalenone (ZL), deoxynivalenol (DON), diacetyl 
scirpenol (DAS), egg protein mixture (EGG) and mycoprotein (MP). These toxins are 
not soluble in water. DAS and DON were serially diluted in chloroform, followed by 
ethanol and then ELISA diluent. DON was dissolved using this method, but DAS 
remained a suspension. ZL was initially dissolved in ethanol and then ELISA diluent and 
remained in solution. Initial experiments indicated that the solvent had little effect on the 
competition assay (data not shown). 
Results have been expressed in bar chart form. A separate graph has been used for each 
different competing antigen; DAS, DON, ZL, Egg, MP. Each graph shows median 
percentage inhibition of IgA and IgG anti-MP antibodies for both subjects and control 
Rio 
groups. Error bars indicate 95% confidence intervals (calculated by the Wilcoxon rank 
test). 
The higher a given value, the more toxin has bound to the antibody and prevented it 
binding to the MP attached to the plate. Conversely, a negative value indicates that the 
toxin has not inhibited the binding of the antibody to the MP attached to the plate, and 
has possibly enhanced this interaction. The subjects and disease controls were compared 
for the ability of the toxin to inhibit or enhance binding of the IgA or IgG antibodies to 
the MP bound to the plate. One subject showed enhanced binding to the antibody bound 
to the plate when the toxins were added in competition. This subject was not used in the 
subsequent analyses comparing the groups. 
In the absence of competing antigen (figure 4.9) there was no difference seen in the shape 
of the titrated curves produced by the affected subjects and disease controls for either IgA 
or IgG antibodies. The optical density of the most concentrated sample of the curves in 
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Diacetyl-scirpenol (DAS) produced very little inhibition of either IgA or IgG antibody 
binding to the plate in both subjects and disease controls (figure 4.10). The values 
obtained for percentage of specific inhibition of binding were, in many of the cases, 
found to be negative values. In competing IgA antibodies, for the two highest 
concentrations of DAS added, the values for the disease controls were significantly more 
negative. At 100µg/m1 of inhibitor, the median percentage inhibition for affected 
subjects was 12.42% (range -13.36% - 33.15%) and the median for disease controls was - 
46.6% (range -120.9% - 32.4%). The competing antigen may have increased the binding 
of the antibody to the plate in the disease controls as compared to the subjects. As the 
concentration of the competing antigen decreased, the differences between the two 
groups became non-significant, indicating that the differential influence of the toxin 
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There was no difference between the disease control patients and the affected subjects in 
the inhibition by DON (figure 4.11). Therefore, if DON has had any effect on these 
subjects, it is probably not through prevention or enhancement of antibody binding and is 
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Levels of percentage inhibition for zearolenone were much higher than for the other two 
toxins in both subjects and disease controls (figure 4.12). For IgA competing antibodies, 
at the highest concentration of ZL added, the values obtained for the disease controls 
were significantly higher (p<0.05). At 100pg/ml of inhibitor, the median percentage 
inhibitions for each group were 65.71% for affected subjects (range 47.31% - 89.96%) 
and 75.81% for disease controls (range 10.62%- 96.83%). Compared with antibodies 
present in the disease controls, antibodies from the subjects were more likely to bind to 
the MP attached to the plate than they were to the ZL added to the samples. As the 
concentration of toxin added decreased, this difference became insignificant. 
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On the whole, in subjects, the addition of egg to the serum had very little effect on the 
binding of the antibodies to the MP attached to the plate (figure 4.13). A few of the 
disease controls had higher levels of inhibition by egg. However, for both groups, the 
median inhibition was about 10% at all concentrations of egg. 
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The addition of mycoprotein as a "self-inhibitor" gave more interesting results. In the 
affected subjects, the addition of MP to the sample almost totally inhibited any binding of 
the antibody to the immobilised MP on the plate (figure 4.14). The disease controls gave 
similar results but the degree of inhibition was not as high as in the affected subjects. At 
the highest concentration of MP added there was a significant difference between the 
subjects and disease controls (p< 0.001). This significance disappeared for the next two 
concentrations of MP added (p=0.49 and p=0.14 respectively. ) However as the level of 
MP was titrated out, the antibodies from affected subjects were significantly more 
inhibited than those from the disease controls (p=0.025, p=0.002, p=0.004, respectively). 
This shows that the affected subjects have antibodies to MP which have a much higher 
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Table 4.7 refers to the influence of the different competing antigens on the relative 
inhibition of binding of IgA and IgG antibodies to plate-bound MP in affected subjects. 
In these subjects, adding MP, as a competing antigen, produces significantly more 
inhibition of binding by IgA antibodies than IgG antibodies across a range of dilutions. 
With the exception of DAS, such differences are not apparent when the various 
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Table 4.8, similarly, looks at these effects in disease controls. Some toxins, particularly 
DON cause significantly more inhibition of binding of IgA antibodies than IgG 
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When we look specifically at the effects of the various mycotoxins on inhibition of IgA 
binding, in subjects compared with disease controls (table 4.9) we can see that there is 
little difference. However, adding MP itself as a competing antigen causes significantly 
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Finally, table 4.10 shows that the various mycotoxins do not differ significantly in their 
ability to inhibit binding of IgG in subjects compared with controls. There are, however, 
significant differences seen when egg or mycoprotein is added as the competing antigen. 
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4.7.2 Competition ELISA with S. cerevisiae 
In subjects and controls, the addition of S. cerevisiae as a competing antigen has no 
significant effect on the binding of either IgA or IgG antibodies. 
4.8.0 Endoscopic & Histological Appearance of Gastric 
Mucosa Pre & Post Mycoprotein Challenge 
4.8.1 Clinical Features 
Three subjects, one male, two female, age range 34-66 years, underwent paired upper 
gastrointestinal endoscopies using intravenous sedation with midazolam. The dose of 
midazolam was titrated according to subjects' conscious level and ranged between 4mg 
and 6mg per procedure (mean 5mg, SD Img). 
No subject experienced vomiting post mycoprotein challenge but all three complained of 
bloating and nausea. These symptoms settled spontaneously in two subjects but the third 
(subject 35, the oldest subject to undergo invasive testing) required treatment with 
intramuscular metoclopramide 10mg. This relieved the feeling of nausea within 15 
minutes. 
4.8.2 Macroscopic Endoscopic Features 
All three subjects tested had evidence of some upper GI pathology- two had a hiatus 
hernia with associated oesophagitis, and one had a moderately severe, Helicobacter 
pylori associated duodenitis. However, only one subject, with oesophagitis, had ever 
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complained of any upper gastrointestinal symptoms (in this case, symptoms of acid 
reflux). Post challenge, one of three subjects showed subjective endoscopic macroscopic 
evidence of an acute gastritis, but this was not confirmed objectively on microscopic 
examination. There was no evidence of a "wheal and flare" reaction described by other 
authors using endoscopic challenge methods (114,115). 
4.8.3 Microscopic Features 
There was no evidence of acute gastritis following oral challenge with the above dose of 
mycoprotein in any of the three subjects examined. One subject had a Helicobacter 
pylori associated antral gastritis which was present prior to exposure to mycoprotein. 
There was no evidence of an excess of lymphocytes or eosinophils in any of the gastric 
biopsies either pre or post challenge with mycoprotein. 
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Endoscopy (subject 35) Pre-challenge Post-challenge 
Oesophagus Hiatus hernia with Hiatus hernia with 
oeso ha itis. oeso ha itis. 
Stomach 3 tiny (<3mm) flat polyps in Flat polyps as before. No 
body of stomach. No gastritis or ulceration. 
gastritis or ulceration. 
Duodenum Normal. Normal. 
No evidence of duodenitis No evidence of duodenitis 
or ulceration. or ulceration. 
Endoscopy (subject 14) Pre-challenge Post-challenge 
Oesophagus Hiatus hernia with Hiatus hernia with 
oeso ha itis. oeso ha itis. 
Stomach Normal. Linear erythema radiating 
No evidence of gastritis or from pylorus. 
ulceration. Mild antral gastritis. 
Duodenum Normal. Normal. 
No evidence of duodenitis No evidence of duodenitis 
or ulceration. or ulceration. 
Endoscopy (subject 47) Pre-challenge Post-challenge 
Oesophagus Normal. Normal. 
No abnormality seen. No abnormality seen. 
Stomach Normal. Normal. 
No evidence of gastritis or No evidence of 
ulceration. gastritis or ulceration. 
Duodenum Erosive duodenitis. Erosive duodenitis. 
Table 4.11 Macroscopic features of gastric mucosa, pre & post 
mycoprotein challenge 
M 
Subject 35 Pre-challenge Post-challenge 
Antrum Gastric mucosa within normal Gastric mucosa of antral type 
limits. No H. pylori. with no evidence of 
histological gastritis. 
Body Gastric mucosa within normal Normal body mucosa only. 
limits. No H. pylori. 
Subject 14 Pre-challenge Post-challenge 
Antrum Gastric antral type mucosa. Gastric antral type mucosa. 
Only a sparse chronic Sparse chronic inflammatory 
inflammatory cell infiltrate in cell infiltrate in lamina propria 
lamina propria. No H. pylori. with 1 cluster of lymphocytes. 
Normal. No evidence of active 
inflammation, H. pylori or 
intestinal metaplasia. 
Body Body type mucosa with some Body type mucosa. Mild 
loss of surface epithelium. infiltrate of chronic 
Focal chronic inflammatory inflammatory cells in lamina 
cell infiltrate in lamina propria. propria. Eosinophils are not a 
No active inflammation or H. feature. 
pylori. No H. loci. 
Subject 47 Pre-challenge Post-challenge 
Antrum Gastric antral type mucosa Gastric antral type mucosa 
with mixed inflammatory cell with mixed inflammatory cell 
infiltrate in lamina propria. infiltrate in lamina propria. 
Polymorphs seen in gland Polymorphs seen in gland 
epithelium. Prominent epithelium. Eosinophils are 
lymphoid aggregates. sparse. Prominent lymphoid 
Moderate numbers of H. aggregates. Moderate 
pylori. H. pylori associated numbers of H. pylori. H. 
gastritis. loci associated gastritis. 
Body Body type mucosa. Mild Body type mucosa. Mild 
mixed inflammatory cell mixed inflammatory cell 
infiltrate with occasional infiltrate. Polymorphs are not 
polymorphs in glands. Small seen. No H. pylori seen. No 
numbers of H. pylori seen. No evidence of intestinal 
evidence of intestinal metaplasia. 
meta Jasia. 
Table 4.12 Microscopic features of gastric mucosa, pre & post 
mycoprotein challenge 
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4.9.0 Isotope Gastric Emptying Studies Pre & Post Oral 
Mycoprotein Challenge 
Only one subject (subject 27) male, aged 42 underwent paired isotope gastric emptying 
studies. Table 4.13 shows the t-half values (time taken for half the ingested test meal to 
leave the stomach) in minutes for both the affected subject (subject 27) and a normal 
control (male, aged 30). The times given are corrected values generated by the Elgems 
(General Electric) software program from the radioisotope decay curve. 
In the baseline, pre-challenge study, the affected subject has a shorter T-half time than the 
normal control. Both values, however, lie within a previously calculated normal range. 
The T-half times were also longer in both the affected subject and the normal control 
following an oral challenge with 5g of cooked mycoprotein, but again, both these values 
are still within the normal range. In these two individuals, at least, the consumption of an 
oral challenge consisting of 5g of cooked mycoprotein did lead to some prolongation of 
solid phase gastric emptying. 
However, even this prolongation did not exceed the previously calculated normal range 
and in view of the extremely small numbers involved, no real conclusion can be drawn 
from this observation. 
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Chapter 5- Discussion 
In this thesis, I have described a group of subjects who all experienced some form of 
physical or clinical reaction following the ingestion of the novel, mycoprotein based 
foodstuff, Quorn®. Particular attention has been paid to those individuals reporting 
symptoms of nausea, bloating and vomiting following consumption of this foodstuff, who 
make up the majority of cases. As the descriptions of the reactions suffered are strikingly 
consistent, it has been assumed that each one has been the victim of the same 
phenomenon. 
5.1.0 Summary Of Findings 
Affected subjects differed significantly from controls in that they were found to have 
higher titres of IgG antibodies to mycoprotein (p=0.019) and IgA antibodies to egg 
(p=0.019) than normal controls. They also had higher titres of IgA antibodies to egg 
(p=0.049) than Crohn's disease controls. No significant difference in titres of IgA 
antibodies to mycoprotein were seen between affected subjects and normal controls. 
However, the range of values for IgA antibodies to mycoprotein in all groups tested 
varied widely, particularly in affected subjects (0-193000 units). It is possible that the 
absence of any difference between affected subjects and normal controls could represent 
a Type II error, or a failure to recognise a true difference. All three disease control groups 
had higher titres of IgA antibodies to mycoprotein when compared to normal controls 
(p=0.003) but only Crohn's disease (p=0.012) and Ulcerative colitis (p=0.023) controls 
had significantly higher titres of anti-mycoprotein IgG. With the exception of Coeliac 
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disease controls showing higher titres of IgA antibodies to egg than Crohn's disease 
controls (p=0.012), there were no significant differences in any antibody class to either 
mycoprotein or egg in any of the disease control groups. 
The presence of atopic disease in affected subjects did not significantly influence 
antibody titres. Only four subjects had detectable levels of mycoprotein-specific IgE 
antibodies, and even then, only in very low concentrations. In Crohn's disease and 
Ulcerative colitis patients, disease activity as measured by elevated levels of IgG, 
albumin, a-1 antitrypsin or haemoglobin in WGLF did not significantly affect antibody 
titres to either mycoprotein or egg. However, Table 4.5 does illustrate a trend towards 
higher titres of all antibodies tested in patients with active Crohn's disease. This does not 
reach statistical significance, but the small numbers of patients involved (14 active, 8 
inactive) may again lead to the possibility of a Type II error. No such differences were 
seen in Ulcerative colitis patients. Affected subjects showed no evidence of antibody 
production to any of the three mycotoxins tested. Competition ELISAs revealed no 
evidence of any cross reaction between mycoprotein and egg, or between mycoprotein 
and S. cerevisiae. 
There was no evidence of any irritant effect on the gastric mucosa in affected subjects 
undergoing upper gastrointestinal endoscopy after ingestion of a mycoprotein challenge. 
There was, however, a high prevalence of minor upper gastrointestinal pathology in 
affected subjects at baseline (i. e. pre-challenge) endoscopy. Ingestion of mycoprotein did 
lead to a slight prolongation of solid-phase gastric emptying as measured by a well 
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validated radioisotope method, but this did not exceed values seen within a previously 
defined normal range. These findings will now be discussed in more detail. 
5.2.0 Potential Sources of Bias Within Study Population 
From the outset, it must be stressed that this group was self-selected, a fact which must be 
borne in mind in terms of potential bias within the study. All had identified the possible 
link between their own reaction and the ingested mycoprotein, and had gone to the 
trouble of reporting their experiences to the manufacturer. This in itself implies a high 
degree of motivation and is borne out by their initial behaviour in writing to describe 
their experiences, and subsequently, their willingness to persevere with questionnaires, 
blood samples and even more invasive tests. This motivation appears to derive from 
purely altruistic principles and not from any hopes of seeking compensation from the 
manufacturer for the discomfort suffered. Indeed, the majority of letters to the 
manufacturer were at pains to point out that the correspondence was not intended as a 
complaint but rather as a means of gaining a better understanding of what had happened. 
Therefore, the study population was identified on the basis of their own description of a 
reaction which had been experienced some time prior to our investigations. These 
descriptions are subject to recall bias, being based on the subjects' own recollection of 
events which had occurred up to 20 months previously. However, they were the only 
data available upon which any observation could be based. 
169 
The field of food related disease, whether in terms of allergy, over- or under-nutrition is 
fraught with the problems associated with recall bias. Retrospectively collected food 
diaries depend on an adequate and accurate recall of foods taken which may be beyond 
the capabilities of a significant minority of the population. Diarists may feel obliged to 
fill in what they feel they ought to be eating (ie what the investigator wants them to eat) 
rather than what they actually consumed. Of course, as previously discussed in the 
methodology section, all medical interactions between doctors and their patients depend 
on the acquisition of information from the patient. The information obtained, whether 
through an interview or the taking of a medical history, or through a questionnaire, will 
always be subject to recall bias. It is an important point and one which has to be borne in 
mind when interpreting any patient derived information. 
Some specific points have been raised in the case of information derived from 
questionnaires. In particular, any information divulged in response to a questionnaire 
relies on patient recall of an event or a diagnosis. The ability to accurately recall events 
will depend on the patient's cognitive function as well as on factors which are specific to 
that patient. For example, an event or diagnosis may be recalled because of its 
association with something which seems quite trivial to the doctor but is of special 
importance to the patient. It is important to ensure that the patient's understanding of that 
event or diagnosis is correct and matches with what the investigator's understanding of 
what has been described. 
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The true scale of the problem, and therefore the denominator in terms of actual number of 
cases, is very difficult to assess. As stated in the introduction to this thesis, the number of 
reports reaching the manufacturer has remained constant over the past few years at 
around 200 cases per annum (Dr G. Rodger, Marlow Foods Ltd, personal 
communication, data on company file). This, of course, may only represent a small 
fraction of those suffering a reaction. Not everyone suffering an adverse event will 
associate it with the ingestion of mycoprotein, nor will they necessarily write to alert the 
manufacturer. However, in the case of food borne infections and food poisoning, it has 
been suggested that there may be up to nine silent, unreported cases for each reported 
case. This very rough estimate suggests that there may be up to 2000 cases of adverse 
reactions due to mycoprotein in the United Kingdom per annum. In 1998, the year this 
study began, 93,932 cases of "food poisoning" were reported in England and Wales alone 
(http: //www. phls. co. uk/ Official website of the Public Health Laboratory Services, 
England and Wales). It can be seen that, numerically speaking at least, reactions to 
mycoprotein foodstuffs are a very small problem. 
Marlow Foods Ltd. had conducted an internal investigation of the serial and batch 
numbers of each product implicated iii a reaction wherever this information was 
available. They concluded that there was no evidence of any particular batch of 
manufactured mycoprotein implicated in these reactions, indicating that it was unlikely 
that contamination of the product had occurred prior to leaving the factory (Dr G. 
Rodger, Marlow Foods Ltd, personal communication). 
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5.3.0 Demographic Considerations 
There was no evidence of geographical clustering of cases (with the previously 
mentioned exception of two cases in Derby, but both bought in different supermarkets in 
different months of the same year). The majority of those affected, in this sample at 
least, were female, but the male to female ratio was not strikingly different. There may 
be a number of explanations for this finding. The majority of affected subjects were 
attracted by the healthy image of mycoprotein products, a non-animal protein source low 
in fat and high in fibre, an image which may be more attractive to health conscious 
females. Female subjects may also be more willing to report a reaction, and more likely 
to take the time to sit down and write to the manufacturer than males. Previous studies 
have also shown a similar pattern in that replies from females outnumber those from 
males (175,176). Thus, it is unlikely this result is a true predisposition to adverse 
reactions to mycoprotein amongst female subjects. 
5.4.0 Potential Role of Atopic Disease and IgE-mediated 
Mechanisms 
Affected subjects reported a high prevalence (48%) of atopic conditions, such as asthma, 
eczema, allergic rhinitis or hayfever. Of the 90 subjects who replied to the questionnaire, 
a history of atopic disease was commonest in those who had experienced the non- 
vomiting reactions (64% reported atopic history). This rose to 100% in the two subjects 
experiencing anaphylactic type reactions and was 66% in those who developed a skin 
rash. The lowest rate of atopic disease (44%) was seen in the subjects who had 
experienced the vomiting reaction (see figure 4.1). This group was further sub-divided 
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on the basis of whether reactions occurred on the first or on subsequent exposure to 
mycoprotein. Of those vomiting the first time they ingested the foodstuff, 48.9% had a 
history of atopic disease, compared with 64.2% of those reacting on subsequent exposure 
(see figure4.2). These figures are considerably higher than the figure of 27% quoted in 
the large population based study of food intolerance by Young et al (174). In that study, 
rates of self-reported reactions to food were higher in those individuals with a history of 
atopy (28%) than in those with no such history (15%). So the presence of atopy is an 
important factor in a substantial number of individuals who experience reactions to food. 
Atopic disease is cited by the American Gastroenterological Association as one of the 
features in the history of a reaction which increases the likelihood of a diagnosis of food 
allergy (151). It would appear that, in the case of individuals who reacted adversely to 
mycoprotein, atopic disease is less important in those subjects who experienced a 
vomiting reaction, compared to those who experienced skin rashes or anaphylaxis. The 
prevalence of atopy is lowest in those subjects who vomited the first time they ingested 
the foodstuff. Perhaps some of these individuals have a predisposition to allergic-type 
reactions not associated with atopic disease. It seems more likely, however, that the 
vomiting reaction has a non-allergic aetiology. The relatively lower incidence of atopy in 
this group may be further "soft" evidence for this. 
Atopy has a strong familial component (269). An individual's lifetime risk of developing 
an atopic disease is increased between 20-40% if one parent is affected, rising to between 
40-60%, if both parents are atopic and up to 80% if both parents express the type of 
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atopic disease (270). It might, therefore, have been useful to investigate whether reactive 
individuals shared any particular HLA-types or could be further categorised in this way. 
Atopic individuals generally have high serum levels of total IgE. Indeed, the clinical 
features of atopic diseases are mediated by IgE-class antibodies. As the non-vomiting 
reactions (anaphylactic-type and skin rashes) followed the classical pattern one might 
expect in IgE mediated reactions, it is not surprising to find a higher incidence of atopy in 
this group. 
IgE mediated reactions are known to fall into two categories depending on the length of 
time between exposure to allergen and onset of reaction. The more typical immediate- 
phase reaction is mediated by degranulation of previously sensitised mast cells with 
release of vasoactive inflammatory mediators, such as histamine. Histamine release 
causes smooth muscle contraction and increased permeability of capillaries and arterioles 
with "wheal and flare" skin lesions. Antigen-induced degranulation of intestinal mast 
cells has been shown to stimulate motor and secretory function in the small and large 
intestine of the rat (271-274). This immediate phase IgE response is important in a 
variety of atopic conditions including allergic rhinitis and atopic dermatitis. 
However, mast cell degranulation also releases other chemokines and cytokines, such as 
eosinophil and neutrophil chemotactic factors, granulocyte/macrophage colony 
stimulating factor (GM-CSF), IL-3 and IL-5 which lead to the recruitment of other 
inflammatory cell types to the site of inflammation (260). The attraction and activation 
of neutrophils, macrophages and monocytes is likely to result in a delayed, but more 
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prolonged inflammatory response. Such a mechanism has been suggested to underlie 
many food hypersensitivities (10). The time scale for the development of a delayed 
phase IgE response is in the order of 6-8 hours, persisting for 24 hours and this would fit 
very well with the clinical history described by those subjects experiencing the vomiting 
reaction after mycoprotein ingestion. 
In the affected subjects in this study, the atopic group did have higher median levels of 
total IgE than the non-atopic group, as would be expected. However, only four subjects 
out of 54 (subjects 5,16,28 and 33) had measurable levels of mycoprotein specific IgE 
class antibodies and these were only detectable in high concentrations of serum (1: 2 
dilution). One of these subjects (subject 28) gave no previous history of atopic disease, 
which is an unexpected finding. Whether this is indeed the case, and subject 28 is truly 
not atopic, or whether this person had some difficulty in understanding the questionnaire 
is impossible to say with any degree of certainty. The fact that he demonstrated a high 
titre of mycoprotein- specific IgE antibody is very suggestive of an atopic tendency. The 
mean total IgE level in serum for the whole group of affected individuals was slightly 
elevated (mean 187, normal range <114kU/L). However, in view of the presence of two 
or three very high "outlier" values within this group, which elevated the mean value, a 
more realistic reflection might be the median value, which at 35 kU/L, was well within 
the normal range. We did not employ RAST testing, another method to assay food- 
specific IgE class antibodies, but relied instead on the ELISA technique. Different 
results may have been obtained if RAST testing had been used as it is a very sensitive 
technique, but lacks specificity, producing significant numbers of false positive results. 
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In conclusion, from the results presented, it is unlikely that the vomiting reaction is truly 
mediated by IgE, or IgE dependent mechanisms. However, the absence of such IgE- 
mediated mechanisms does not exclude the possibility of some other, humorally- 
mediated immunological effect. 
5.5.0 Role of IgA & IgG Antibodies In Serum & Whole Gut Lavage 
Fluid 
The presence of detectable levels of food specific antibodies in the sera of patients with 
inflammatory bowel disease and Coeliac disease has traditionally been ascribed to the 
phenomenon of increased intestinal permeability (81,275). Increased permeability has 
been shown to be a feature of Coeliac Disease and to a lesser extent, Crohn's disease and 
Ulcerative colitis (276,277). The diseased or inflamed intestine may present a less 
effective barrier to the passage of substances from the lumen across the intestinal wall. 
This means that the underlying immune cells in the deeper layers of the gut wall are 
exposed to a greater antigenic load in the form of partially digested food components. 
The increased antigen presentation leads to activation of T-helper cells, enhanced 
proliferation of lamina propria B-cells which differentiate into immunoglobulin secreting 
plasma cells and increased antibody production. Antibodies of both IgA and IgG classes, 
to a variety of food antigens, have been demonstrated in patients with untreated Coeliac 
disease (278,279). In a study of 14 untreated Coeliac patients, Hvatum et al (275), 
showed elevated levels of IgA antibodies to the milk and egg proteins, a-lactalbumin and 
ovalbumin, and elevated IgG subclass antibodies, particularly IgG4 subclass, to ß- 
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lactalbumin, a-lactalbumin and ovalbumin. This may be part of a normal, non- 
pathological humoral immune response to dietary antigen (280). However, IgG4 is the 
IgG subclass most commonly implicated in allergic reactions to dust, pollens and bee 
venom (281) and thus, may also be implicated in allergic reactions to foods. 
Unfortunately, we did not examine IgG subclass responses, but it would be unusual to see 
an allergic reaction mediated by IgG4 with no corresponding activation of IgE. 
As previously stated, normal subjects will produce IgG antibodies to a range of food 
components. These may be seen in 9.2% of randomly tested blood donors (282) and are 
more common in the presence of atopic diseases, such as eczema. These antibodies are a 
physiological phenomenon reflecting exposure of the individual to these foods. One 
would expect, however, that over time the levels of such antibodies would fall as, through 
repeated exposure over time, the body becomes "tolerant" to that particular 
immunological stimulus. It may be of some significance then, that titres of IgA- and IgG 
class antibodies to both mycoprotein and egg were measurable at all in the sera of 
affected subjects. 
IgA is the predominant immunoglobulin class secreted by mucosal surfaces including the 
intestinal epithelium. Although in health, very little is detectable in the serum, increased 
levels are suggestive of overproduction at the mucosal level, with a possible "overspill" 
into the systemic circulation. Of the 54 affected subjects, seven had no detectable titre of 
IgA class antibodies to mycoprotein. Of this group of seven, two also had no IgA class 
antibody titres to egg protein. There is a possibility that this may simply be a chance 
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finding, of little consequence, but IgA deficiency is associated with Coeliac disease and 
may be present in up to 20% of such individuals (2). It is possible that these two 
individuals (subjects 36 and 38), may in fact be hitherto undiagnosed Coeliac patients. 
Furthermore, IgA deficiency removes one of the mucosal barrier's most effective lines of 
defence against enteric infection and may predispose to such infections, an alternative 
explanation for their symptoms. Unfortunately, serum immunoglobulin levels were not 
tested in this group, so no definite diagnosis can be made. 
In the case of antibodies to mycoprotein, it was demonstrated that all groups of disease 
controls had significantly higher titres of IgA class antibodies than normal controls. 
There was no significant difference in titres between normal controls and affected 
subjects. In the case of IgG antibodies, however, the situation is different. Affected 
subjects had significantly elevated titres of mycoprotein-specific IgG compared to normal 
controls (p=0.002) and these levels exceeded those seen in disease controls. This could 
be taken to show that there is some breakdown of the normal immunoregulatory 
mechanisms, such as oral tolerance, in the affected subjects or an enhanced level of 
humoral immune response in these individuals compared to normal controls. 
No data on intestinal permeability were available on any of the affected subjects or 
normal controls, and only on a few of the Coeliac disease controls. It was therefore, not 
possible to see if any correlation existed between the level of antibody response 
generated and the degree of intestinal permeability. This would have been an interesting 
experiment, but it is likely that no such relationship exists. There was no evidence that 
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the disease controls with active disease, in whom one might expect an increased intestinal 
permeability, had significantly higher titres of mycoprotein or egg specific antibodies, 
although, as discussed in section 5.1.0 there was a trend towards higher values in those 
with active disease. 
Increased intestinal permeability has been described in a subgroup of first degree 
relatives of patients with Crohn's disease (283,284), and also in one study, in unaffected 
spouses (285) who have no evidence of clinical disease. Therefore, while increased 
permeability may reflect active disease in those with inflammatory bowel disease, it may 
also be seen in the absence of inflammation. The increased permeability seen in 
unaffected relatives may actually be a result of a specific genetically determined defect of 
intestinal permeability, associated with inflammatory bowel disease. The precise 
relationship between increased intestinal permeability and the presence of circulating 
antibodies to foods is unclear, but may be less straightforward than simply increasing the 
exposure of mucosal immune cells to luminal contents. 
One might expect, if the titre of food specific antibodies depends purely on the degree of 
intestinal permeability, that the relative patterns of antibody response to mycoprotein and 
egg would be broadly similar. This was not the case. The pattern of IgA and IgG 
antibody class response to egg albumin is rather different to that seen to mycoprotein. 
No patient had any recent history of gastroenteritis, alcohol abuse or use of non-steroidal 
anti-inflammatory drugs, all of which may affect intestinal permeability. 
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All subjects recruited to the present study were enrolled throughout 1997. Serum 
samples were collected and stored to await assay over a four week period in May 1998. 
Data regarding the precise date on which subjects experienced their first (and subsequent) 
reactions to mycoprotein are incomplete. Where dates are available the information 
given is, as previously discussed, subject to recall bias and may not be accurate. The 
length of time taken to realise mycoprotein may be implicated, write to the manufacturer, 
become involved in the study and provide a sample of serum is variable. Of those 
subjects where such data is available, the shortest time taken from reaction to serum 
sampling was four months, and the longest 20 months. The earliest documented reaction 
suffered amongst affected subjects was in October 1996. 
There is not sufficient data from the group of affected subjects to make any meaningful 
comment on whether the length of time between experiencing an adverse reaction and 
submitting a serum sample influences the level of antibodies detected in serum. Data 
from individuals suffering from enteric infections such as Salmonella enteritidis have 
shown that serum antibodies to the pathogen are absent at one year following the initial 
infection, while antibodies in intestinal secretions may persist as a "footprint" of infection 
long after this. It may not be relevant, however, to compare events occurring after 
exposure to an intestinal pathogen to those related to ingestion of foodstuffs, where one 
might expect a greater degree of immune tolerance and down-regulation. The mucosal 
immune response exists to neutralise the former while tolerating the presence of the 
latter. The one subject who did undergo WGL, showed high levels of antibodies in her 
serum and did indeed have evidence of anti-mycoprotein antibodies in the WGLF. She 
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was a particularly reliable historian who had experienced a reaction just over 12 months 
previously. Again, as repeated time and time again in this thesis, her case alone does not 
prove that WGLF antibodies persist for many months in all individuals but it does at least 
tell us that antibodies can be detected even 12 months after a reaction has occurred. 
It should be noted, however, that there was considerable overlap in the range of antibody 
titres obtained in all groups to both foods tested. With this in mind, the results of the 
serum levels of IgA and IgG antibodies must be viewed with caution. Care should be 
taken to avoid reading too much into these results. In addition, Quorn®, although, still a 
novel foodstuff, is fairly universally available in supermarkets in the United Kingdom. 
Therefore, it is possible that some of the control subjects had experienced reactions to the 
foodstuff, invalidating their use as a control. Of the five normal controls who had 
consumed mycoprotein, none had experienced any problems or adverse reactions. The 
disease controls were never asked specifically whether they had personally experienced 
any problems after consuming mycoprotein products, but none had ever reported any 
reaction which was in any way similar to that described by the subjects. 
It would have been of great interest to perform WGL on all 54 volunteers who provided 
samples of serum for analysis, and to have assayed these intestinal secretions for the 
same IgA, IgG and IgE antibodies to mycoprotein and egg. Without the benefit of such 
studies we can only speculate on events at a mucosal level in the affected subjects 
reacting to mycoprotein. It has been a message which this laboratory has preached for 
many years that serum studies do not accurately reflect events at a mucosal level. 
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However, it would have, been impractical to have obtained WGLF from each of these 
subjects, and while many would willingly consent to giving a blood sample, far fewer 
would have agreed to undergoing WGL even if it had been practical to perform these 
procedures at home. The original decision to perform initial screening studies in serum 
was made with full knowledge of the likely problems which might be encountered trying 
to obtain WGLF from each questionnaire respondent. 
5.6.0 Competition ELISAs- Potential Role of Cross-Reactivity 
The results of the competition ELISAs were interesting, as these were designed to 
investigate the possibility of either exposure to mycotoxins, or to some other substance 
which might cross-react immunologically with these toxins. Tee et al had previously 
demonstrated multiple common allergenic determinants between the fungal species 
Aspergillus fumigatus, Cladosporium herbarum and F. graminearum (12), raising the 
possibility that individuals allergic to these moulds could react adversely to inhaled or 
ingested mycoprotein. However, in common with this thesis, their results were largely 
negative, indicating that this theoretical risk was unlikely to be a major problem 
clinically. 
Although levels of serum IgA in subjects and disease controls were broadly similar, the 
competition assays showed that there were qualitative differences between the antibodies 
of individuals from each of these groups. Where a difference was seen, the subjects had 
antibodies which had a consistently higher affinity for the mycoprotein than for either the 
egg albumin or mycotoxins. The significance of this is not clear, but may reflect an 
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immunological mechanism which would make these subjects react more violently to 
mycoprotein. This could have occurred by prior exposure to cross-reacting antigens. 
Possible mechanisms of environmental exposure might include inhalation of airborne 
mould spores or ingestion of foods made from cereals contaminated by moulds. 
Contamination of cereal crops around the world with Fusaria species, including 
Fusarium graminearum, and their toxins has been well documented (286). Minute 
quantities of mycotoxins have even been discovered in beer in Czechoslovakia (287). In 
the Czech study, the authors concluded that even assuming an annual beer intake of 150 
litres per person, the cumulative dose of deoxynivalenol was not hazardous. It may 
however, be sufficient to cause priming of the intestinal immune response, awaiting the 
subsequent ingestion of a mycoprotein meal. 
The disease controls may also have been previously exposed as they too had shown 
antibody responses to the mycoprotein. If the increased affinity for antigen seen in the 
subjects is a true result then this would indicate that exposure to mycoprotein in these 
subjects had indeed caused some subclinical sensitisation to the food product. This may 
imply some immunoregulatory defect or breakdown of oral tolerance. The fact that the 
majority of subjects (>80%) described a reaction to mycoprotein on their first exposure 
unfortunately does not bear this out, but would still be consistent with the theory of prior 
cross-sensitisation. Further studies would be required to see if different epitopes of the 
mycoprotein are recognised in the different patient groups. 
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In the competition assays, the most significant differences seen are in the inhibition of 
binding of IgA antibodies rather than IgG antibodies to mycoprotein on a solid surface 
compared «ith free mycoprotein in solution. These show that IgA antibodies have a 
greater affinity for bound mycoprotein than IgG antibodies. This observation may 
indicate that the reactions seen are mediated more at a mucosal (ie IgA secreting) level 
than at a systemic (ie IgG secreting) level. 
One of the initial hypotheses was that these reactions may be due to sensitivity to egg 
albumin used in the manufacturing process of these foods. The IgA competition assays 
using egg as the competing antigen showed very little inhibition of binding, (<10%), at 
all concentrations of egg used. This indicates that egg albumin sensitivity is unlikely to 
be a significant factor in these reactions. 
All the above observations are based on measurement of antibody levels within serum. 
As such, we are relying on the generation of an antibody response to a soluble or at least 
partially soluble antigen. Therefore, the conclusions reached based upon these results 
may not hold true if the clinical reaction is actually mediated by some insoluble 
component of the mycoprotein material which was discarded at the beginning of the 
experiments, during processing of the mycoprotein antigen for the ELISA process. 
Serum measurements may not accurately reflect what is happening at the level of the 
intestinal mucosal lining, but serum has been used as it is the most convenient fluid to 
sample. Studying immune responses in the form of measuring levels of antibodies and 
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cytokines produced in the gut at a mucosal level is fraught with difficulties, not the least 
of which is gaining access to the intestinal tract. 
One very useful technique, which does allow the researcher an insight into immune 
processes at the mucosal level, is whole gut lavage (WGL). This was initially described 
by Gaspari et a! (83)but taken up and greatly developed by the late Professor Ferguson in 
Edinburgh. It has been widely used within the Gastrointestinal Unit, Western General 
Hospital. Edinburgh to give information on gut inflammation, blood and protein loss. 
One affected subject (subject 5) did undergo WGL and was found to have detectable 
levels of mycoprotein antigen-specific IgA antibodies in WGLF. This person also had 
high levels of mycoprotein- specific IgA and IgG antibodies in serum. This finding 
indicates that even many months after the initial exposure to antigen, and the intervening 
period when no antigen was ingested, some individuals are still producing detectable 
amounts of specific antibodies at a mucosal level. 
Overall, the presence of these antibodies, whether in serum or in whole gut lavage fluid, 
although of interest, may represent an epiphenomenon, that is, a coincidental finding 
'which may not have a direct causal link with the underlying aetiology of the reaction. 
Their presence does serve as a "footprint", showing prior exposure to the mycoprotein, 
and an indication of some level of activation of the mucosal immune system. Subtle 
differences noted between results for IgA and 1gG classes of antibodies, particularly in 
the competition assays, suggest that this reaction does occur more at a mucosal level than 
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a systemic level. Whether the presence of elevated titres of mycoprotein- specific 
antibodies represents a cause or an effect of the adverse reactions is unclear. 
5.7.0 Investigation Of A Direct Irritant Effect On Gastric Mucosa 
On the basis of the histories given by those suffering a vomiting reaction, namely, 
symptoms of nausea and abdominal bloating within a few hours of ingestion of the 
m)-coprotein, followed by complete relief of these symptoms by vomiting, the possibility 
of a direct irritant effect on the mucosa of the upper gastrointestinal tract needed to be 
actively excluded. This is especially so as the majority of subjects had symptoms on the 
first exposure to the product with no history of prior sensitisation. The more directly 
invasive tests were used to investigate this possibility further. Endoscopy allows direct 
visualisation of the gastrointestinal mucosa and identification of the cardinal signs of 
inflammation if these are present. In the diagnosis of food allergy, it may be used as an 
adjunct to taking a good history and tests to detect food-specific IgE mediated reactions. 
Its main role was originally as a means of obtaining biopsy material from the 
gastrointestinal tract for histological examination. The histological features of biopsies 
from 53 children suffering from a food allergy, affecting the rectum or foregut, were 
reported in 1986, in a retrospective series by Goldman and Proujansky (166). The 
commonest presentations of allergic gastroenteritis were vomiting, abdominal pain and 
weight loss, affecting children aged between six months and 17 years. There was a 
differential distribution of microscopic abnormalities within the stomach, with the gastric 
antrum most frequently involved (22/22 cases) and the gastric body less frequently 
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(11/21). A diffuse and intense infiltration of eosinophils was noted in the antrum and a 
much less marked, focal infiltration in the body of the stomach. 
Direct application of potential allergens to the gastrointestinal mucosa via an endoscopic 
catheter was reported in Germany in 1988 (114). Using the technique of intragastral 
provocation under endoscopic control (IPEC), they studied 30 well- characterised 
patients with proven food allergy and 10 previously healthy volunteers, by endoscopic 
administration of homogenised food suspensions. After challenge, the macroscopic 
appearance of the gastric mucosa changed, with the appearance of mucosal swelling and 
discrete area of haemorrhage. Histologically, there was evidence of increased numbers of 
lymphocytes in the gastric mucosa of food-allergic patients prior to challenge, but no 
change in the number of these cells following challenge. However, microscopic erosions 
of the gastric mucosa were seen following challenge. 
Bischoff et a! described a positive "wheal and flare" reaction to at least one of three 
colonoscopically injected food antigens within minutes of injection in 54/70 patients 
tested. The presence of such a mucosal reaction correlated *%ith immunohistochemical 
markers of cosinophil and mast cell activation but not with serum concentrations of total 
or food-specific IgE (116). "fluse invasive methods are not frequently employed in the 
routine diagnosis of food allergy. However, a modification of Reimann and Lewin's 
technique was used to endoscopically assess the effect of an orally administered 
mycoprotein challenge in affected subjects. The previously noted macroscopic and 
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histological abnormalities (114,116,166) were particularly useful when assessing the 
gastric biopsy material pre and post mycoprotein challenge. 
The results of the endoscopic studies were of interest. However, the nature of this 
project, particularly the need for subjects to travel to Edinburgh, meant that the eventual 
number of subjects studied was small. Therefore, in spite of each subject acting as their 
on internal control, it is difficult to reach meaningful conclusions from only three cases. 
However, some interesting observations can be made. All three subjects had some 
evidence of pre- existing minor upper gastrointestinal pathology although, of these, only 
one %%-as symptomatic (section 4.8.1). All three subjects experienced symptoms following 
ingestion of the test meal but it should be stressed that the presence of symptoms alone is 
very subjective, and impossible to interpret as the challenge was neither placebo- 
controlled nor blinded. Endoscopic appearances of gastritis, with congestion of the 
gastric mucosa, often correlate poorly with histological features, and great care has to be 
exercised in the interpretation of an endoscopic finding of gastritis (288). The 
endoscopic and histological diagnoses were at variance in two cases and as a result, the 
presence of an acute inflammatory infiltrate histologically has been taken as the standard 
for the diagnosis of gastritis. Apart from one patient with Helicobacter pylori associated 
gastritis, histologically there was no abnormality noted in the epithelium of the gastric 
antrum or body prior to mycoprotein challenge. In particular there was no evidence of 
an excess of l)mphoc)les or cosinophils, either pre or post oral mycoprotein challenge. 
As far as possible, efforts were made to reproduce the conditions under which the 
original reactions had occurred without exposing any of the volunteer subjects to undue 
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distress. It could be argued that the dose of mycoprotein administered, or the time for 
which that dose was in contact with the gastric mucosa prior to the second endoscopy 
was insufficient to cause a noticeable effect. Bischoff's colonoscopic reactions were said 
to reach their maximum at between 10 and 15 minutes post-challenge (116), so it is 
possible that any reaction had dissipated before the second endoscopy. 
In this small number of susceptible individuals, there was a high frequency of 
asymptomatic, and unexpected, minor upper gastrointestinal pathology but no evidence 
of acute gastritis or worsening of pre- existing gastritis following oral ingestion of 
mycoprotein. With the caveat that the testing procedure may not have picked up the 
macro- or microscopic features of an acute reaction as above, I infer from these findings 
that there is no direct irritant effect of mycoprotein on the gastric mucosa in these 
individuals. It must be assumed therefore that the idiosyncratic vomiting reaction is due 
to some other mechanism, perhaps delayed gastric emptying. This may be further 
exacerbated by pre- existing, asymptomatic upper gastrointestinal pathology. 
The finding of minor degrees of upper gastrointestinal pathology on endoscopy has been 
mirrored in a paediatric study from Finland which set out to determine whether children 
with recurrent bouts of abdominal pain included an excess of individuals suffering from 
food allergy. Eighty four children under the age of 15 years underwent skin prick and 
patch testing as well as upper gastrointestinal endoscopy and biopsy. On the basis of 
open elimination-challenge testing with various foodstuffs the authors found that 28/84 
(33%) had evidence of food allergy and that 38/84 (45%) had evidence of minor 
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cndoscopic pathology, «ith oesophagitis, lymphonodular and erosive duodenitis being 
the most common abnormalities (289,290). 
In our study, only two subjects gave any prior history of gastrointestinal symptoms, and 
certainly no history of gastrointestinal disease. However, it is possible that some of these 
people may suffer from a latent or occult gastrointestinal disease such as Coeliac disease, 
although their symptomatology is not entirely suggestive of this. The possibility of 
undiagnosed Coeliac disease is further strengthened by the two subjects discussed in 
section 5.4.0 %ith no detectable IgA antibodies to mycoprotein or egg protein, raising the 
suspicion of IgA deficiency. It would have been possible to test the sera of these 
individuals for IgA class anti-Endomysium antibodies which are highly specific and 
sensitive for Coeliac Disease (2). However, as we did not have consent for this test from 
any of our subjects and as a positive result could have serious long-term implications in 
terms of treatment and lifestyle, it was decided not to proceed with this line of enquiry. 
5.8.0 Effect of Mycoprotein Challenge on Solid-phase Gastric 
Emptying 
One particular mycotoxin, deoxynivalenol, otherwise known as "vomitoxin", has been 
sho%Nn to cause vomiting in rats by delaying gastric emptying via an effect on peripheral 
scrotonin-3 receptors (291). The possibility that this may also happen in humans was 
explored by studying gastric emptying. Unfortunately, only one subject attended for 
isotope gastric emptying studies. It was particularly difficult to recruit subjects for this 
investigation, as it involved two whole days away from work and family. In addition, 
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because of the nature of the investigation and the small amount of radio-activity involved, 
only male subjects (already in the minority) or female subjects who were not of child- 
bearing age (%%ho were reluctant to travel) could be included. In an internal, non-blinded 
comparison, %%hen compared to the previously defined normal range, there was no 
underlying abnormality of solid-phase gastric emptying before ingestion of a 
mycoprotein challenge. Following ingestion, there was a slight increase in the time taken 
for half the test meal to empty from the stomach but even then, solid-phase gastric 
emptying was still well within the normal range. The results were remarkably similar to 
those seen in an age and sex matched normal control. Ideally, further studies of gastric 
emptying pre and post mycoprotein challenge need to be performed in affected subjects 
to address this issue properly. 
5.9.0 Other Possible Factors 
There was no suggestion of any excess of psychological morbidity in any of the affected 
subjects %%ho returned a completed questionnaire. However, the primary purpose of the 
questionnaire was not to elicit a history of any such problems. The accuracy of the 
histories obtained by questionnaire relied entirely upon the goodwill of the subjects 
concerned to notify (without prompting) any history of depression, anxiety or other 
psychological problems. There is still considerable stigma attached to psychological or 
psychiatric disease, and of course, many individuals will not wish to raise the subject if it 
can be avoided. i lowever, the reactions described were all temporally associated with 
ingestion of mycoprotein and there is really no reason to suspect that the vomiting 
reaction is in any way psychogenic. Similarly, the clinical features consistently described 
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by each subject do not fit with the rare cyclical vomiting syndrome, most commonly 
described in children, but kno%%n to affect adults (292). 
Another possible insight into the aetiology of this reaction comes from a study performed 
to investigate the effects of a high fibre meal on subsequent short- term eating behaviour. 
In a within patient design, Burley et al fed 18 lean, healthy subjects a lunch containing 
either I lg of fibre (mycoprotein containing meal) or 3g of fibre (an isocaloric, chicken 
containing meal). In all other respects but the fibre content, these meals were identical. 
No differences were seen in eating behaviour during the meals; amounts eaten, rates of 
consumption and overall motivation to continue eating were identical. However, there 
was an 18% reduction in the amount of energy consumed at a subsequent evening meal 
%%hcn subjects had eaten the high fibre mycoprotein for lunch. This difference was highly 
significant (p<0.001) indicating that the mycoprotein meal had a significant impact on 
subjects' late satiety, as measured by energy consumption 4-6 hours later. For the 
purposes of their study, the authors concluded that their data had clear implications for 
the control of appetite and body weight (293). however, it is of note that these otherwise 
healthy individuals had subtle but measurable decreases in satiety around six hours after 
ingestion of a m)-coprotein containing meal. This made them feel sufficiently "full", six 
hours later, to cat an average of 18% fewer calories than they would have done following 
a meal containing chicken. It is possible that the bloating, nausea and eventual vomiting 
suffered by the affected subjects described in this thesis may be an exaggerated form of 
this process. %%hich may indeed be mediated by alterations in upper gastrointestinal 
motility, in a spectrum ranging from the very subtle to the clinically relevant. 
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5.10.0 Outcome of present study 
This was in effect a negative study, a matter of disappointment for the investigators, but 
more importantly, of reassurance to both the manufacturer and ultimately to the 
consumer. The present study did not identify any group of individuals at particularly high 
risk of adverse reactions to mycoprotein, in terms of their age, gender, past medical and 
allergic history and atopic status. No areas of potential concern within the manufacturing 
process of the mycoprotein-based foodstuffs were identified. In particular, there was no 
immunological evidence of any of the affected subjects having been exposed to 
potentially harmful mycotoxins. This is of great reassurance and does indicate that the 
present systems to detect the presence of such mycotoxins in any batch of mycoprotein 
are efficient at preventing the exposure of the consumer to these dangerous substances. 
As such, this study had relatively little impact on the manufacturer's policies in terms of 
changing labelling or manufacturing processes. 
One area highlighted as obviously deficient was in the collection of an adequate dataset 
of information on those individuals who had experienced adverse reactions. In future, as 
a consequence of this study, all reactions will be recorded using the questionnaire 
detailed in Appendix 1. 
5.11.0 Future work 
The negative findings of this study are of course disappointing and yet there are a number 
of areas %%hich merit further study. 
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The problems with recruiting subjects willing to travel to Edinburgh to undergo further 
testing. whether in the form of WGL, endoscopy or gastric emptying studies proved to be 
much greater than originally anticipated. However, given the media and lay public's 
increasing suspicion of the medical and scientific community in the context of 
innumerable high-profile cases of misconduct, to have managed to persuade five people 
to travel across the UK and undergo "tests" is no mean achievement. 
It would be wrong to assume that a second cohort of subjects would be any more 
amenable to travel than the present cohort and so any further work would ideally have to 
avoid such travelling. This would necessitate near-patient testing and testing in a form 
'hich did not inconvenience the subjects and was as non-invasive as possible. In the 
present study, information regarding only the systemic immune response is available in 
the majority of subjects (only one subject had agreed to undergo WGL). Information on 
responses at the mucosal level would be very useful and would indicate whether any 
reaction did indeed occur at that level in response to mycoprotein. 
To develop new assay techniques would of course be the subject of a further thesis in 
itself. A novel technique might involve direct or indirect methods of examining mucosal 
immune responses. Direct methods might include examination of intestinal biopsy 
material from affected subjects, normal and disease controls, attempting to isolate lamina 
propria lymphocytes in tissue culture. The results of in vitro stimulation with 
mycoprotein of lymphocytes from different patient groups could be compared with 
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stimulation by conventional mitogens by measuring production of proinflammatory 
cytokincs as well as cytokines important in allergic responses such as IL-5 and IL-10. 
Descriptive studies of cytokine release in organ culture of small intestinal biopsy material 
might also give insight into events at a molecular level in the intestinal mucosa. Of 
course. obtaining biopsy material involves an invasive procedure in the form of an 
endoscopy. %%hich again would require volunteer subjects to travel to Edinburgh. 
In order to look at events at a mucosal level indirectly, I would propose to assay markers 
of granulocyte activity, such as calprotectin, a neutrophil enzyme, and eosinophil cationic 
protein or cosinophil protein X in stool samples (133-135). These three enzymes are 
sufficiently stable in faecal samples to allow subjects to provide a sample which could be 
sent by courier or by first class post to the Gastrointestinal Unit for assay. This would 
also allow comparison with levels of all three proteins in the stools of immunologically 
healthy individuals as well as with those of patients with inflammatory bowel diseases 
from data held in the Unit. Elevated levels of eosinophil-associated proteins would be 
most relevant in the context of a putative food hypersensitivity reaction. Comparison 
with patients with inflammatory bowel disease and coeliac disease would indicate 
whether any elevations observed were restricted to those suffering from hypersensitivity 
reactions or formed part of a more generalised non-specific inflammatory response. It 
would be useful to see whether any relationship existed between levels of faecal 
calprotectin and eosinophil proteins in food allergic patients, normal controls and 
inflammatory bowel diseases. A positive correlation would favour a non-specific 
inflammatory response involving neutrophil and eosinophil activation, while a selective, 
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isolated rise in ECP or EPX in the food allergic group would strongly support the pivotal 
role of cosinophil activation in the aetiology of such reactions. 
Ideally, it would be very useful to see whether an oral challenge with mycoprotein 
produces measurable activation of the intestinal immune system. There are ethical 
problems involved in re-challenging otherwise healthy individuals with an allergen that 
previously made them ill, and which has the potential to cause even more serious adverse 
effects, including anaphylaxis. If such a re-challenge were to take place, it should be in 
an environment in «hich full resuscitation facilities and personnel are available in order 
to minimise the risk to the subject under study. Effectively this means either a trip to 
Edinburgh for the subject or the investigator travelling to a hospital or clinic close to the 
subject. I feel that the difficulties of the former option have already been demonstrated 
by the present study. The problems of the latter option, where the investigator might find 
himself administering test food challenges in surroundings unfamiliar to him, and where 
he is unfamiliar to local staff are potentially extremely hazardous. This option is difficult 
to justify in the investigation of a condition where avoidance of the offending substance 
is the only treatment required to ensure that subjects remain healthy. In view of these 
problems, both practical and ethical, such a re-challenge study would be very difficult to 
perform. 
If sufficient historical N% GLF samples had been available within the Unit to allow paired 
testing of mycoprotein antibodies in both the sera and WGLF in patients with 
inflammatory bowel disease, this would have given valuable insights into the mucosal as 
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well as the systemic response to mycoprotein in these patients. These could have been 
compared «ith the historical data obtained by O'Mahony et al regarding the presence of 
systemic and mucosal antibodies to other food antigens in this group of patients. In 
recent years, the WGL procedure has been rarely performed and there is no ongoing 
collection and storage of samples. As a consequence, historical samples are now very 
scarce, making the study of paired samples difficult. 
The perceived prevalence of food allergy and intolerance is on the increase and many 
othen%ise healthy individuals are keen to discover what is at the root of their symptoms 
of nausea, bloating and diarrhoea in response to a variety of foods. A whole industry has 
grown up around this field and it is possible to make a living a an alternative practitioner 
in many of the major cities in the UK by offering consultations, a bewildering array of 
tests and advice on exclusion diets to people who believe they are suffering from food 
allergies. In spite of this, it is apparently difficult to recruit subjects for food allergy 
studies in the sphere of conventional medicine. Whether this represents a growing 
interest in alternative therapies or a growing distrust of conventional medicine is not 
clear. The latter possibility is however very important in the field of food intolerance, 
where subjects feel that neither they nor their symptoms are taken seriously or believed 
by conventional practitioners. In the absence of robust, reliable, non-invasive methods of 
diagnosing food allergy or intolerance, this unfortunate situation is likely to persist. 
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5.12.0 Conclusions 
In the course of this work, it has not been possible to conclusively identify any definite 
cause of these reactions, nor any obvious predisposing factors. The antibody studies do 
not support the notion that the vomiting reactions suffered by affected subjects are due to 
a humorally mediated, immunological reaction, or true food allergy. The role of the 
mycotoxins known to be produced by Fusaria species, namely zearalenone, 
deox}nivalenol and deoxyscirpenol would appear to be negligible, which is as one would 
hope with the strict regulations which exist for their detection during the process of 
manufacture. The results of competition ELISAs would support this. In the small 
number of subjects who attended for endoscopy, there was a surprisingly high prevalence 
of minor upper gastrointestinal pathology noted even before administration of 
mycoprotein, which might suggest some latent or sub-clinical upper gastrointestinal 
disease. IIowever, these observations are based on findings in only three patients and 
should be viewed with great caution. Mycoprotein ingestion did lead to a prolongation of 
solid phase gastric emptying compared to baseline in the one affected subject who 
underwent testing. However, a similar effect was seen in a normal control subject, and in 
both cases, solid phase gastric emptying remained within the normal range. It is possible 
that the subtle changes in satiety seen with hours of mycoprotein ingestion described by 
Burnley in a study of normal, healthy volunteers (293), could reach a clinically relevant 
level in a small number of individuals who are exquisitely sensitive to alterations in upper 
gastrointestinal motility. Finally, there is the unsatisfactory possibility that this may be 
an idiosyncratic reaction to a foodstuff without any measurable physiological basis, a true 
food intolerance. 
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Better labelling of the product, making it obvious that it is derived from a mushroom 
protein, should result in fewer adverse reactions in those individuals who are aware that 
they are sensitive to mushrooms. However, this will have little impact on the small 
number of people «ho appear to have a predisposition to what may be an adverse effect 
of the product on upper gastrointestinal motility. Thankfully, the scale of the clinical 
problem is very small, at least in numerical terms, and once the problem is identified, 
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Appendix 1- Postal Questionnaire 
BY ASKING THE FOLLOWING SERIES OF QUESTIONS I AIM TO BUILD UP A 
SHORT MIEDICAL HISTORY TO ALLOW ME TO OBTAIN A FULLER PICTURE OF 
YOUR GENERAL HIEALTII, PAST AND PRESENT. NOT ALL THE QUESTION, 
THEREFORE. RELATE TO YOUR EXPERIENCES AFTER CONSUMING QUORN 







PRrS%. NTIrG PROBLEM 
(Pkasc give a bietaccount of your experience after consuming Quorn) 
Date Of Birth 
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PAST MEDICAL HISTORY 
(include any operations or chronic illnesses e. g. asthma, eczema, diabetes, high blood pressure, 
heart problems or breathing problems) 
DRUG HISTORY 
(Include any tabitts or medicines prescribed by your GP and any other remedies you may use) 
ALLERGY HHISTORY 
As fir u )ov Lnow. arc )ou allergic to anything? 
e. g. 
Foadtuffs YIN 
c utPwrkus Y/N 
! ºtital l Jc' is kry Y/ N 
Drugs / Antibiotics YIN 
If u). plat ghc details 
Do) ou sut%t from any of the following: 
Asthors YIN 
fczcma / Pcnnititis Y/N 
1t )f cf YIN 
224 
FAMILY HISTORY 
Are )ou a%% are of any health problems or allergies in any member of your immediate family? 
Fate 
Mother 
Sisters or Brothers 
Uncles or Aunts 
Gr ndparmu 
SOCIAL IUSTORY 
Pkasc girt brief dcuils of the following; 
Do) ou smote? YIN 
Do )ou drink alcohol? Y/N 
MANY" THANKS FOR TAKING TIIE TIME TO ANSWER TILE ABOVE QUESTIONS. 
1-OUR REPLIES WILL BE TREATED IN THE STRICTEST CONFIDENCE. 
DR ALAN SII AN 
RESEARCI1 FELLOW 
CASTRO-1\TISTINAL LABORATORY 
WESTERN GENERAL HOSPITAL 
EDINB ; RGII 
E114 : XU 
225 
Appendix 2 Abstracts arising from thesis 
1. Shand AG, A1dhousMMC, Ferguson A. An unusual cause of vomiting. Oral 
presentation to the Caledonian Society of Gastroenterology Autumn Meeting, 
Kirkcaldy. November 1998. (Withdrawn at sponsor's request) 
2. Shand AG, Aldhous M. Ghosh S, Ferguson A. Can serum levels of IgA and IgG 
antibodies to a novel fungal dietary protein differentiate between Crohn's Disease and 
Ulcerative Colitis? Oral presentation to the Caledonian Society of Gastroenterology 
Spring Meeting Aberdeen, June 1999. 
3. Shand AG. Aldhous SMC, Ghosh S. Circulating antibodies to dietary antigens in 
inflammatory bo«el disease-a breakdown of bystander suppression? Gut 1999, 
45(suppl V) A346. Poster presentation to 7th United European Gastroenterology 
Week. Rome. November 1999. 
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Appendix 3 Papers arising from thesis 
1. Shand AG, Aldhous AMC, Ghosh S. Investigation into adverse gastrointestinal 
reactions to mycoprotein. (Submitted to Clinical & Experimental Allergy) 
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Appendix 4 Local ethics committee submission 
LOTHIAN RESEARCH ETHICS COMMITTEE 
APPLICATION FORM IN RELATION TO A REQUEST FOR 
ETHICAL APPROVAL -1997 
THIS FORM IS VALID FOR USE ONLY UNTIL THE END OF 1997 
(AltInfonria ön must be completed In typeface) 
1.1 
REGISTER ENTRY (The information In Section 1 will be held on a computer 
database as the Register of Proposals and will be open to the relevant NHS bodies. ) 
Title of the proposed research: 
CLINICAL STUDIES OF THE MECHANISMS OF ADVERSE REACTIONS 
TO MYCO-PROTEIN 
--1.2 AIMS Öf e study: (A brief explanation In layman's terms of the purpose of 
the research and how it will advance medical knowledge or benefit individual 
Myco-Protein is related to mushrooms and to other fungi, and foods based on 
myco-protein are now_widely_consumed, ---The-manufacturers-of-myco-protein 
foodsrectiveýi'rom time to time, letters from individuals who feel that they have 
had an adverse reaction to one or more of these foods. The aim ofthis study is 
to establish the underlying mechanism behind these reported-adverse reaet#öns; 'by 
cliniial interviews with a selection of people affected and a limited number of the 
diagnostic tests. 
228 
1.3 Method: (A simple description Including a brief outline of what is required of the 
research subjects Including whether the project design is open, random, stratified, 
within subject, blind, what measurements will be made, what statistical analysis will 







design of the prcqecL) 
An open study, which wM involve a structured clinical interview and clinical 
examination of up to 40 people who report that they have had adverse reactions 
to myco-protein in food. Further investigation on the likely cause of the reaction 
will be carried out in groups of 6 affected people at a time, involving upper GI 
endoscopy in 6 people, whole gut lavage test in 6 people, a radioisotope test of 
emptying of the stomach in 6 people and also a radioisotope test of the stomach 
emptying in 6 volunteers who have not reported any adverse reactions to myco- 
protein in food Finally, tests for antibodies to the constituents of myco-protein 
foods will be set up and assays performed in serum and intestinal fluid samples 
from healthy individuals, diseases which cause intestinal inflammation or allergic 
reactions, and from people who have had clinical reactions to myco-protein. 
Name and address of the organisation carrying out the research: 
Gastrointestinal Unit, Western General Hospital, Edinburgh EH4 2XU 
Name and address of the principal researcher. (The member of the 
resea th team to vAiom all correspondence will be directed. ) 
Professor Anne Ferguson 
s) and qualifications of the research team: 
ImmuaoIogy Gridüate and icaIReseaich-Fellowto be äppointed. -- 
(e. g. hospi Is I, doctors surgery, eta 
The Western General l1ospitaL--- 
Name the premises in which the research will be carried out: 
Name(s) of the relevant NHS Trusts : 
The Western General Hospital NHS Trust. 
Medical support and other facilities available: 
A dedicated Clinical Fellow will offer medical support to the work. Limited other 
facilities (eg. for endoscopy studies of gastric emptying and for Out Patient Clinic 
assessment) have been costed and the resources of the Trust will be used with 
appropriate ro-imbursement made. 
2 229 
1.10 Can you confirm that you have complied with Scottish Office and 
any relevant national guidelines? 
marketing suveiHarce eta): 
(ABPI, ARSAC, Guidelines on post- 
YES 
1.11 Is this multi-centre research? 
NO 
2 SUBJECTS 





HEALTHY VOLUNTEERS IN THE COMMUNITY* 
0 
OTHER (Please specify) 1_J 
People who have written to the manufacturers of myco-protein foods, indicating 
that they have had an adverse reaction to such foods. 
' If students. has the relevant institution's Ethics Committee been consulted? YESINO 
2.2 For Volunteer Studies, do you accept the responsibility for 
ascertaining that, on recruitment and during the study, volunteers 
do not have, or acquire, a health status contra-indicating the 
study? (Volunteers for non-therapeutic research need not be In perfect health 
providing that their participation wit not affect their underlying condition. Researchers 
should be satisfied about the state of health of such persons and a statement of any 
current medication being taken should be required from all recruited. ) 
YES 
2.3 Flow many subjects Wit! be involved? 
40 myco-protein sensitive subjects; 6 healthy volunteers; serum and intestinal 
secretions from up to 100 GI Unit pätients (-iterial already collected and stored 
therefore there will be no additional procedures or discomfort to these latter 
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2.4 Ust inclusion criteria: 
Individuals who have reported one of two types of adverse reaction to myco- 
protein containing foods - gastrointestinal reaction, with vomiting 2 -4 hours after 
having a meal containing myco-protein; and the rare allergic type reactions with 
swellings of the lips and mouth on contact with the substance in an atopic 
individual 




How will the subjects be recruited and selected? 
A list of subjects who have written to the manufacturers of myco-protein will be 
provided to the investigators and the subjects will be selected for ease of travel to 
Edinburgh. - 
2.7 Will any payments be made to subjects? (if so. pease provide 
details and explanation) 
Travelling expenses only. 
2.8 A copy of the PatientlSubject Information Sheet MUST be 
attached. (See Appendix 4 for guidance notes for the 
Patient/Subject Information Sheet) 
Where applicable, copies of all letters of introduction to patients 
or professionals should be attached 
2.9 What Investigations or interventions will be carried out on the 
--- subjects? -(Please explain In terms appropriate to-an-informed-layman. Give details of procedures such as X-rays, cane cation, endoscopy, anaesthesia, eta 
1. Structured clinical interview, a thorough clinical history including all aspects of 
gencral-health -as well as the reaction to the myco-proteincontaining foods; 
standard clinical examination confinded to the heart, respiratory system and 
examination of the abdomen (unless the patient has other specific symptoms 
which require more detailed examination) 
2. In 6 people, examination of the upper gastrointestinal tract by flexible 
endoscopy in the baseline state, and 2-4 hours after ingestion-of 60 grams of 
myco-protein. 
3. Collection of pure parotid saliva and collection of whole gut lavage fluid from 
up to 6 myco-protein sensitive individuals in whom the clinical history suggests an 
immunological basis to the gastrointestinal reactions. 
4. In 6 myco-protein intolerant men, or post menopausal or sterilised women; 
and in 6 health male volunteers, a standard radioisotope test of gastric emptying 
of solid and fluid phases of a test meal; in the baseline state and with myco- 
protein incorporated in the test meal. 
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2.10 What possible risks and/or discomfort to the subject can be 
foreseen? (State possible injuries to subjects and the probability of them occurring 
and specify possible discomfort, pain, limitation of activity or inconvenience likely to 
be marred by subjects. Were samples are to be taken, please specify the nature 
and amount 
In the subjects undergoing GI endoscopy, throat irritation and occasionally 
retching (the individuals will be given the option of having the procedure carried 
out with sedation or simply with a local anaesthetic throat spray); for the 6 
subjects who may have whole gut lavage carried out, bloating, nausea and 
occasionally anal irritation may occur because of the volume of fluid to be 
ingested. Theoretical very low risk associated with the irradiation involved in the 
test of gastric emptying. 
2.11 What measures will be taken to minimise or remove such risks or 
discomfort? 
A dedicated Clinical Research Fellow will be involved in all of the studies and will 
ensure that patients are subject to as little discomfort and stress as possible. 
2.12 Will the General Practitioner or consultant in overall charge of a 
subject be notified of the subject's participation in the study? 
YES 
If not, why not? (Full reasons must be given as indicated in the Guidance 
Notes. ) 
3 COMPENSATION 
3.1 In the event of death, damage or lasting disability OCCURRING AS -_ A RESULT OF NEGLIGENCE on the part of the researcher, who 
will accept responsibility for compensation? (A written statement from 
the employer-of-the researcher, accepting responsibility, should be provided-where-- 
the researcher is NOT a contract holder with Lothian Health or an NHS Trust. Where 
the researcher holds a regular or honorary NHS contract with Lothian Health or an 
NHS Trust and Is undertaking research In terms of this contract, management 
approval of the research will constitute acceptance of liability for negligence and 
MUST be obtained before research commences. In respect of research on healthy 
volunteers. researchers are expected to have appropriate arrangements in hand-for- 
com ion 
UNWED have negotiated appropriate arrangements with the company funding 
this research. Professor Ferguson and the Clinical Research Fellow will have 
membership of a medical defence union. 
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3.2 In the event of a research subject being harmed, other than by 
negligence, by the drugs, equipment or materials, etc. involved in 
the research, who will compensate subjects? (Arrangements for 
compensation In the event of a research subject being harmed, whether by 
negligence or not. will vary according to what type of body is sponsoring the research 
proposal but must comply with ABPI Guidelines. NHS bodies such as Trusts are 
NOT legally empowered to offer advance indemnity to participants in research 
projects. ) 
As in 3.1 above. 
3.3 If a pharmaceutical company is Involved in the research, does it 
undertake to compensate subjects in the terms of the ABPI 
Guidelines? The answer to this question must include a clear 
statement regarding "No Fault' compensation. (A written statement 
from the pharmaceutical company to this effect MUST be provided. A suggested 
Wo ng that WILL be acceptable is attached as Appendix 1. ) 
YESINO 
REPLY -A food company is involved in the research and agrees to 
compensate subjects in terms analogous to the ABPI guidelines. 
3.4 If items of medical equipment or other products under research 
are to be used, does the manufacturer undertake to compensate 
subjects? 
REPLY - Not relevant 
4 CONSENT 
- -YESINO 
4.1 How will informed consent be obtained from the subject, or for a 
minor, from the subject's parent or-guardian? (The format of the sample 
attached as Appendix 5 should normally be used and a completed copy must be 
attached. If a different form is to be used it must contain all the information on the 
stanaaM form and a co must be submitted with this application. ) 
In wrWn& 
4.2 How much time will be allowed between giving an explanation of 
me researcn ana requesting consent? (Justify if less than 24 hours) 
Subjects %%iill be contacted at first by letter, and then a telephone discussion will 
be used to explain the clinical interview. Arrangements about the endoscopy, 
gastric empt)ing and gut lavage test will be made at the clinical interview, 
allowing a minimum of a week between giving explanation and requesting 
consent. 
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4.3 If the subject will be In a dependent relationship to the 
investigator, please state what steps will be taken to conform to 
"Basic Principle No. 10" of the Helsinki Declaration which states 
that When obtaining informed consent for the research. project, the 
physician should be particularly cautious if the subject is in a dependent 
relationship to him or her or may consent under duress. In that case the 
Informed consent should be obtained by a physician who is not engaged in 
the Investigation and who Is completely independent of this official 
relationship 
Not relevant. 
4.4 What steps will be taken to satisfy an informed layman that the 
subject In a study (other than a minor) who is unable or 
questionably able to give Informed consent had Indicated his/her 
willingness to participate? (such as the assistance of an independent 
oolleague, or of the next of kin, or other methods as appropriate. ) 
Not relevant. 
4.5 Give the name of a doctor or other suitable person independent of 
the trial to whom the subject being asked to take part in the trial 
can refer for impartial advice and has consented to assist: 
I Dr Subrats Ghosh. 
WHERE DRUGS ARE GIVEN IT IS RECOMMENDED THAT THE 
LOCAL HOSPITAUTRUST PHARMACY MANAGER BE NOTIFIED 
5 PHARMACEUTICAL OR OTHER PRODUCTS 
(11 no such products are to be used please go to question 6) 
5.1 Is a pharmaceutical (or other) product(s) (e. g. appliances, 
prostheses, equipment for IV therapy, etc. ) to be ' used , in : this 
study? 
YE /NO 
5.2 Name of product(s) and manufacturer. (Also specify special diets 
Isotopes. vaccines. and state mute, the doses to be used, the recommended range 
and duration of therapy if applicable, frequency and precautions in administration. ) 
Food quality myco-protein (Marlow Foods). A foodstuff used by millions of 






Mechanism of action (Describe briefly) 
Usage to date (Including extent of use in man) 
Toxicity and side effects (Known and anticipated, where possible avoiding 
technical jargon and describe the procedures and precautions in monitoring) 
Withdrawal of subjects (Under what circumstances may patients be 
wtt&avn from the study? ) 
Subjects may vhithdraw from the study at any time. 
5.7 Does the pharmaceutical (or other) product possess one of the 
following for use in this way: REPLY - not relevant. 
A Product Licence YESINO 
Product Ucence No. 
A Clinical Trial Certificate (CTC) YESINO 
---- -A Clinical Trial Exemption Certificate (CTX) -----------YESINO - ---- 
A Doctors and Dentists Exemption Certificate (DDX) YESINO 
5.8 Has C. S. M. approval been given for all drugs to be used? If not, 
give an explanation present status of. the drug(s). If the research 
Involves 
-the -use of medicines 
for purposes or in ways-that-have 
not been approved by the C. S. M. and a CTC or CTX are not 
available, a Doctors and Dentists Exemption may be required and 
should be enclosed If appropriate. Please contact the Research 
Ethics Sub-Committee Chairman for advice. 
Copies of the relevant licence or certificate MUST be enclosed. (In 
the case of the Product Licence the Licence Number will-suffice: )- 
If the pharmaceutical (or other) product does not posses a 
product licence then a clear statement regarding "No Fault" 
compensadon MUST be enclosed. 
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5.9 Ust all other products or equipment to be used: . 
6 RADIATION 
(It no radiation Is to be used please go to question 7) 
6.1 Is it intended to make any additional exposures to ionising 
radiations? (For example X-rays or Radionuclide investigations) 
YES 
6.2 If It Is Intended to administer radioactive substances, has 
approval been obtained from-the-Administration of Radioactive 
Substances Advisory Committee (ARSAC) for this particular 
research study? (A copy of the relevant permission should be enclosed or 
forwarded when available) 
YES 
6.3 Who Is the ARSAC licence holder? 
Dr Malcom Merrick. 
6.4 If It Is Intended to use additional X-ray exposures has this been 
discussed-with the- Radiology_Department? 
_ 
REPLY - not relevant 
YESINO 
_ 6.5 
In the case of fluoroscopyfhas-the person who is clinically or 
physically directing the x-ray exposures received adequate 
training in matters of radiation safety? 
REPLY - not relevant 
YESINO 
6.6 What is the estimated radiation dose to the patient? 
(The advice of the Radiation Protection Adviser for X-rays [Mr JR Williams, 
Department of Meckal Physics and Medal Engineering, Western General Hospital 
should be obtained. ) 
TV 
7 DATA PROTECTION 
7.1 Are you registered under the Data Protection Act? YES 
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7.2 Will all research be conducted in accordance with current codes 
of practice and data protection legislation? 
YES 
8 MANAGEMENT INFORMATION: 
8.1 Does the project involve other disciplines? (e. g. General Practice 
Raddogy, Haematology, Clinical Chemistry, Pharmacy, Nursing, etc. Please 
specify) 
Nuclear medicine, endoscopy. 
8.2 Will the project have any effect on the workload of nurses, 
laboratories, pharmacy, imaging, outpatient departments, etc.? 
Please specify. (This should be discussed with the individual departments or 
staff affected) 
No. 
8.3 Specify any resource implications for the NHS arising from this 
project (Staffing, tests, pharmaceutical costs, consumables, etc. ) 
None. (costs of the various tests will be re-imbursed to the Trust) 
8.4 By what date is It anticipated this research will have concluded? 
December 1998. 
9 MISCELLANEOUS 
9.1 Will the project receive financial or other material support from a 
-Government Agency, Research- Council-charity; -drug company, 
etc.? If so, specify the name and source(s) of support. 
A research contract is being negotiated between-jhe-University of Edinburgh, 
UNWED, and Marlow Foods. 
9.2 Specify any financial or other direct benefit to investigators, their 
department or institution arising from this study. Please give 
details: (e. g. a University Ethics Committee-, ff-University staff or students are to 
be used as subjects, multi-centre trials, eta) 
No direct benefit to the investigators. 
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9.3 Other points that you may wish to make in justification of the 
Myco-protein based foods are proving to be highly acceptable and extremely safe, 
highly nutritious and relatively inexpensive new foods. It will be important to 
establish the mechanisms of the rare adverse reactions, so that by appropriate 
product libelling, individuals who may be at particular risk of developing such 
reactions can be forewarned. 




ý! .:. 47L. '- 
SIGNATURE OF INDEPENDENT ADVISER (As in 0 4.5)..... ... ......... 
SIGNATURE OF SUPERVISOR (As in a 1.6) ............................................... 
NAME OF SUPERVISOR (Please print) .............................................. ......:::: 
ADDRESS OF SUPERVISOR ...................................................................... 
..... n. __.. _... _ .................................................. N............................................ 
TELEPHONE NUMBER .............................................................................. 
FAX NUMBER_ .................................................................,,,......................... 
DATE........... ........................ (This form is NOT valid for use after 31112197) 
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CLINICAL STUDIES OF THE MECHANISMS OF ADVERSE REACTIONS 
TO MYCO-PROTEIN 
Background to proposed research 
Myco-protein is one of several novel foods which have been developed recently. The 
basic constituent of myco-protein is fungal mycelia, which contains mainly protein and 
chitin. The material also contain egg white, which is predominantly composed of egg 
proteins including ovalbumin. The material is highly nutritious, of a texture similar to 
meat, and readily modified and flavoured to produce a wide range of food products. 
hlyco-protein"based foods are labelled as being unsuitable for people who are allergic 
to mushrooms or to eggs. 
The manufacturers are contacted from time-to-time by people who report that they 
have unpleasant reactions after eating myco-protein. 
a) Less than 5% of reports are of reactions consistent with classical allergy to a food 
ingredient, e. g. skin_tash.. swelling of the lips and mouth immediately afier_ccntact-with 
the substance. 
b) 95% of reports are of a very consistent gastrointestinal reaction. The person vomits 
2-4 hours after taking a meal containing Quorn. After vomiting has occurred, later 
symptoms are unusual. 
Possible mechanisms of acute, allergic-type reactions 
Less than 5% of reports are of reactions consistent with classical IgE-mediated allergy 
to a food ingredient, e. g. skin rash, swelling of the lips and mouth immediately after 
contact with the substance. A significant minority of the population will be sensitised, 
either by inhalation of fungi or by sensitisation to egg in childhood (or very, very rarely 
to mushrooms). Individuals already sensitised in this way could have an allergic 
reaction to myco-proteins even on the first exposure. It is also theoretically possible 
that eating myco-protein could induce food allergy to myco-protein or egg, because of 
physicochemical or dose effects. In this case, reactions would occur after two or more 
exposures. 
There is abundant knowledge of egg allergy. Allergy involving fungi other than 
mushrooms would normally be manifest as lung disease. There are particular sub- 
groups (such ns. those with cystic fibrosis and with farmer's lung) who-night. in theory 
be at risk from IgE- (and in the case of farmer's lung, IgG-) mediated reactions to 
myco-protein_ 
Possible mechanisms of gastrointestinal reactions 
95% of reports arc of a gastrointestinal reaction. The person vomits-2-4-hours after 
taking a meal containing myco-protein. After vomiting has occurred, later symptoms 
are unusual. The remarkably consistent clinical pattern suggests that there is likely to 
be a single explanation for these reactions and that this will be a real and organic one. 
This could be immunological or non-immunological, and related to any of several 
properties of the fungus protein, the fibre-like chitin, or the egg-white proteins. 
a) IgE-mediated allergy to a component of the mycoprotein which is generated only 
after partial digestion, thus explaining the 2 hour delay. Were this so, reactions would 
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generally occur in atopic individuals known to be sensitised to other foods; or 
individuals with respiratory allergies involving other fungi. 
b) if the mechanism of satiety relates to an effect of mycoprotein in slowing the rate of 
gastric emptying. an extreme varient of this, perhaps in people with co-existing mild 
gastrointestinal motility problems, could lead to vomiting. 
c) An immune reaction (not involving IgE) to either the protein of the mycelia or egg 
white proteins. The time frame would suggest an IgG/IgM immune complex reaction 
rather than T-cell mediated. This could produce either gastritis or duodenal 
inflammation entirely consistent with the time frame and clinical descriptions of the 
reactions. 
Studies to be undertaken 
1. Direct clinical assessment o[people. who report adverse reactions to myco- 
protein 
Structured clinical interview will be conducted with 30-40 people who report that they 
have had adverse reactions to myco-protein, both of the rare allergic type and the 
gastrointestinal reaction. This would identify co-factors relevant to likely pathogenesis 
including known histamine sensitivity, known atopy, egg and mushroom intolerance, 
respiratory diseases associated with allergy to fungi, gastroduodenal diseases including 
heartburn, duodenal ulcer, gastric ulcer, gastritis. It will probably be necessary to 
suppplement information provided by the affected person, with data from patients' 
general practitioners, and from hospital records in some cases. I do not envisage any 
difficulties in obtaining this help from fellow professionals, as long as the reasons for 
the enquiry are clearly and courteously explained. Our experience in Scotland has been 
that occasionally a hospital prefers case records to be reviewed within its premises - in 
which case the clinical research fellow would travel to do so. 
2. Studies of mechanisms of gastrointestinal reactions 
2.1. In 6 people who have had severe reactions to myco-protein, upper gastrointestinal 
endoscopy v ill be performed here. in Edinburgh, in the baseline state and 2-4 hours_ . 
after oral feeding of myco-protein, in order to establish the presence or absence of 
gastritis and duodenitis, 
2.2 If evidence emerges (from blood tests) to suggest that there is an immunological 
basis to the gastrointestinal reactions, then collection of pure parotid saliva and of---. 
whole gut lavage fluid will be performed in 6 severely affected people, with 
measurements of specific antibodies to myco-protein and egg antigens. 
2.3 In 6 healthy male volunteers, the effects of myco-protein on gastric emptying of 
solid and fluid phases of test meal will be measured using standard radio-isotope 
techniques. 
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2.4 Tests of gastric emptying will also be carried out in 6 myco-protein-intolerant ''-. 
people, in the baseline state and with myco-protein incorporated in the test meal. Since 
the test involves exposure to a low dose of radiation, only men or post-menopausal or 
sterilised women will be asked to participate in these studies. 
3. Antibodies to mycelia and egg proteins 
3.1 Technical developments relating to antibodies 
ELISA tests will be set up to measure antibodies of IgG, IgA and IgE classes to egg 
albumin, Fusarium gramirnuium and also to the fungus, Aspergillusfumigatus, know 
to have a degree of immunological cross-reactivity with Fusarium graminarium. 
Further characterisation of the proteins to which antibodies are directed will be 
performed by immunoblotting techniques and by competition ELISA. Antibody tests ; _. _. 
wiU be optimised for use in samples of blood (serum), pure parotid saliva and in 
intestinal seuctions. Reagents for skin testing for immediate and -delayed type hypersensitivity will also be developed. 
3.2 Patterns of antibody in healthy individuals and in specific disease states 
We have abundant amounts of material already stored, collected for other purposes, 
from patients with gastrointestinal and immunological diseases. Thus, antibodies to 
fungal and egg antigens will be measured in serum, saliva and intestinal secretions of 
20 healthy adults, 10 immunologically normal children, 10 patients with severe allergic 
eczema (known to have IgE, IgG and IgA antibodies to many foods), 10 patients with 
cystic fibrosis (known to have IgE antibodies to aspergillus), 10 patients with small 
bowel Crohn's disease (known to have and IgA_antibodies to_many foods. 
-And microbial antigens including yeasts). ý 
3.3 Patterns of antibody in people who have had clinical reactions to myco- 
protein 
Serum and parotid saliva specimens will be tested, from up to 40 people who have had 
gastrointestinal reactions (e. g. those who will be. attending for clinical assessment); and 
serum from as many as possible of those people who report allergic-type reactions (I 
will ask the patients' general practitioners to collect blood samples and post these to 
us). In addition. we will study mucosal antibodies in intestinal secretions, collected at 
endoscopy from the people described in section 2.2 above. 
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LOTHIAN RESEARCH ETHICS COMMITTEE 
STANDARD CONSENT FORM 
TITLE OF THE PROPOSED RESEARCH: 
Clinical studies of the Mechanisms ofAdverse Reactions to Myco-Protein 
NAME OF INVESTIGATOR: 
Professor Anne Ferguson 
ADDRESS: 




FURTHER INFORMATION IS AVAILABLE FROM: (A person who is not 
invo 
UST ANY DRUGS TO BE GIVEN IN THE STUDY EXPLAINING THEIR 
ACTION: 
UST ANY PROCEDURES REQUIRED IN-ADDITION TO THE STANDARD 
PROCEDURES: 
For most patients, only a general clinical assessment will be carried out. 
In selected patients (the study doctor will discuss with you if we are planning to 
invite you to be one of these selected patients) depending on the nature of the 
clinical history of reactions, one or more of the following tests may be done. 
1. Uppcr gastrointcstinal cndoscopy on two occasions. 
2. Whole gut linage test on one occasion. 
3. Test of Auuic cmpt)mg on two omsisons. 
'ved in the study) 
Dr Subrad Ghosh 
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"I agree to participatelto the patientisubject participating' in this . 
'" " :. 
study. 
"I have read this consent form and Patient/Subject Information Sheet 
and had the opportunity to ask questions about them. 
"I agree for notice to be sent to my/the patient'slsubject's" General 
Practitioner about my/their' participation in this study. 
"I agree to the provision of any clinically significant information to 
my/tire patient'slsubject's General Practitioner. 
"I understand that I amlthe patientlsubject Is* under no obligation to 
take part in this study and that a decision not to participate will not 
alter the treatment that Uthe patient/subject would normally receive. 
"I understand that I have/the patientisubject has' the right to,. v. tharav: =_-- 
from this study at any stage and that to do ao will not affect myltheir* 
treatment. 
"I understand that this is non-therapeutic research from which Uthe 
patientusubjecr cannot expect to derive any benefit. " 
Signature of PatienUSubjecuParent or Guardian* 
Nan e of PadenUSubject. 
Signature of Investigator ................................. _......................... 
Date: ,... »»»».. »............ 
_ ____' Delete as appropriate ---- 
Four copies to be made 
Top copy to be retained by Investigator 
Second copy to be retained by patientisubject 
Third copy to be sent to patient'a/subject's General Practitioner 
An additional copy to be filed In any relevant hospital case notes 
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GUT LAVAGE TEST FOR RESEARCH STUDIES 
Information for patients and volunteers. 
Antibodies are the molecules which neutralise and kill infectious agents 
such as bacteria and viruses. Certain types of antibodies can also 
cause allergic diseases and diarrhoea. 
Tests on blood give very little information on gut immunity because the 
relevant antibodies are present in digestive juices from the stomach and 
lower down In the bowel. Our recent research has led to the discovery 
of the gut lavage test, a simple and safe way for us to obtain digestive 
juices from the intestine, so that measurements of intestinal antibodies 
can be performed. 
What the gut lavage test would mean for you is as follows: 
(The test is normally performed in a quiet area of the Western General 
Hospital, staffed by specially trained nurses). 
You can eat and drink normally until midnight. 
The next morning. you will be given a glass of bland fluid to drink, every 
10-15 minutes for about two hours. 
The fluid passes along the bowel hike water along a hosepipe). 'Aster 1 
1 112 hours your bowels will move normally a couple of times. Then you 4 
will pass clear fluid from the bowl. This clear fluid will be collected by a 
nurse or doctor. 
The test-is--then complete and you can eat and drinf-normally. _. You 
should expect to have several more watery bowel motions in the course 
of the day. 
While you are having the gut lavage test, a doctor will- record some 
simple details of your present and past health. AL Lod sample will also 
be taken for reference purposes. I'! 
Thank you for offering to help with our research. Yoü should not find 
the test distressing, but please note that if you do you are completely 
free to stop the test at any time. 
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INFORMATION FOR PATIENTS RE GASTROINTESTINAL ENDOSCOPY 
Thank you for agreeing to have a gastrointestinal endoscopy test on two occasions, as 
part of our research programme on clinical reactions to myco-protein. 
The endoscopy test is very straight forward. We will ask you to fast for about 4 hours 
prior to the test. There Is the option of having the test carried out quickly with a local 
anaesthetic spray to your throat and no other sedative, or alternatively a simple 
injection of a tranquilliser into a vein which makes you sleepy for 1- 2 hours, you have 
a natural sleep after the procedure and normally recall very little of it. 
At endoscopy a slim black tube will passed by the doctor through your throat into the 
stomach and duodenum. and if there are any patches which look inflammed, small 
biopsies. about the size or a rice grain. will be taken through the instrument. 
You may feel irritation at the back of your throat. and patients occasionally are 
nauseated and retch a little. 
We will ask you to have a second endoscopy. two to four hours after taking a meal of 
myco-protein which we will provide. As we will explain to you when you attend for 
d'nical assessment. the reason for this is to see if the myco-protein produces irritation 
or inflammation of the äning of the stomach. Once again. small biopsies will be taken if 
there are any apparently inflammed areas in the stomach. 
Note that you are completely free to decide not to continue with the research study and 
the endoscopy, at any time. 
One of the GI research team doctors will be present when you are having the 
endoscopy tests. 
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INFORMATION FOR PATIENTS AND VOLUNTEERS ABOUT THE TEST OF 
GASTRIC EMPTYING 
Thank you for agreeing to have a test of gastric emptying as part of the research 
project on reactions to myco-proteins. 
The procedure is straight forward. You will be asked to come to the hospital having 
fasted from midnight the evening before. On one occasion, you will have the standard 
test; and on a second occasion you will have the standard test to which a small amount 
of myco-protein has been added. 
The standard test involves taking some scrambled eggs together with a drink. There is 
ä tiny tiace of radio activity incorporated in these materials (equivalent to one or two 
days background exposure In the UK). 
You will then have the radio activity in your stomach area measured by a simple 
machine. Al we wid ask you to do is sit quietly and have the radio activity pattern of 
your abdomen checked every 15 minutes or so for up to 3 hours. 
If at any time you wish to discontinue the test then you are completely free to do so. 
One of the GI Research team will be present when you are having the gastric emptying 
test in case you have any concerns or problems during the procedure. 
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1702/97/41109 
eve at.: Wove at.: 
05 August 1997 
Professor A Ferguson 
GI Unit 
Western General Hospital 
Crewe Road 
EH4 2XU 
Dear Professor Ferguson 
LOTHIAN 
Research protocol 1702/97/4/109: Clinical studies of the 
mechanisms of adverse reactions to myco-protein. --- 
Thank you for submitting the above protocol for ethical approval. The 
Medicine and Clinical Oncology Research Ethics Sub-Committee will 
consider this protocol at its next meeting which will be held on 
Wednesday 13 August 1997. I will notify you of the outcome of this 
consideration as soon as possible. 
Under the terms of the Scottish Office Home and Health Department 
Guidelines on Local Research Ethics Committees a copy of your request 
has been sent to the NHS body under the auspices of which the research 
is intended to take-place. It is that NHS body-which has the responsibility 
of deciding whether or not the research should go ahead taking account of 
the advice of the Research Ethics Sub-Committee. 




Medicine and Clinical Oncology 
Research Ethics Sub-Committee 
Please quote the above reference on all correspondence 
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*wo 1702/9714/109 "OY. 441: 
3 September 1997 
Professor A Ferguson 
Gastrointestinal Unit 
Western General Hospital 
Crewe Road 
Edinburgh EH4 2XU. 
Dear Professor Ferguson, 
LOTHIAN 
Request for Ethical Approval---1702/97/4/109 : Clinical studies of 
the Mechanisms of adverse reactions to myco-protein 
Thank you for submitting the above protocol for ethical approval. The 
Medicine/Clinical Oncology Research Ethics Sub-Committee has discussed 
this protocol but has deferred making a decision and continued 
consideration of the application for the following reasons: 
"a fuller Patient Information Sheet is required giving more details 
about the study and including the name/address etc of the 
Independent Adviser 
" clarification of whether the subjects will have all the tests or only one 
" the significance of having groups of 6 people 
" an indication of the risk of potential harm to subjects who have a 
protein allergy 
The next meeting of the Sub-Comm ittcc v. -ill be held on 1 October 1997. It--- 
would be appreciated if the required amendments could be available prior 
to that date. 
Should you have any queries regarding the above, please contact myself 
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